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Introduction 
Hepatocellular carcinoma (HCC) 
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and the third most 
common cause of cancer death. It accounts for 85-90% of liver cancers and develops in the 
background of chronic liver inflammation caused by viral infections by hepatitis B (HBV) and hepatitis 
C virus (HCV) infections, intoxications (e.g. aflatoxin B1), alcohol abuse and non-alcoholic 
steatohepatitis (NASH) (Yang & Roberts, 2010; Blonski, Kotlyar & Forde, 2010; Oyagbemi, Azeez & 
Saba, 2010). Other factors increasing the risk of developing HCC are iron overload syndrome, tobacco 
use  (Blonski, Kotlyar & Forde, 2010) and genetic conditions like hemochromatosis and α1-antitrypsin 
deficiency (Berasain, Castillo, Perugorria, Latasa, Prieto, & Avila, 2009). All these conditions may 
result in liver fibrosis and cirrhosis, which are detectable in 70-90% of all HCC cases (El-Serag & 
Rudolph, 2007). 
The incidence in HCC has been increasing over the last decades. When in 2002 626,000 incident cases 
emerged and 598,000 patients died of HCC worldwide, these numbers increased to 748,000 new 
cancer patients and 696,000 deaths in 2008. As most cases of liver cancer are detected at very late 
stages, the numbers of new cases and deaths, unfortunately, are of similar height (Yang & Roberts, 
2010). Nowadays, HCC has become the fastest growing cause of cancer death among male US adults 
(El-Serag & Rudolph, 2007) with a 5-year survival rate below 9%  (Berasain, Castillo, Perugorria, 
Latasa, Prieto, & Avila, 2009) 
80% of HCC cases occur in developing countries in sub-Saharan Africa and Eastern Asia mostly 
because of intoxications and viral infections. But since 1978, HCC incidence has been decreasing in 
these areas, but has been increasing in developed countries. There is also a shift to younger ages 
(around 45-60 years) in age distributions of todays HCC patients noticed, when compard to the late 
1990s (around 65 years) (El-Serag & Rudolph, 2007). Among the factors causing the increase and age 
shift in developed countries - and which are thought to become even more prominent in the near 
future - are the metabolic syndrome, diabetes mellitus and NASH (Yang & Roberts, 2010).  
 
Hepatocarcinogenesis 
Hanahan and Weinberg proposed six changes in normal cells in their 2000 review ‘The Hallmarks of 
Cancer’ (Hanahan & Weinberg, 2000), which are necessary for the development of malignant cancer 
(see Figure 1) and added two more so-called ‘Emerging Hallmarks’ and two ‘Enabling Characteristics’ 
(see Figure 2) to their 2011 published review ‘The Hallmarks of Cancer: The next Generation’ 
(Hanahan & Weinberg, 2011). According to this widely accepted hypothesis, a cell must 1) gain self-
sufficiency in growth signals, 2) gain insensitivity to anti-growth signals, 3) gain a limitless replicative 
potential, 4) evade apoptosis, 5) sustain angiogenesis and 6) gain the ability to invade the 
surrounding tissue. Two abilities that have been proposed and have now been added to the former 6 
hallmarks are 7) the ability to deregulate and reprogram the cellular metabolism to enable further 
cell growth and proliferation, and 8) the capability to evade the immune system. Especially the latter 
is a quite interesting characteristic as many tumors attract immune cells in order to make them 
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release chemicals (e.g. reactive oxygen species), which are mutagenic and could lead to genetic 
changes in tumor cells, or growth factors to sustain proliferation, survival factors that help 
circumvent apoptosis, proangiogenic factors or matrix-modifying enzymes for the invasion of 
surrounding tissue and metastasis (Hanahan & Weinberg, 2011). 
 
Figure 1: The Hallmarks of cancer. Taken from:  Hanahan & Weinberg, Hallmarks of Cancer: The next Generation, 2011. 
The two ‘enabling characteristics’ that help cells acquire functions for the transformation into tumor 
cells are ‘genome instability and mutation’ and ‘tumor-promoting inflammation’. ‘Genome instability 
and mutation’ is generated through defects in mechanisms responsible for either detecting DNA 
damage or repairing DNA damage or preventing mutagenic substances from causing damage in the 
cell. All these changed mechanisms result in a certain instability of the genome enabling an evolving 
tumor cell to accumulate favorable mutations and at the same point maintaining a minimum stability 
for further proliferation (Hanahan & Weinberg, 2011). 
‘Tumor-promoting Inflammation’ is a second important characteristic enabling the generation and 
promotion of preneoplastic lesions by resulting in release of the already mentioned growth factors, 
survival factors, proangiogenic factors and matrix-modifying enzymes as well as reactive oxygen 
species. Almost every neoplastic lesion is believed to contain immune cells, mostly of the innate 
immune system, and this accumulation of immune cells seems to be important for the very first 
stages of preneoplastic progression into neoplastic lesions leading to the development of cancer 
(Hanahan & Weinberg, 2011). 
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Figure 2: Emerging hallmarks and enabling characteristics. Taken from: Hanahan & Weinberg, Hallmarks of Cancer: The 
next Generation, 2011. 
HCC development is almost undetectable in patients suffering from liver diseases without liver 
cirrhosis, but increases dramatically when a cirrhotic liver develops. Therefore cirrhosis seems to be a 
prerequisite for liver tumor formation (El-Serag & Rudolph, 2007; see also Figure 3).  
NASH is found to develop into a cirrhotic stage in 10-29% of patients within 10 years and is 
distinguished from a simple fatty liver (hepatosteatosis) by inflammation caused by infiltration of 
immune cells, damage and death of hepatocytes and sometimes even fibrosis (Cohen, Horton & 
Hobbs, 2011).  
 
Figure 3: Mechanisms inducting liver cancer at the cirrhotic stage. Taken from El-Serag & Rudolph, 2007. 
Hence, inflammation in the liver seems to play a mature part in the development and progression of 
cirrhosis and furthermore, liver cancer. This could be demonstrated by Park and colleagues (Park et 
al., 2010) who showed a tumor promoting effect of low-grade inflammation caused by genetic and 
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dietary obesity in a mouse model of liver cancer. These mice did not develop liver cancer when they 
were kept on a normal diet and were administered a carcinogenic chemical, but did so when they 
were genetically obese or kept on a high fat diet. They also showed that the pro-inflammatory 
cytokines IL-6 and TNFα where elevated in this low-grad inflammatory stage and that these cytokines 
are needed for propagation of steatohepatitis and tumor-promotion. Therefore obesity seems to be 
a bona fide tumor promotor as soon as carcinogenesis is initiated, most probably due to its ability to 
induce inflammation.  
 
Obesity 
Overweight is defined by the World Health Organization (WHO) by a body-mass-index (BMI) of more 
than 25kg/m2 and less than 30kg/m2, which is also referred to as ‘grade-1-overweight’. Obesity is 
defined by a BMI of more than 30kg/m2.  
Excess body weight is associated with an increase in total cancer risk, with the highest increase being 
found in HCC. This was shown in several studies, for example in a 2007 published meta-analysis of 11 
studies clarifying the risk of developing HCC. Both, overweight and obese patients were examined 
and a 17% increase in risk of developing HCC in overweight patients, and an 89% increase in 
developing HCC in obese patients was found (Blonski, Kotlyar, & Forde, 2010). Although there are 
several other studies proposing (similar or) even higher risk factors for the development of HCC in 
overweight, obese or diabetic patients, all studies did find a positive correlation of cancer incidence 
with increasing excess body weight.  
Furthermore, excess body weight was shown to result in a 1.52-fold and 1.62-fold increase in total 
cancer-related death in men and women, respectively. The relative risk of men with a BMI higher 
than 35kg/m2 for death from liver cancer was even 4.52-fold increased when compared to men with 
normal weight (Calle, Rodriguez, Walker-Thurmond & Thun, 2003). 
Obesity is often accompanied by high blood pressure, peripheral insulin resistance and type-2-
diabetes (T2D). Especially peripheral insulin resistance in muscle, liver and adipose tissue leads to 
decreased glucose uptake in these tissues (resulting in hyperglycemia), uninhibited glycogenolysis in 
the liver (but interestingly with retained lipogenesis) (Cohen, Horton, & Hobbs, 2011) and uninhibited 
lipolysis in adipose tissue. Usually, binding of insulin to the insulin receptor results in PI3K activation, 
which further results (via PKB/Akt and PKC-λ/ζ) in GLUT4 translocation to the plasma membrane and 
increases glucose transport into the cell. In adipocytes, insulin usually also inhibits lipolysis and 
therefore release of free fatty acids (FFA) (via hormone-sensitive lipase and adipose triglyceride 
lipase) into the plasma and inhibits glycogenolysis in the liver (Schenk, Saberi & Olefsky, 2008). But 
the exact interplay is not fully resolved yet, as there are findings in mice with reduced synthesis, 
mobilization, or β-oxidation of fatty acids, which show hepatic steatosis without insulin resistance. 
Findings in human individuals suffering from genetic defects in APOB or ATGL show similar effects, 
namely increased hepatic TG contents or even steatosis without insulin insensitivity (Cohen, Horton, 
& Hobbs, 2011). 
Adipose tissue in obese individuals contains very often a high fraction of bone marrow-derived 
macrophages and the amount increases with the degree of obesity. These macrophages express 
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TNFα and IL-6 and IκB and contribute to insulin resistance, glucose intolerance and hyperinsulinemia 
(Schenk, Saberi, & Olefsky, 2008).  
As two-thirds of US adults are already overweight and one-third are obese, and obesity is a major risk 
factor for NAFLD and NASH, other liver diseases and liver cancer, these metabolic disorders might 
become major health problems in the future (Yang & Roberts, 2010; Schenk, Saberi & Olefsky, 2008). 
 
Non-alcoholic fatty liver disease (NAFLD)  
Non-alcoholic fatty liver disease (NAFLD) comprises a set of liver disorders ranging from simple 
hepatic steatosis to non-alcoholic steatohepatitis (NASH, which includes hepatocyte death, fibrosis 
and cirrhosis) (Masterton, Plevris & Hayes, 2010). It is the most common liver disease in the US, 
affecting about 24% of the US population, and about 10-35% of adults worldwide (Park et al., 2010; 
Masterton, Plevris & Hayes, 2010). The prevalence of NAFLD increases with increasing degree of 
obesity, ranging from 9% in individuals with a BMI below 25kg/m2 to 51% in individuals with a BMI 
higher than 35kg/m2 (Cohen, Horton, & Hobbs, 2011).   
NAFLD is considered to develop because of two ‘hits’, the first one being steatosis, which is storage 
of fat in the liver, followed by oxidative stress leading to inflammation (Masterton, Plevris & Hayes, 
2010). Steatosis develops when more food is consumed than needed for energy production and the 
storage capacity of adipocytes is reaching its maximum, resulting in the alternative deposition of fat 
in the liver. This progression is a severe problem as the uptake of free fatty acids (FFAs) into the liver 
is not thought to be regulated (Savage & Semple, 2010). This assumption is supported by the finding, 
that in genetic diseases, like glycogen storage disease type 1a and citrin deficiency, which result in an 
increase in the production of fatty acids, the increased flux of FFAs to the liver is sufficient to cause 
steatosis (even in the absence of insulin resistance) (Cohen, Horton, & Hobbs, 2011).  
In the human body excess nutrients are stored mainly as triglycerides (TG) for future breakdown and 
energy production (catabolism), as they provide a higher caloric density (9kcal/g) compared to 
carbohydrates (4.5kcal/g) and proteins (4kcal/g). As increased liver TG levels are the hallmark of 
NAFLD (Greenfield, Cheung, & Sanyal, 2008), steatosis therefore is defined either by hepatic TG levels 
being higher than 55mg/g of liver or TG droplets within hepatocytes exceeding 5% of the cytoplasm 
(Cohen, Horton, & Hobbs, 2011).  
Unfortunately, the exact pathogenesis in cellular and molecular terms of steatosis and the possible 
progression to NASH and cirrhosis have not been entirely elucidated yet (Masterton, Plevris & Hayes, 
2010), as has the contribution of insulin resistance in the development of NAFLD. Insulin resistance 
might be a cause or a consiquence of NAFLD (Cohen, Horton & Hobbs, 2011).  
NAFLD together with hypertension, insulin resistance, obesity and dyslipidaemia are summarized as 
the ‘metabolic syndrome’ or ‘syndrome X’. Several studies found a positive correlation in the number 
of features defining the metabolic syndrome with the chance of developing NASH (Greenfield, 
Cheung, & Sanyal, 2008). 
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Non-alcoholic steatohepatitis (NASH) 
In some cases NAFLD proceeds to non-alcoholic steatohepatitis (NASH), which is characterized by 
infiltration of the liver by immune cells, death of hepatocytes, production of collagen by stellate cells 
(fibrosis) and sometimes also cirrhosis. Exact numbers are missing, but about one-third of NAFLD 
patients who undergo liver biopsy show indications of NASH (Cohen, Horton, & Hobbs, 2011). 
Patients suffering from hepatocellular carcinoma (HCC) are in 70-90% of all cases also diagnosed with 
cirrhosis (El-Serag & Rudolph, 2007) and sometimes also with just some features of NASH and are 
therefore categorized as ‘cryptogenic cirrhosis’. This leads to the assumption that HCC might develop 
at different stages of NASH (Greenfield, Cheung, & Sanyal, 2008), but there definitely is a lot of data 
confirming the association between chronic inflammation and cancer development (Berasain, 
Castillo, Perugorria, Latasa, Prieto, & Avila, 2009). 
NASH, like NAFLD, might be subclinical for years and might just show elevated liver transaminases, 
like aspartate aminotransferase (AST), and alanine aminotransferase (ALT). Fatty liver might be 
detected on ultrasound and tomography, whereas liver biopsy remains the only diagnostic method 
to estimate the progression of NAFLD/NASH as it is still impossible to distinguish NAFLD from NASH 
by imaging technologies (Greenfield, Cheung, & Sanyal, 2008).  
Adipose tissue might also play a role in the pathogenesis of NASH due to its ability to secrete a 
variety of factors (e.g.: CCL2, IL-1b, MIF, adiponectin, leptin; Schenk, Saberi, & Olefsky, 2008; 
Toffanin, Friedman, & Llovet, 2010), among them tumor-necrosis-factor-α (TNFα) and interleukin-6 
(IL-6) (Schenk, Saberi, & Olefsky, 2008). Both factors are elevated in livers and blood of NASH 
patients. The major source of at least TNFα was found to be adipose tissue associated macrophages, 
whose number positively correlates with BMI, but the exact mechanisms of activation and infiltration 
of macrophages are not fully clarified yet. All the cytokines produced by adipocytes and 
macrophages, such as TNFα, IL-6 or leptin, result in an increase in activity of hormone sensitive lipase 
which leads to an elevation of free fatty acid (FFA) levels in the circulation. This elevation of FFAs and 
their unregulated uptake into the liver (Savage & Semple, 2010) is believed to be the cause for 
lipotoxicity resulting in hepatocyte injury (Greenfield, Cheung & Sanyal, 2008). 
Leptin seems to act as a mediator between adipose tissue and the innate immune system, as leptin 
levels are elevated in obesity and the metabolic syndrome. Leptin promotes proliferation of 
mononuclear cells and increases the activity of diacylglycerol acyl transferase (DGAT), which 
facilitates the binding of a single FFA to a molecule of diacylglycerol to form a molecule of 
triacylglycerol (or triglyceride, TG) and therefore removes the otherwise toxic FFAs from the 
circulation. Furthermore leptin promotes the production of collagen in activated stellate cells, which 
is a prerequisite for fibrosis. The production of collagen is also stimulated by insulin (Greenfield, 
Cheung & Sanyal, 2008).  
Besides inflammation, ER stress resulting in activation of the unfolded protein response (UPR) seems 
to play a role in NASH development. Both, inflammation and UPR activation result in NF-κB and JNK 
activation (Cohen, Horton, & Hobbs, 2011). 
In the following, free fatty acids and inflammation are discussed in more detail. 
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Free fatty acids (FFAs) 
Triglycerides (TG) are composed of a molecule of glycerol and three molecules of fatty acids, each of 
which is coupled to the glycerol via an ester bond. Glycerol is an intermediate of glycolysis and 
gluconeogenesis, whereas there are three different sources of fatty acids for triglyceride production 
in the liver: 1) diet, 2) lipolysis by adipocytes and 3) de-novo-lipogenesis (DNL). Fatty acids from diet 
result from lipolysis via lipases (e.g. lipoprotein lipase) and fatty acids from DNL mainly are a result of 
carbohydrate derived acetyl-coenzyme A (acetyl-CoA) (Cohen, Horton, & Hobbs, 2011, see Figure 4). 
About 60% of FFAs in liver TGs derive from adipose tissue, 15% of FFAs in liver TGs derive from diet 
and 25% derive from de-novo lipogenesis (DNL) (Savage & Semple, 2010), the latter (DNL) is 
increased in patients with NAFLD. This is most probably because of SREBP1c-mediated induction of 
DNL by insulin (Greenfield, Cheung, & Sanyal, 2008). Activation of SREBP1 further stimulates 
glycolysis. n3-PUFA reduce the amount of SREBP1 resulting in downregulation of stimulatory effects 
caused by insulin and reduction of DNL (Masterton, Plevris, & Hayes, 2010). Another cause of 
increased levels of fatty acids resulting in hepatic steatosis is decreased TG removal via VLDL particles 
(He, Lee, Febbraio, & Xie, 2011). During fasting, exercise, stress or inflammation lipolysis in adipose 
tissue is activated resulting in an increase of FFA levels. These levels are reported to range from 90-
1200µM, with basal levels around 300-500µM (Lee, Zhao, & Hwang, 2009). 
 
 
Figure 4: Metabolism of triglycerides in the liver. Taken from: Cohen, Horton & Hobbs, 2011. 
Free fatty acids (FFAs) are either released from the cell membrane by phospholipases or taken up by 
the cell from the unbound pool of fatty acids (in contrast to the albumin-bound fatty acids) in the 
blood. The unbound fatty acids are in equilibrium with the albumin-bound forms. The concentration 
of these unbound fatty acids is believed to be at least 3 orders of magnitude lower than the total 
concentration of the fatty acids, placing it in physiological concentrations of ≤50nM. Furthermore, 
the physiological, molar ratio of fatty acids to BSA (ν) was calculated to be ~0.1:1 – 3:1. Uptake of 
FFAs was reported to be a linear function of total FFA concentration or a saturable function of the 
unbound FFA concentration in primary hepatocytes. More than 90% of FFA uptake in hepatocytes is 
now believed to occur via a saturable pathway at FFA:BSA ratios of ~3:1. This leads to the conclusion 
that FFA uptake (at least in hepatocytes) is facilitated and occurs via transporters, in contrast to 
unfacilitated uptake via passive diffusion through the lipid bilayer. Experiments further showed that 
fatty acid uptake is temperature sensitive (Berk & Stump, 1999).  
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Richieri and colleges (Richieri, Anel, & Kleinfeld, 1993) reported that the concentration of unbound 
FFA at a given chain length and FFA:BSA ration depend on degree of ‘unsaturation’ due to increased 
water-solubility with increasing number of double bonds. Furthermore, the presence of albumin 
prevents the formation of stable micelles in aqueous solutions, thereby strengthening the 
assumption of FFA uptake from the unbound pool of FFAs. 
 
Effects of impaired metabolism of FFAs 
Fatty acids are either stored as TGs in adipose tissue, muscle and liver or they are used for energy 
production by oxidizing them to CO2 via a process termed ‘β-oxidation’ in the mitochondria. The rate 
limiting step in this process is the binding of fatty acids to L-carnitine, with is used as a transporter. 
The ligation of carnitine and fatty acids is catalyzed by the enzyme carnitine palmitoyltransferase-I 
(CPT-I) (Schenk, Saberi, & Olefsky, 2008).  
When storage or oxidation of FFAs are already maximized, fatty acid intermediates like ceramide or 
diacylglycerol accumulate and these intermediates are hypothesized to inhibit insulin signaling 
(either via activation of the mTOR/p70S6K, JNK, IKK and PKC pathways or via inhibition of AKT/PKB 
signaling by ceramide). Fatty acids have been shown to induce insulin resistance in part through 
inhibitory IRS-1 phosphorylation resulting in inhibition of the association of IRS-1 with the insulin 
receptor (Schenk, Saberi, & Olefsky, 2008). In muscle, insulin signaling can also be inhibited by FFAs 
resulting in decreased glucose uptake and increased insulin secretion by the pancreas (Greenfield, 
Cheung, & Sanyal, 2008). Furthermore, FFAs are precursors of regulators of immune reactions. 
 
Types and effects of free fatty acids 
Omega-3 (n3 or Ω3), n6 and n9 (oleic acid derived) polyunsaturated fatty acids (PUFAs) have 
immunomodulatory effects (Greenfield, Cheung, & Sanyal, 2008).  
Omega-3 (n3 or Ω3) fatty acids derive from α-linolenic acid (ALA) and have to be taken up by diet as 
they cannot be synthesized in the human body. α-Linolenic acid is metabolized in the liver to 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). These two fatty acids are precursors 
for eicosanoids, lipid mediators of inflammatory responses (Wall, Ross, Fitzgerald, & Stanton, 2010; 
see Figure 5). 
EPA has been reported to reduce inflammation by inhibiting the production of TNF and IL-1 and 
treatment of various cancer cell lines with EPA showed less proliferation and invasiveness. Omega-3 
fatty acids have further been shown to reduce primary tumor growth and metastasis in mice and 
humans (Boutros, Somasundar, Razzak, Helton, & Espat, 2010), as well as lymphocyte proliferation 
and neutrophil chemotaxis (Greenfield, Cheung, & Sanyal, 2008). 
Although the exact molecular mechanisms of the anti-tumorigenic properties of n3-PUFA are not 
entirely elucidated yet, these kinds of fatty acids are thought to replace arachidonic acid in 
phospholipids in the cell membrane thereby reducing or even inhibiting COX-2 mediated production 
of pro-inflammatory eicosanoids and reducing production of VEGFs. This is especially true in the 
membrane of erythrocytes, neutrophils, monocytes and liver cells (Wall, Ross, Fitzgerald, & Stanton, 
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2010). Other hypotheses suggest n3-PUFA-mediated alterations in AP1 and NF-κB signaling leading to 
reduced production of pro-inflammatory cytokines like TNFα (Boutros, Somasundar, Razzak, Helton, 
& Espat, 2010).  
Especially the conversion of the n3-PUFA EPA by COX and LOX enzymes results in less inflammatory 
or anti-inflammatory acting eicosanoids like the 3-series prostaglandins or the 5-series leukotrienes 
(see Figure 5). EPA has further been shown to decrease the degradation of IκB, the inhibitor of the 
transcription factor NF-κB in human monocytes. NF-κB regulates the transcription of cytokines (IL-1, 
IL-2, IL-6, IL-12 and TNFα), chemokines (IL-8, MCP-1) and inflammation-associated enzymes like iNOS 
or COX-2. DHA can be converted into resolvins by LOX (most probably by 5-LOX and 15-LOX; 
Gleissman, Johnsen, & Kogner, 2010), which are local-acting mediators resulting in reduction of 
neutrophil infiltration and lowering of overall inflammatory responses (Wall, Ross, Fitzgerald, & 
Stanton, 2010). Protectins and resolvins are also needed for the resolution of an inflammatory 
response (Gleissman, Johnsen, & Kogner, 2010).  
A study examining the relationship between plasma free fatty acid levels and levels of inflammatory 
markers in 1,123 persons found a positive correlation between the total n3-PUFA concentration with 
lower IL-6, TNFα and CRP levels and higher levels of anti-inflammatory markers (Wall, Ross, 
Fitzgerald, & Stanton, 2010).  
Omega-6 (n6 or Ω6) fatty acids derive from linoleic acid (LH), which is further converted into 
arachidonic acid in the liver. This fatty acid is a precursor for pro-inflammatory eicosanoids like 
prostaglandin E2 (PGE2) and leukotriene B4 (LTB4). PGE2 can induce the production of IL-6 in 
macrophages, whereas LTB4 induces the production of TNFα, IL-1β and IL-6 by macrophages and acts 
as a chemoattractant for leukocytes and might also activate neutrophils (Wall, Ross, Fitzgerald, & 
Stanton, 2010). 
As modern western diets contain high contents of n6-PUFA and low contents of n3-PUFA, enzymes 
which are needed for the conversion of both types of fatty acids primarily convert n6-PUFA rather 
than n3-PUFA due to their higher availability. At a ratio of n3-PUFAs to n6-PUFAs of 1:4 these 
enyzmes would convert n3 rather than n6 fatty acids, but due to the increased consumption of 
vegetable oils the ratio is 1:16 (n3:n6) providing higher amounts of n6 fatty acids (Wall, Ross, 
Fitzgerald, & Stanton, 2010). 
As unsaturated fatty acids contain double bonds they may react with oxygen and form peroxidized 
fatty acids as it is the case when fat containing food is heated for a long time at temperatures above 
100°C. Furthermore, these oxidized PUFAs can cause lipid peroxidation in the membrane of cells 
(Sagmeister, 2009) and this might result in a change of eicosanoid production (Greenfield, Cheung, & 
Sanyal, 2008). 
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Figure 5: conversion of n6 and n3-PUFA into physiologically active molecules. Taken from: Wall, Ross, Fitzgerald, & 
Stanton, 2010. 
For conversion or β-oxidation, fatty acids have to be taken up into the cell which occurs either by 
uptake via CD36 (or fatty acid translocase; FAT), liver fatty acids-binding protein (L-FABP) or fatty acid 
transport proteins (FATPs) (He, Lee, Febbraio, & Xie, 2011). Furthermore, FFAs may induce signaling 
via binding to specific fatty acid receptors. 
 
Free fatty acid receptors 
CD36 
CD36 (or fatty acid translocase; FAT; see Figure 6) is a ~88KDa glycoprotein which is expressed in a 
variety of cell types including endothelial cells, macrophages, dendritic cells, hepatocytes, 
adipocytes, cardiac and skeletal myocytes and epithelial cells. Besides its function in angiogenesis 
and as a pattern recognition receptor (PRR), CD36 is a translocase for long-chain fatty acids in 
adipocytes, myocytes, enterocytes, hepatocytes, Kupffer cells and hepatic stellate cells (He, Lee, 
Febbraio, & Xie, 2011; see also ) and might interact with other membrane receptors such as TLR, 
integrins and tetraspanins. Its expression is controlled by PPARγ, pregnane X receptor (PXR; liver-
specific) and liver X receptor (LXR; liver-specific) and is upregulated upon binding of a ligand 
(Silverstein, Li, Park, & Rahaman, 2010). Its expression is also increased significantly in hepatocytes 
by a high-fat diet, therefore contributing in the development of obesity and correlating positively 
with liver fat content in NAFLD patients. This is further supported by the 2.6-fold increase in CD36 
protein levels and the 1.7-fold induction of hepatic TG storage in HFD-fed mice (He, Lee, Febbraio, & 
Xie, 2011).  
Inhibition of CD36-facilitated uptake of lipids prevented lipotoxicity (Silverstein & Febbraio, 2009), 
further supporting its role in hepatic lipid uptake. In macrophages, CD36 is the major receptor 
responsible for the uptake of oxidized low-density lipoprotein (LDL) suggesting a role in the 
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progression of macrophages into lipid-laden foam cells in the development of atherosclerosis (He, 
Lee, Febbraio, & Xie, 2011). The binding of oxidized LDL by macrophages via CD36 leads to activation 
of the transcription factor NF-κB, partly through interaction with a TLR4/6 heterodimer (Stewart, et 
al., 2010). Activation of CD36 on endothelial cells results in activation of fyn-kinase and p38-MAPK 
(Silverstein, Li, Park, & Rahaman, 2010). 
 
Figure 6: Function and regulation of CD36 in hepatic lipid metabolism. Taken from: He, Lee, Febbraio, & Xie, 2011. 
 
Toll-like receptors 
Toll-like receptors (TLRs) are germ-line encoded pattern recognition receptors (PRRs) involved in the 
detection of conserved pathogen associated molecular patterns (PAMPs) and are mainly expressed in 
macrophages and adipocytes. They are type I transmembrane receptors with an extracellular 
leucine-rich repeat and a cytoplasmic Toll/interleukin-1 receptor homology domain. So far 13 
different TLRs have been identified in humans (Lee, Zhao, & Hwang, 2009). Their signaling is 
propagated through myeloid differentiation primary response gene 88 (MyD88), TRIF and TRAM 
which leads to activation of NF-κB. Ligand-mediated activation of CD36 by oxidized LDL (oxLDL) 
results in interaction of Lyn-kinase with CD36 and further in heterodimer formation of TLR4/6, which 
subsequently associate with CD36. This was shown by co-precipitation experiments performed in 
THP1 monocytes which were activated by oxLDL. Ligand internalization resulted in signaling from the 
CD36/TLR4/TLR6 complex leading to transcription of IL-1β, production of ROS via MyD88 and 
activation of NF-κB (Stewart, et al., 2010). 
TLRs were further shown to be able to bind saturated fatty acids including lauric and palmitic acid, 
and unsaturated fatty acids. The expression of TLR4 can be increased by high glucose and by oxLDL 
and the activation of TLR4 by saturated fatty acids (in macrophages and endothelial cells) leads to 
activation of NF-κB and the expression of IL-1, IL-6 and IL-8. Activation of TLRs occurs via formation of 
dimers, homodimers in the case of TLR3 and TLR4, and heterodimers in the case of TLR4/6, TLR1/2 
and TLR2/6. The latter might also form a complex with CD36. MyD88 dependent signaling 
(downstream of TLR) includes activation of p38MAPK and JNK and furthermore NF-κB and AP1, 
resulting in the expression of pro-inflammatory cytokines. MyD88-independent signaling leads to 
delayed activation of NF-κB. Whereas TLR2 and TLR4 can be activated by saturated fatty acids, like 
palmitic acid, the binding of n3-PUFAs, inhibits this SFA-induced activation. The n3-PUFA EPA was 
shown to inhibit SFA-induced expression of COX-2 in murine macrophages and TNFα in human THP1 
cells. Most probably the inhibitory effect of n3-PUFA on SFA-induced activation of TLRs, especially 
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TLR4, is by inhibiting TLR-dimerization and translocation into lipid rafts along with attenuation of 
adaptor (MyD88 and TRIF) recruitment (Lee, Zhao, & Hwang, 2009).  
TLRs are also expressed in liver cells; for example, TLR4 has been detected on all types of liver cells 
and is involved not only in the production of pro- and anti-inflammatory cytokines but also in the 
generation of ROS. TLR2 expression has been reported in hepatocytes, Kupffer cells, stellate cells and 
endothelial cells, and its activation leads to the production of pro-inflammatory cytokines (Gao, 
Jeong, & Tian, 2008). 
 
G-protein coupled receptors 
G-protein-coupled receptors (GPR) are seven-transmembrane-receptors which activate G-proteins. 
Activation results in downstream signaling via cAMP, phospholipase-C and mitogen-activated protein 
kinases (MAPKs). GPRs capable of binding FFA are distinguished by the length of FFA they bind; short-
chain FFAs can activate GPR41 and GPR43; medium-chain FFAs activate GPR84 and long-chain FFAs 
activate GPR40 and GPR120. The activation of the latter was shown by the increase in [Ca2+] and ERK 
activation upon stimulation of GPR120 by FFAs. This receptor is expressed in adipocytes, pro-
inflammatory macrophages and negligibly in muscle and hepatocytes.  
Stimulation of GPR120 with DHA or a synthetic agonist (GW9508) resulted in anti-inflammatory 
effects in macrophages shown by the inhibition of TAK1 phosphorylation and activation resulting in 
attenuation of both TLR (TLR2/3/4) and TNFα inflammatory signaling pathways. This most probably 
occurs via association of β-arrestin2 with the cytoplasmic domain of GPRs followed by receptor 
internalization. Upon internalization of the complex, β-arrestin2 associates with TAB1 thereby 
blocking TAB1-TAK1 association and inhibiting TAK1-mediated downstream signaling via IKKβ/NF-κB 
and JNK/AP1 (see Figure 7).  
 
Figure 7: possible mechanism of n3-PUFA-mediated attenuation of TLR and TNFR signaling via GPR120. Taken from: Oh, 
et al., 2010.  
GPR120 was further shown to play a role in n3-PUFA mediated insulin sensing as demonstrated by 
comparing obese WT with GPR120-KO mice. Both groups of mice became equally obese and insulin 
resistant, but n3-PUFA supplement improved insulin sensitivity in WT but not in GPR120-KO mice. 
Furthermore, HFD led to an increase in liver TGs, DAGs, SFAs, monounsaturated FAs and n6-PUFA in 
both groups of mice. n3-PUFA supplement reduced the increase of these lipids in WT but not in 
GPR120-KO mice. This points to an important role of GPR120 in n3-PUFA-mediated reversal of 
steatosis as this was also observed in several studies of obese patients. 
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In 3T3-L1 adipocytes, DHA stimulation of GPR120 led to an increased GLUT4 translocation to the cell 
surface and an increased glucose uptake. In the HFD or obese mouse model, GPR120 expression was 
induced in adipose-tissue-associated-macrophages as well as in Kupffer cells (Oh, et al., 2010). 
 
Peroxisome proliferator activated receptors  
Peroxisome proliferator activated receptors (PPARs) are nuclear receptors, which are capable of 
binding fatty acids, especially n3-PUFA, and eicosanoids and act as transcription factors in the cell. 
PPAR-mediated signaling is important in many cellular processes including differentiation, 
inflammation, cancer progression, insulin sensing and several metabolic disorders (Wall, Ross, 
Fitzgerald, & Stanton, 2010).  
Especially PPARα was shown to be activated by n3-PUFA in the liver which resulted in upregulation of 
genes involved in fatty acid and lipid metabolism (‘β-oxidation’) and suppression of TNFα and IL-6 
production. A further study demonstrated the prevention of steatohepatitis in mice infused with an 
PPARα agonist (Masterton, Plevris, & Hayes, 2010). 
 
Nucleotide-binding oligomerization domain proteins  
Nucleotide-binding oligomerization domain proteins (NODS) are cytoplasmic pattern recognition 
receptors that can be activated by saturated fatty acids (like lauric acid) resulting in the activation of 
the transcription factor NF-κB. Activation of NODs is thought to occur via homodimer formation and 
further recruitment of RICK/RIP2 which leads to the activation of NF-κB and subsequent 
inflammatory gene expression and activation of p38MAPK and JNK. As it is the case with TLRs, the 
SFA-induced activation of NF-κB and expression of IL-8 could be inhibited by n3-PUFA via binding to 
NODs (Lee, Zhao, & Hwang, 2009). 
 
TR4/NR2C2 
TR4/NR2C2 is a nuclear receptor which is expressed in testis, brain, kidney, liver and adipose tissue. 
FFAs and eicosanoids might bind TR4, thereby enhancing its activity as a transcription factor. TR4 
plays a role in the regulation of lipid metabolism and gluconeogenesis. Male TR4-KO mice were 
shown to be resistant against HFD-induced obesity, hepatic steatosis, white adipose tissue 
inflammation, insulin resistance and glucose intolerance. Their livers showed reduced lipid 
accumulation compared to controls. The expression of several genes in the livers of TR4-KO mice was 
reduced including CD36, Cidea and Cidec (cell death–inducing DFFA-like effector a and c, 
respectively), which are involved in triglyceride accumulation in lipid droplets and regulation of  
lipolysis, Mogat1 (monoacylglycerol O-acyltransferase 1), which is important in TG synthesis and 
PPARγ. In addition, TR4 also seems to regulate CD36 expression in macrophages (Kang, et al., 2011). 
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Inflammation and inflammation associated factors 
As already mentioned, inflammation seems to play an important role in the development and 
promotion of preneoplastic into neoplastic lesions and was therefore considered an ‘enabling 
characteristic’ for the development of cancer by Hanahan and Weinberg (Hanahan & Weinberg, 
2011). During inflammation, several factors are secreted for sustaining proliferation (growth factors), 
for circumventing apoptosis (survival factors), for angiogenesis and for the invasion of surrounding 
tissue and metastasis (matrix-modifying enzymes).  
Elevated levels of the pro-inflammatory cytokines TNFα, IL-6 and C-reactive protein (CRP) have been 
found in diabetic and insulin resistant patients. Furthermore, JNK and IKK were found to be 
upregulated and activated resulting in the phosphorylation of AP1 (cFos/c-Jun) and NF-κB, both of 
which activate inflammatory pathways. This activation of pro-inflammatory cytokines, kinases and 
transcription factors found already at an insulin resistant stage, which is often associated with or 
leads to NAFLD, might provide an explanation for the inflammation that results in the progression to 
NASH (Schenk, Saberi, & Olefsky, 2008). 
A second possibility for the activation of inflammatory pathways (NF-κB and JNK) is the production of 
ROS caused by the increased demands on the ER by the accumulation of intracellular lipids which is 
observed in obesity and NAFLD. Oxidative stress can further induce DNA damage and result in the 
generation of favorable genetic changes predisposing for the development of cancer (Toffanin, 
Friedman, & Llovet, 2010). 
Park and colleagues (Park, et al., 2010) showed that lipid accumulation furthermore results in a low-
grade inflammation leading to an increase in IL-6 and TNFα levels via production by adipocytes and 
Kupffer cells. Both cytokines are critical for the development of steatohepatitis and the induction of 
cell proliferation through JAK/STAT and ERK activation leading to HCC development (Toffanin, 
Friedman, & Llovet, 2010). In addition, the transcription factor STAT3 is not only involved in 
proliferation, but also in survival, angiogenesis, invasion and tumor promoting inflammation. In 
epithelial cells active STAT3 leads to the upregulation of chemokines for the attraction of immune 
and inflammatory cells. These cells further propagate STAT3 activation in epithelial cells through 
release of IL-6 (via JAKs; Janus kinases) and other cytokines (Li, Grivennikov, & Karin, 2011) as well as 
growth factors (via EGFR or VEGFR; Berasain, Castillo, Perugorria, Latasa, Prieto, & Avila, 2009). 
Especially tumor–associated macrophages (TAMs) might play a major role in this process as they are 
the most abundant type of immune cells in the tumor microenvironment and they may contribute to 
tumor growth not only by releasing factors like IL-6 or TNFα but also epidermal growth factor 
receptor (EGFR) ligands and CXCL12 (Berasain, Castillo, Perugorria, Latasa, Prieto, & Avila, 2009).  
Tumor growth is further supposed to be supported by IL-6 via the upregulation of anti-apoptotic 
factors like Bcl-xL or promitogenic factors like mcl-1, c-Fos, c-Myc and c-Jun. Under normal conditions 
STAT3 activity is regulated by suppressors of cytokine signaling (SOCS, especially SOCS3), which are 
activated by STATs, thereby forming a negative feedback loop. Hepatocyte specific deletion of SOCS3 
resulted in an increase in the number and size of tumors in DEN-induced HCC in mice. STAT3 activity 
in tumor cells promotes IL-6, IL-10 and VEGF production. Loss of SOCS3 expression in liver 
parenchymal cells showed enhanced liver regeneration and neoplastic transformation (Berasain, 
Castillo, Perugorria, Latasa, Prieto, & Avila, 2009). 
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Furthermore, the NF-κB and STAT3 pathways are cross-linked. NF-κB activation results in expression 
of IL-6 and COX2, which in turn lead to the activation of STAT3. Genes associated with tumor 
progression (Bcl-xL, survivin, mcl1, VEGF and MMP9) are regulated by both factors (Berasain, Castillo, 
Perugorria, Latasa, Prieto, & Avila, 2009). 
NF-κB gets activated in inflammatory cells either by activation of TLR and downstream signaling via 
MyD88 or by the pro-inflammatory cytokines TNFα and IL-1β. The importance of this transcription 
factor in tumor development was shown by several deletion or inhibition experiments. When IKKβ, 
the beta-subunit of the IκB kinase, was deleted in myeloid cells, a reduction in the number of tumors 
was found in a model of colitis-associated cancer. The deletion of IKKβ in Kupffer cells in a model of 
chemically induced HCC did also result in a reduction in tumor load, and further less production of 
TNFα, IL-6, HGF and inhibition of hepatocyte proliferation. In a mouse model of inflammation driven 
HCC, were multi drug resistance protein 2 (Mdr2) was knocked out resulting in the development of 
HCC at 8-10 months of age, the inhibition of the degradation of IκB (inhibitor of κB signaling) in the 
liver blocked tumor development (Berasain, Castillo, Perugorria, Latasa, Prieto, & Avila, 2009) most 
likely due to the TNF dependent activation of NF-κB for HCC development in this model and the 
possible requirement of NF-κB for the production of chemokines for the recruitment of inflammatory 
cells thereby maintaining a tumor promoting microenvironment (Grivennikov & Karin, 2011). The 
tumor promoting effect of NF-κB is most likely a result of its ability to prevent apoptosis and its 
regulation of genes involved in epithelial-mesenchymal transition (EMT) (Berasain, Castillo, 
Perugorria, Latasa, Prieto, & Avila, 2009). 
In contrast, hepatocyte-specific ablation of NF-κB signaling via deletion of the IKKβ gene resulted in a 
higher liver tumor incidence in DEN treated animals, most probably through enhanced JNK1 activity 
(Berasain, Castillo, Perugorria, Latasa, Prieto, & Avila, 2009) and increased DEN induced hepatocyte 
death resulting in increased compensatory proliferation of premalignant hepatocytes. In contrast to 
the Mdr2-knock-out model, the DEN induced HCC model is not TNF/TNFR dependent (Grivennikov & 
Karin, 2011). In the following, inflammation-associated factors important for this work are discussed 
more precisely.  
 
TNFα 
Tumor necrosis factor α (TNFα) is a pro-inflammatory and pleiotropic cytokine produced by different 
types of cells including macrophages, T-cells and adipocytes (Schenk, Saberi, & Olefsky, 2008; 
Toffanin, Friedman, & Llovet, 2010; Grivennikov & Karin, 2011). TNFα plays an important role as a 
tumor promoting agent in a variety of cancers including obesity-induced HCC and is needed for 
obesity-induced hepatosteatosis and steatohepatitis. Its cancer promoting characteristic is most 
likely caused by its ability to activate the transcription factors NF-κB and AP1 (cFos/c-Jun), both of 
which stimulate cell proliferation and survival. TNFα-mediated NF-κB activation further stimulates 
the production of ROS (Toffanin, Friedman, & Llovet, 2010) and the production of IL-6 (Park, et al., 
2010). This was also shown by the inhibition of TNFα which reduced the production of IL-6 
(Grivennikov & Karin, 2011).  
In hepatocytes, TNFα (together with IL-6, IL-1 and IFN-γ) stimulates the production of high levels of 
secreted PRRs (Gao, Jeong, & Tian, 2008). Its expression and protein levels were also found to be 
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elevated in normal liver and HCC of obese mice (Toffanin, Friedman, & Llovet, 2010; Park, et al., 
2010) and were increased in obese humans (Grivennikov & Karin, 2011). 
Lipid accumulation seems to be dependent on TNFα-mediated signaling, as TNFR1-KO mice showed 
reduced lipid accumulation and infiltration of macrophages and neutrophils induced by HFD 
(Toffanin, Friedman, & Llovet, 2010). Knock-out of TNFR1 furthermore resulted in the attenuation of 
HCC development and neutralization of TNFα using specific antibodies led to apoptosis of 
transformed hepatocytes, thereby supporting the assumption of its role in initiation and promotion 
of liver cancer (Berasain, Castillo, Perugorria, Latasa, Prieto, & Avila, 2009). 
TNFα is produced as a ~24kDA precursor, which, upon cleavage and shedding from the cell 
membrane (~17kDa), becomes active. This shedding event is catalyzed mainly by ADAM17/TACE 
(Becker, Gilles, Sommerhoff, & Zahler, 2002). 
 
COX-2 
Cyclooxygenase 2 or prostaglandin synthase 2 (PTGS2) catalyzes the conversion of unsaturated fatty 
acids into eicosanoids. Arachidonic acid (n6-PUFA) is the preferred substrate resulting in the 
production of pro-inflammatory eicosanoids (e.g.: 2-series prostaglandins, 4-series leukotrienes), 
whereas n3-PUFAs might act as competitive inhibitors (Lee, Zhao, & Hwang, 2009) and might also be 
converted to non- or even anti-inflammatory eicosanoids (3-series prostaglandins, 5-series 
leukotrienes) (Wall, Ross, Fitzgerald, & Stanton, 2010). Expression of COX2 can be enhanced in a 
TLR4-dependent manner, resulting in elevated PGE2 production. 
Prostaglandin E2 (PGE2) activates the expression of amphiregulin in colon cancer cells through 
elevation of cAMP levels and protein kinase A (PKA) activation and elevated levels were also found in 
liver cancer, probably contributing to carcinogenesis. Enhanced COX-2 expression was further 
observed in chronic liver inflammation, cirrhosis, human and experimental HCC. (Berasain, Castillo, 
Perugorria, Latasa, Prieto, & Avila, 2009).  
 
iNOS 
Inducible nitric oxide synthase (iNOS) is an enzyme expressed in macrophages that catalyzes the 
reaction of arginine with NADPH and oxygen to yield nitric oxide (NO) which is used in antimicrobial 
and antitumor activities. Upon excess production of NO tissue damage and inflammation develop. 
NO production via iNOS in macrophages is induced by LPS, TNFα or IFNγ via the transcription factor 
NF-κB. Saturated and unsaturated fatty acids were shown to induce NO production in murine 
macrophages at low concentrations mostly via activation of NF-κB in a time dependent manner (de 
Lima, de Sa Lima, Scavone, & Curi, 2006). 
 
IL-6  
Interleukin 6 (IL-6) is a cytokine that acts either directly via the binding to the IL-6 receptor and its co-
receptor gp130 or indirectly via the binding to the soluble form of the IL-6 receptor and further to 
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gp130 on the surface of a target cell via ‘trans-signaling’ (Li, Grivennikov, & Karin, 2011). Production 
of IL-6 can be induced by IL-1 and TNF signaling (Park, et al., 2010). This leads to downstream 
activation of STAT3 (Grivennikov & Karin, 2011). Il-6 can propagate inflammation and stimulates 
triglyceride secretion (Park, et al., 2010). 
Increased levels of IL-6 were found in obese mice (Toffanin, Friedman, & Llovet, 2010) (Park, et al., 
2010) and are associated with most HCC risk factors including hepatosteatosis, obesity and liver 
cirrhosis. IL-6 is a critical tumor promotor in HCC, as IL-6 deficient mice were resistant to HCC 
development when treated with diethylnitrosamine (DEN). The source of IL-6 in this model seemed 
to be Kupffer cells. These cells were further capable of binding IL-1α, which might have been released 
by damaged hepatocytes, leading to IL-6 production by Kupffer cells and resulting in proliferation of 
surviving hepatocytes which might harbor oncogenic mutations (Grivennikov & Karin, 2011). 
Furthermore, IL-6 KO mice showed reduced lipid accumulation and reduced infiltration of 
macrophages and neutrophils induced by HFD (Toffanin, Friedman, & Llovet, 2010).  
Male mice showed enhanced liver tumor development compared to females when treated with DEN 
and did also show higher levels of DEN-induced IL-6 production. This higher level could be decreased 
to the level observed in female mice upon treatment with an estrogen receptor agonist, indicating a 
suppressive function of estrogen signaling in IL-6 mediated inflammation in females (Berasain, 
Castillo, Perugorria, Latasa, Prieto, & Avila, 2009; Yang & Roberts, 2010).  
 
ADAM17/TACE 
Tumor necrosis factor alpha converting enzyme (TACE) or a disintegrin and metalloproteinase 
(ADAM) 17 is a zinc-containing sheddase (or α-secretase) that cleaves membrane-bound proteins 
from the cell surface thereby converting them into their mature, soluble form in a process termed 
‘ectodomain-shedding’. ADAMs are type-I transmembrane proteins which contain an inhibitory pro-
domain, a catalytic metalloproteinase domain, a disintegrin domain, an EGF-like domain, a 
transmembrane domain and a cytoplasmic domain (see Figure 8; Scheller, Chalaris, Garbers, & Rose-
John, 2011). ADAM17 has been found to be upregulated in chronic liver injury and human HCC tissue 
(Berasain, Castillo, Perugorria, Latasa, Prieto, & Avila, 2009) and also seems to play a role in 
development as knock-out mice show perinatal lethality due to defective cardiac valvulogenesis  
(Gutiérrez-López, et al., 2011). 
The first protein recognized to be shed by TACE was TNFα, but TGFα, HB-EGF, amphiregulin, p55-
TNFαR, p75-TNFαRII, IL-6R, HER-4, Notch, L-selectin, ICAM-1, VCAM-1, RANKL, CSF-1 and VEGFR2  
(Scheller, Chalaris, Garbers, & Rose-John, 2011) are also shed by TACE. These proteins are mostly 
shed at basal levels by other sheddases than TACE (e.g.: ADAM10, MMP7; Alvarez-Iglesias, Wayne, 
O'Dea, Amour, & Takata, 2005), but stimulation-induced increase in shedding is most likely due to 
TACE. Doedens et al. showed that TACE activity on murine monocytes (DRM cells) could be increased 
when cells were stimulated with a phorbol ester (PMA), which did not affect the abundance of TACE 
on the cell surface. Basal shedding which was not caused by TACE could also be detected (Doedens, 
Mahimkar, & Black, 2003). Alvarez-Iglesias et al. (Alvarez-Iglesias, Wayne, O'Dea, Amour, & Takata, 
2005) showed LPS-induced increase in TACE activity in a human monocytic cell line (THP1). LPS-
treatment did also not change TACE abundancy on the cell surface. The same group showed an 
  Introduction   
21 
 
increase in TACE activity on MonoMac-6 cells upon treatment with PMA. Scott et al.  (Scott, et al., 
2011) found LPS-induced and ROS-dependent TACE activation without altering TACE abundancy on 
the cell membrane in primary human monocytes. 
ADAM17/TACE is produced as a zymogen which has to be activated by the removal of an inhibitory 
cysteine switch, which inhibits TACE activity at the catalytically active, zinc-ion containing site (Scott, 
et al., 2011). Control of proteolytic cleavage might also occur via spatial segregation of the enzyme 
and its substrates. The covalent modification of the inhibitory pro-domain by oxidation via ROS (and 
maybe - although unlikely - RNS) has also been postulated, as has the presence of TACE inhibitors 
complexed with TACE in unstimulated cells (Doedens, Mahimkar, & Black, 2003). In primary human 
cells the pro-domain is most likely removed intracellularly, therefore pro-domain removal at the site 
of action, at the cell membrane, seems unlikely (Scott, et al., 2011).  Gutiérrez-López et al. showed 
that in human leukocytes and endothelial cells the tetraspanin CD9 interacts with TACE and this 
interaction results in reduced TACE-mediated shedding of TNFα and ICAM-1. This could be abrogated 
by treatment with PMA, which resulted in dissociation of CD9 with TACE (Gutiérrez-López, et al., 
2011). 
Signaling involved in direct TACE activation seems to be dependent on p38MAPK, which gets 
activated by ROS, at least in primary human monocytes. Furthermore, there seems to be a threshold 
of p38MAPK activation below which TACE activity does not increase (Scott, et al., 2011) 
It is now suggested, that full activation of TACE requires all steps including expression, translocation 
to the cell membrane, disulfide bridge rearrangement, spatial distribution and abrogation of 
inhibition. As all this is concluded from in-vitro studies, the exact in-vivo regulation of TACE has still 
to be fully elucidated. This might still take some time as appropriate in-vivo models, like mouse 
models, might show different substrate specificities, as for example murine IL-6R is shed by ADAM10, 
whereas it is shed by ADAM17/TACE in humans (Scheller, Chalaris, Garbers, & Rose-John, 2011).  
 
 
Figure 8: Schematic structure and domains of ADAM17/TACE. Taken from: Scheller, Chalaris, Garbers, & Rose-John, 2011. 
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Aims of the thesis 
 
Hepatocellular carcinoma is one of the most common causes of cancer related death worldwide and 
develops in the background of chronic liver inflammation which might be caused by a fatty liver. As 
free fatty acids (FFA) levels are increase in individuals suffering from obesity and non-alcoholic fatty 
liver disease (NAFLD) we were interested in the role FFAs play in the onset of liver inflammation. 
Therefore we studied the effects of FFAs on transcription, kinase phosphorylation, protein secretion 
and activity and the in-vivo effects of oil-treatment on rats. 
The aims of this thesis were: 
(i) To analyze the viability of primary rat liver cells in response to increasing concentrations 
of α-linolenic acid (ALA), as this FFA is reported to have anti-inflammatory properties. 
(ii) To study the secretion of tumor-necrosis-factor-α from primary rat liver cells treated 
with FFAs. TNFα levels are increased in diet-caused obesity which causes hepatosteatosis 
and steatohepatitis and the cytokine further acts as a tumor promoting agent. 
(iii) To examine the possible involvement of p38MAPK and Erk, both of which are kinases 
involved in stress induced pathways, in FFA-mediated inflammatory signaling. 
(iv) Investigation of changes in the expression of the inflammation-associated genes iNOS, 
COX-2, TNFα and IL-6 in cells treated with free fatty acids. 
(v) Inhibition of CD36, a translocase and receptor of free fatty acids and examination of the 
resulting changes in gene expression and signaling in primary rat endothelial cells and 
Kupffer cells. 
(vi) Establishment of a real-time enzyme assay measuring the activity of ADAM17/TACE on 
live primary rat Kupffer cells using a fluorogenic substrate, as this specific enzyme is 
responsible for the conversion of a variety of proteins involved in inflammatory 
responses and is reported to be overexpressed in HCC. 
(vii) Comparison of in vivo changes in oil-treated rats and water-treated controls with a 
special focus on the levels of free fatty acids and alterations in total gene expression in 
the liver.  
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Materials and methods 
 
Materials 
Reagent Supplier 
Acrylamide Biorad (Hercules, CA) 
Agarose Biozym (Hessisch Oldendorf, Germany) 
α-linolenic acid Sigma (St.Louis, MO) 
Ammonium-persulfat (APS) Sigma (St. Louis, MO) 
Ascorbat Merck (Darmstadt, Germany) 
50 bp DNA marker Fermentas (Burlington, Ontario) 
5x Biorad protein assay Biorad (Hercules, CA) 
Bovine serum albumin (BSA) Sigma (St. Louis, MO) 
Bovine serum albumin (BSA), fatty acid free Sigma (St. Lois, MO) 
Bromophenol blue Sigma (St. Louis, MO) 
Calciumchloride Merck (Darmstadt, Germany) 
Chloroform Merck (Darmstadt, Germany) 
Collagenase, Typ2 CLS2 Worthington (Lakewood, NJ) 
Dabcyl-TNFα-Edans Bachem (Bubendorf, Switzerland) 
10mM dNTP mix Fermentas (Burlington, Ontario) 
Dexamethasone Serva (Heidelberg, Germany) 
Dimethylsulfoxide (DMSO) Sigma (St. Louis, MO) 
ECL-Plus Western Blotting Detection Kit GE Healthcare (Uppsala, Schweden) 
Ethylenediaminetetraacetic acid (EDTA) Sigma (St. Louis, MO) 
Ethanol Merck (Darmstadt, Germany) 
Ethidiumbromide Sigma (St. Louis, MO) 
Fetal calf serum (FCS) PAA (Pasching, Austria) 
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Gentamycin Serva (Heidelberg, Germany) 
Glucagon Sigma (St. Louis, MO) 
Glucose Merck (Darmstadt, Germany) 
Glutamax Invitrogen (Carlsbad, California) 
Glycerin Sigma (St. Louis, MO) 
Glycin Sigma (St. Louis, MO) 
Heparin sodium salt Serva (Heidelberg, Germany) 
HEPES Sigma (St. Louis, MO) 
Hexamer Primer Fermentas (Burlington, Ontario) 
Insulin Sigma (St. Louis, MO) 
Isopropanol Merck (Darmstadt, Germany) 
KH2PO4 Merck (Darmstadt, Germany) 
Linoleic acid Sigma (St.Louis, MO) 
Lipofectamin Invitrogen (Carlsbad, California) 
Lipopolysaccharid (LPS): Sigma (St. Louis, MO) 
6x loading dye Fermentas (Burlington, Ontario) 
Methanol Merck (Darmstadt, Germany) 
β-Mercaptoethanol Sigma (St. Louis, MO) 
5x MMLV Buffer  Fermentas (Burlington, Ontario) 
MMLV reverse transcriptase Fermentas (Burlington, Ontario) 
NaCl Merck (Darmstadt, Germany) 
Na-Deoxycholat Sigma (St. Louis, MO) 
Na2HPO4 Merck (Darmstadt, Germany) 
NaH2HPO4*2H2O Merck (Darmstadt, Germany) 
NaOH Merck (Darmstadt, Germany) 
Na3VO4 Merck (Darmstadt, Germany) 
NP-40 Sigma (St. Louis, MO) 
  Materials and methods   
25 
 
Nuclease free water Promega (Madison, WI) 
Palmitic acid Sigma (St. Louis, MO) 
Penicillin G sodium salt Sigma (St. Louis, MO) 
Penicillin-streptomycin PAA (Pasching, Austria) 
Percoll GE Health care (Uppsala, Schweden) 
PMSF (protease inhibitor) Roche (Basel, Switzerland) 
Potassium chloride, KCl Merck (Darmstadt, Germany) 
Pyruvat Sigma (St. Louis, MO) 
Ponceau S Sigma (St. Louis, MO) 
Skim milk Sigma (St. Louis, MO) 
Sodium dodecyl sulfate (SDS) Sigma (St. Louis, MO) 
Sulfosuccinimidyl oleate sodium (SSO) Santa Cruz Biotechnology (Santa Cruz, CA)
Streptomycin sulfate salt Sigma (St. Louis, MO) 
TAPI-2 Enzo Life Sciences (Farmingdale, NY) 
Taqman Gene Expression Assays  Applied Biosystems (Carlsbad, California) 
TaqMan® universal master mix  Applied Biosystems (Carlsbad, California) 
TEMED (N,N,N’,N’-Tetramethylendiamine) Sigma (St. Louis, MO) 
TMB Substrate Kit Thermoscientific, Rockford 
TriFast Peqlab (Erlangen, Germany) 
Triiodthyronin Serva (Heidelberg, Germany) 
Tween 20 Biorad (Hercules, CA) 
Trizma base Sigma (St. Louis, MO) 
Trypan blue Invitrogen (Carlsbad, California) 
Table 1: Reagents and supplier. 
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Buffers and solutions 
 
20mM Tris.HCl pH 7.4 
 
50mM Tris.HCl pH 7.4 
 
250mM Tris.HCl pH 7.4 
 
ADAM17/TACE Activity Substrate solution 
Dabcyl-TNFα-Edans (DABCYL-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-Arg-EDANS Trifluoroacetate salt; 
Bachem): 1mg of Dabcyl-TNFα-Edans was dissolved in 635,4µl 20mM Tris.HCl pH 7.4 to yield a 1mM 
stock solution which was stored at -20°C until used. 
 
ADAM17/TACE Activity Inhibitor solution 
TAPI-2: (IC3; N-(R)-(2-(Hydroxyaminocarbonyl)methyl)-4-methylpentanoyl-L-t-butyl-glycine-L-alanine 
2-aminoethyl amide; Enzo Life Sciences): 1mg of TAPI-2 was dissolved in 481,6µl 20mM Tris.HCl 
pH7.4 to yield a 5mM stock solution which was stored at -20°C until used. 
 
1x Assay Buffer for ELISA 
5 g BSA, 0.5 ml Tween 20 in 1 liter 1xPBS pH 7.4 
 
BSA buffer pH 7.4 
contains per liter: 8.3 g NaCl, 0.5 g KCl, 2.4 g HEPES, 6 ml 1M NaOH, 1 g Bovine Serum Albumin (BSA) 
96%, 10 mg Gentamycin 
 
Collagenase buffer pH 7.5 
contains per liter: 6.8g NaCl, 0.4g KCl, 1g glucose, 1g HEPES, 60mg penicillin G sodium salt, 100mg 
streptomycin sulphate salt, 110mg pyruvat, 294mg CaCl2, 0.0013% BSA, 0.7nM Glucagon, 10nM 
Triiodthyronin, 6.7nM Insulin, 100nM Dexamethasone, 400mg collagenase 
 
Hank’s buffered salt solution (HBSS) for ADAM17/TACE activity assay 
0.137M NaCl, 5.4mM KCl, 0.25mM Na2HPO4, 0.44mM KH2PO4, 1.3mM CaCl2, 1.0mM MgSO4, 4.2mM 
NaHCO3 
 
10x HBSS buffer for HC-Percoll solution 
80g NaCl, 4g KCl, 2g MgSO4.7H2O, 0.6g KH2PO4, 10g Glucose, 0.6g Na2HPO4.2H2O, in 1 liter ddH2O  
 
Laemmle electrophoresis buffer 
3 g Trizma Base, 14.4 g Glycin, 1 g SDS in 1 liter ddH2O 
 
5x reducing Laemmle sample loading buffer 
300mM Tris.HCl pH 6.8, 60% Glycerol, 10% SDS, 0.025 % Bromophenol blue, 7% β-Mercaptoethanol 
 
1x PBST 
1x PBS (pH 7.4) supplemented with 0,05% Tween 20 
 
Percoll solutions for NPC purification 
Stock Percoll Solution (SPS) contains 90% Percoll and 10% 10x PBS 
50% Percoll-solution: 50% SPS + 50% PBS  
25% Percoll-solution: 25% SPS + 75% PBS 
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Percoll solution for HC purification 
Stock Isoosmotic Percoll (SIP) contains 90% Percoll and 10% 10x HBSS 
 
Perfusion buffer pH 7.4 
contains per liter: 6.8 g NaCl, 0.4 g KCl, 1g glucose, 1g HEPES, 200µl 4N NaOH, 60mg penicillin G 
sodium salt, 100mg streptomycin sulphate salt, 12.4 mg heparin sodium salt, 110mg pyruvat, 
0.0013% BSA, 0.7nM Glucagon, 10nM Triiodthyronin, 6.7nM Insulin, 100nM Dexamethasone. 
 
1x Phosphate Buffer Saline (PBS) pH 7.4 
5.68g NaCl, 1.44g Na2HPO4, 2.96g NaH2PO4.2H2O in 1 liter  
 
10x Ponceau-S-Solution  
2% Ponceau, 10% acetic acid in 1x PBS 
 
RIPA Buffer 
500mM NaCl, 50mM Trisma base pH 7.4, 0.1% SDS, 1% NP-40, 0.5% Na-Deoxycholat, 1mM Na3VO4, 
1mM PMSF 
 
1x TBST 
1x TBS (pH 7.4) supplemented with 0.05% Tween 20 
 
Transfer buffer 
3 g Trizma base, 14.4 g Glycin, 5% Methanol in 1 liter of ddH2O 
 
Tris based buffer 
50mM Tris.HCl pH 8.0; 100mM NaCl; 10mM CaCl2.2H2O; 0.01% Triton-X-100 
 
1x Tris-borat-EDTA buffer (TBE) 
10.8 g Trizma base, 5.5 g boric acid, 4 ml 0.5 M EDTA (pH 8) in 1 liter of ddH2O 
 
1x Tris buffered saline (TBS) pH 7.4 
0.05 M Trizma base, 0.3 M NaCl 
 
1x Wash Buffer for ELISA 
1x PBS (pH7.4) supplemented with 0.05% Tween 20 
 
Western blot stripping solution pH 2.2 
15g Glycine, 10ml 10% SDS (or 1g SDS), 10ml Tween 20 in 1 liter of ddH2O  
 
 
Media 
 
HC culture medium 
Williams-Medium E (Invitrogen, San Diego, CA), 10µl/ml Glutamax, 20mM HEPES, 10µg/ml 
Gentamycin, 0.0013% BSA, 0.7nM Glucagon, 10nM Triiodthyronin, 6.7nM Insulin, 100nM 
Dexamethasone, 0.151mM Ascorbat. 
 
HC plating medium 
HC culture medium supplemented with 10%FCS 
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NPC medium 
RPMI1640 (Sigma), 10%FCS, 0.01g Gentamycin per liter medium 
 
Kupffer cell medium 
RPMI1640 (Sigma), 10%FCS, 0.01g Gentamycin per liter medium 
 
Endothelial cell medium 
EBM-2 + EGM-2MV (Lonza, Basel, Switzerland) 
 
Washing medium 
Minimum essential medium (Sigma St. Louis, MO) supplemented with: 20mM HEPES, 10µg/ml 
Gentamycin, 10µl/ml Glutamax 
 
ECII medium 
RPMI1640 (Sigma), 20% FCS, 170µM Penicillin, 70µM Streptomycin and 1µM Dexamethasone 
 
HAM’s tissue culture medium and Leibovitz L-15 medium 
Were kind gifts from the laboratory of Dr. Brigitte Marian. 
 
Cell culture 
Animals and in vivo treatment 
Wistar rats were kept at the ‘Division for Decentralized Biomedical Facilities of the Medical University 
of Vienna’ under standard SPF conditions. Female wistar rats (8-10 weeks of age) were treated once 
or daily on 6 consecutive days with a dose of 1ml Mazola® oil per 100g body weight by gavage. 
Control groups were given the same volume of water by gavage. Rats were sacrificed 20 hours after 
the last administration. 
Collagenase perfusion of the rat liver 
The livers of untreated or oil-treated rats were perfused with collagenase according to the technique 
of Seglen (Seglen, 1976) with modifications described (Parzefall, Monschau, & Schulte-Hermann, 
1989; Pertoft & Smedsrod, 1987). Perfusions were kindly performed by Dr. Sandra Sagmeister, Mag. 
Therese Böhm and Marzieh Nejabat, MD. Wistar rats were anesthetized with a chlorinated 
hydrocarbon of similar vapour pressure as isoflurane. Therefore the animals were gased with a 
mixture of dinitrogen oxide (N2O) at 1200 ml/min and oxygen at 800 ml/min which is passed through 
a vaporizer filled with a chlorinated hydrocarbon and set to a concentration of 4 %. The abdomen 
was cut open, a cannula was inserted into the portal vein and ligated. The lower vena cava was 
immediately cut and perfusion was started. First perfusion buffer was pumped through the liver with 
a flow rate of 15 ml/min. After approximately ten minutes the liver was freed of blood. The perfusion 
continued with pumping collagenase buffer with a flow rate of 10 ml/min through the liver. The 
temperature of both buffers was 37°C. On average the liver tissue was sufficiently decomposed after 
10 minutes. The softened liver was excised and put into ice-cold washing medium (adapted from 
Sagmeister, 2009). The liver capsule was cut open with sterile scissors and cells were collected in 
washing medium by gentle shaking of the capsule. The gained cell suspension was filtered through a 
105µm mesh (Polyester precision mesh) to get rid of non-separated cells. This was repeated 
approximately 4 times using a total volume of 100ml washing buffer until no more cells could be 
collected by shaking the capsule.  
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Purification of primary rat non-parenchymal cells (NPCs) 
The filtered cell suspension was centrifuged for 5 min at 55xg and 4°C. The pellet was used for 
purification of hepatocytes, the supernatant was centrifuged for 10min at 1200xg and 4°C to collect 
NPCs. The resulting pellet was resuspended in 10ml of BSA buffer and carefully pipetted onto a two-
step discontinuous NPC percoll gradient (20ml of a 50% Percoll underneath 19ml of a 25% Percoll) 
which was centrifuged at 1200xg for 30min and 4°C without any acceleration or deceleration, to 
avoid any mixing of the two Percoll solutions. The fraction containing NPCs located at the interface of 
the 25% and 50% Percoll solutions was collected, diluted with BSA buffer and centrifuged for 10min 
at 1200xg and 4°C. The resulting pellet was resuspended in NPC medium and cells were counted and 
viability was determined in a Neubauer counting chamber.  
 
Purification of primary rat hepatocytes 
The pellet obtained after the first centrifugation step was resuspended in 20ml washing medium and 
centrifuged for 5min at 300rpm (=17xg) to get rid of residual collagenase buffer. The resulting pellet 
was resuspended in 25ml washing medium and mixed with 24ml SIP. This Percoll-cell suspension was 
centrifuged for 10min at 550rpm and 4°C. The supernatant was discarded and the pellet was 
resuspended in 40ml washing medium followed by centrifugation for 2min at 550rpm and 4°C to get 
rid of residual Percoll. The pellet was resuspended in 25ml washing medium and centrifuged for 5min 
at 300rpm and 4°C. The pellet was resuspended in 20ml washing medium and centrifuged for 5min at 
300rpm and 4°C. Following this, the pellet was resuspended in HC plating medium and counted and 
viability was determined in a Neubauer counting chamber. 
 
Determination of cell viability 
Viability of primary rat liver cells was determined by the trypan blue dye exclusion test after 
purification in a Neubauer counting chamber. Trypan blue stained cells were considered dead 
because of damaged cell membranes allowing the dye to enter the cell. 50µl of cell suspension were 
mixed with 50µl of trypan blue dye and vital and dead cells were counted. Only the vital cell count 
was used for calculation of cells to be plated.  
 
Culture of primary rat non-parenchymal cells 
NPCs were plated onto collagen coated dishes after counting and allowed to adhere for 2h in NPC 
medium. Cells were checked for adherence visually and washed once with 1x PBS to get rid of 
nonattached cells and cell debris. This was followed by treatment of the cells. 
If desired, NPCs were separated into Kupffer cells and endothelial cells by selective adherence. The 
NPC fraction was therefore plated onto non-coated dishes and Kupffer cells were allowed to adhere 
for 30-40 min. After this period of time the supernatant containing endothelial cells was collected, 
centrifuged for 5 min at 1000rpm and resuspended in endothelial cell medium. Following counting of 
endothelial cells they were plated onto collagen-coated dishes. 
 
Culture of primary rat hepatocytes 
Percoll-purified primary rat hepatocytes were plated onto collagen coated dishes and allowed to 
adhere for 2h in hepatocyte plating medium. Cells were checked for adherence visually followed by 
treatment of the cells. 
 
Culture of cell lines 
THP1 cells were kept in RPMI 1640 medium supplemented with 10% fetal calf serum at 37°C and 5% 
CO2
 in a humidified atmosphere. Medium was changed every 2-3 days and cells were passaged every 
4-6 days. 
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ECII cells were kept in RPMI 1640 medium supplemented with 20% FCS, 170µM Penicillin, 70µM 
Streptomycin and 1µM Dexamethasone at 37°C and 5% CO2 in a humidified atmosphere on collagen-
coated dishes. 
 
Treatment of cells with free fatty acids 
Free fatty acids were dissolved in ethanol upon arrival and stored as 50mM stocks solutions in liquid 
nitrogen to prevent oxidation. Appropriate volumes of stock solution were dissolved in the 
respective treatment media (HC culture medium supplemented with 0.1% BSA for HCs, NPC medium 
for NPCs, RPMI 1640 supplemented with 10% FCS for THP1 monocytes, ECII medium for ECII cells) and 
solutions were dispersed by sonication.  
 
FFA concentration EtOH 
500µM 1% 
250µM 0.5% 
100µM 0.2% 
75µM 0.15% 
50µM 0.1% 
25µM 0.05% 
10µM 0.02% 
1µM 0.002%
Table 2: FFA concentrations used for cell treatment and their corresponding concentrations of ethanol in the medium. 
 
Treatment of cells with Sulfosuccinimidyl oleate sodium (SSO) 
Cultured primary rat non-parenchymal cells were treated with 500µM SSO for 30min followed by 
addition of palmitic acid (10µM final concentration), ethanol (0.02% final concentration) or LPS (final 
concentration 10ng/ml). The time point of PA, EtOH or LPS treatment, respectively, was considered 
as time point = 0. DMSO served as solvent control as SSO was dissolved in DMSO and stored as stock 
solution of 250mM.  
 
Cytotoxicity assay 
Cell viability was measured by uptake of neutral red into lysosomes of viable cells in 24-well plates 
(BD Falcon; 2x105 of primary HCs, THP1, ECII per well, respectively) or 12-well plates (BD Falcon; 
1.5x106 of NPCs per well). After plating cells were allowed to attach for 2h. This was followed by 
incubation for 24h with medium containing 0.1% BSA (HCs) or 10% FCS (NPCs, THP1) or 20% FCS 
(ECII) and varying concentrations of free fatty acids (ranging from 0 - 500µM) or the corresponding 
ethanol concentrations (see Table 2). Cells were incubated with their respective treatment medium 
(without FFAs, but) supplemented with 50mg/L neutral red. Each neutral red solution was incubated 
at 37°C for 30min and filtered before application to get rid of non-dissolved neutral red crystals. After 
a 2h incubation period cells were washed twice with 1xPBS and lysed with a 1% acetic acid solution in 
70% ethanol for 10min. Absorbance of 100µl of each well’s supernatant was measured at 562nm. 
Cell viability of each treatment was assayed in triplicate and calculated as fold corresponding ethanol 
control. 
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Detection of mRNA 
RNA isolation using the TriFast reagent 
RNA isolation using the TriFast reagent is based upon the method of Chomczynski & Sacchi 
(Chomczynski & Sacchi 1987). Medium was sucked off and cells were washed once with 1xPBS. 
TriFast reagent was added to each well (usually 300µl for a 6-well) and cells were scraped off. The 
TriFast lysed cell suspension was transferred into 2ml Eppendorf tubes and stored at -20°C or 
immediately used for RNA isolation. Chloroform (1/5 of the used TriFast volume) was added and 
tubes were gently inverted for 15sec and allowed to rest for 10min at room temperature. Tubes were 
then centrifuged for 15min at 12000xg and 4°C. The upper, aqueous phase was transferred into a 
new tube, isopropanol (1/2 of the used TriFast volume) was added and RNA was precipitated over 
night at -20°C. On the following day the tube was centrifuged for 8min at 12000xg and 4°C to collect 
the RNA. The supernatant was discarded and the pellet was washed gently with 70% ethanol. The 
pellet was again centrifuged for 8min at 12000xg and 4°C and the residual ethanol was discarded. 
The pellet was allowed to dry and dissolved in DEPC-treated water. The RNA concentration was 
measured with a Nanodrop ND-1000 spectrophotometer. Samples were stored at -80°C until used.  
 
RNA isolation using miRNeasy Mini kit (Qiagen) 
RNA of hepatocytes and non-parenchymal cells of oil-treated and control rats was isolated using the 
miRNeasy Mini kit (Qiagen). First, cells (15x106 NPCs or 2x106 HCs, respectively) were resuspended in 
700µl QIAzol Lysis Reagent (Quiagen) and homogenized by centrifugation for 2 min at 13000xg in 
QIAshredder homogenizer spin columns (Qiagen). The lysed and homogenized flow-through was 
stored at -80°C until used for RNA isolation. 
For RNA isolation, samples were thawed at room temperature. 140µl of chloroform were added to 
each sample and tubes were shaken vigorously for 15 sec. Tubes were placed at room temperature 
for 3 min followed by centrifugation for 15 min at 12000xg and 4°C. The upper, aqueous phase was 
transferred into a new tube, 1.5 volumes of ethanol were added and mixed by pipetting. The samples 
were loaded into RNeasy Mini columns (Qiagen) and centrifuged for 15 sec at 13000xg and room 
temperature and flow-through was discarded. Columns were washed once with 700µl of RWT buffer 
(Qiagen) and twice with 500µl RPE buffer (Qiagen). This was followed by elution of the RNA by 
addition of 30µl of RNAse-free water (Qiagen) to each column and centrifugation for 1 min at 
13000xg. Isolated RNA samples were stored at -80°C until used. 
 
Reverse transcription PCR 
For reverse transcription of RNA into cDNA 1µg of RNA was filled up with DEPC-treated water to a 
total volume of 15µl. 0.625µl of random hexamer primer were added and samples were heated for 
2min at 72°C. To each sample 9.375µl of mastermix (see Table 3) were added and samples were 
incubated for 1 hour at 42°C for reverse transcription, followed by incubation for 5min at 94°C to 
inactivate the MMLV reverse transcriptase. Samples were then filled up to a total volume of 100µl 
with DEPC-treated H2O and stored at -20°C. 
 
Reagent Volume [µl]
5x MMLV buffer 5 
10mM dNTPs 1.5625 
RNAse Inhibitor 0.625 
DEPC-treated H2O 1.1875 
MMLV reverse transcriptase 1 
Total 9.375 
Table 3: Mastermix for reverse transcription of one RNA sample. 
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Polymerase chain reaction (PCR) 
1µl of cDNA was mixed with 24µl of mastermix (see Table 4). PCR was performed in a thermocycler 
(C1000, Thermal Cycler, Biorad) using primers, temperatures and durations listed in Table 5 and 
Table 6. 
 
Reagent Volume [µl]
Forward primer 1 
Reverse primer 1 
DEPC H2O 9.5 
2x mastermix 12.5 
Total 24 
Table 4: Mastermix for standard PCR. 
Stage Temperature Duration
Cycle 1 95°C 5 min 
Cycle 2   
- Denaturation 94°C 30 sec 
- Annealing 60°C 30 sec 
- elongation 72°C 30 sec 
Cycle 3 72°C 7 min 
Table 5: Cycles for standard PCR, for the amplification of cDNA in hepatocytes cycle 2 was repeated 35-times, in 
endothelial and Kupffer cells 40-times, if not stated otherwise. 
Primer Sequence Product size 
CD36-for 5’ GTA TGG TGT GCT GGA CAT TG 3’ 162bp 
CD36-rev 5’ CCA GTT ATG GGT TCC ACA TC 3´ 
β-actin-for 5’- ATG TTG CCC TAG ACT TCG AG – 3’ 175bp 
β-actin-rev 5’- TCA TGG ATG CCA CAG GAT TC  - 3’
Table 6: Primers used for standard PCR (Eurogentec). 
Quantitative real-time PCR (qRT-PCR) 
For qRT-PCR analysis 1µl cDNA was mixed with 11.5µl of qRT-PCR mastermix (see Table 8). 12µl of 
this mixture were transferred into a Fast Optical 96-Well Reaction Plate (Applied Biosystems). All 
samples were measured in duplicates in an ABI-PRISM 7500 Sequence detection system (Applied 
Biosystems).  
 
Stage Temperature Duration Cycles
1 50°C 2 min 1 
2 95°C 10 min 1 
3 95°C 15 sec 40 
 60°C 1 min 40 
Table 7: Cycles for qRT-PCR 
 
The Ct-values of each measured probe were normalized to β-2-microglobulin. The resulting gene 
expression levels were calculated according to the ΔΔ-Ct method (Applied Biosystems). 
 
Reagent Volume [µl]
Primer 0.625 
DEPC-treated H2O 4.625 
2x GE mastermix 6.25 
total 11.5 
Table 8: Mastermix for qRT-PCR. 
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Taqman Gene Expression Assay Assay ID 
COX-2 Rn01483828_m1
iNOS Rn00561646_m1
TNFα Rn99999017_m1
IL6 Rn99999011_m1
β2-Microglobulin Rn00560865_m1
Table 9: Taqman Gene Expression Assays used for qRT-PCR. 
 
Agarose-gel electrophoresis 
RNA samples from in-vivo treated rats or PCR products were run on a 1.5% agarose gel to estimate 
the integrity of the RNA visually or for densitometry of PCR-products, respectively. The desired 
amount of agarose was dissolved in 1xTBE and heated in a microwave. The agarose gel was poured 
into a gel apparatus (BioRad) together with ethidium bromide (3.5µl - 7µl depending on the volume 
of the agarose gel). After the gel solidified, 1µl of each sample (diluted with 4µl of DEPC-treated 
water and 1µl of a 6x loading dye) was loaded onto the gels. Samples were run for approximately 25 
min at 80V. The separated bands were visualized by UV light in a Geldoc2000.   
 
Bioanalyzer 
Isolated RNA samples from in-vivo treated rats were analyzed on RNA 6000 nanochips (Agilent 
Technologies) in an Agilent 2100 Bioanalyzer (Agilent Technologies) for RNA integrity before having 
them analyzed on a RNA-mircoarray. Only RNAs with integrity units (RIN) above 8 were used for the 
mircoarray.  
Analysis of RNA samples was done according to manufacturer’s instructions as described in Agilent’s 
RNA 6000 Nano Kit Quick Start Guide. Briefly, the RNA 6000 Nano gel was filtered through a spin 
filter and aliquoted. The RNA 6000 Nano dye was equilibrated to room temperature for 30min, 
vortexed, spun down and 0.5µl of dye were added to 32.5µl of filtered gel. The solution was vortexed 
and centrifuged for 10min at 13000xg and room temperature. 9µl of gel-dye mix was added to a RNA 
6000 Nano chip. Then, 5µl of RNA 6000 Nano marker were added to each sample well and to the 
ladder well, respectively. 1µl of ladder was added to the ladder well and 1µl of sample was added to 
each sample well, respectively. The chip was vortexed for 1min in the IKA vortexer at 2400rpm. The 
chip was transferred to the Agilent 2100 Bioanalyzer and analysis was started.   
 
RNA-microarray Array Transcriptome Analysis 
RNA-microarray Array Transcriptome Analysis using the GeneChip Rat Genome 230 (Affymetrix) was 
kindly carried out by Markus Jeitler, BSc. at the Core Facility Genomics of the Medical University of 
Vienna led by Dr. Martin Bilban. 
 
Detection of protein 
Protein isolation 
The medium was removed and the cells were washed once with ice-cold 1xPBS. Then the cells were 
scraped off in RIPA buffer (75 µl per 6-well) on ice to be able to detect phosphorylation of proteins. 
The samples were homogenized by sonication for 1sec (Bandelin electronic sonopuls) and 
centrifuged for 5 min at 15000xg and 4 °C. Protein samples were stored at -20 °C. 
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Determination of protein concentrations 
Protein concentration was determined according to Bradford using a 1:5 dilution of 5x Protein assay 
reagent (Biorad). To estimate the concentrations of the protein samples a standard curve was done 
using BSA as standard protein. Concentrations ranged from 0 – 6µg/µl were used for the standard 
curve. 1µl of each sample was added to 9µl of water in a 96-well. 100µl of 1x Protein assay reagent 
was added to each standard and sample well and the absorbance at 595nm was measured in a plate 
reader (Tecan infinite 200Pro using Tecan i-control 1.7.1.12 software). The concentration of each 
sample was calculated from duplicates. 
 
SDS-PAGe 
Equal amounts of each protein sample were filled up with RIPA buffer to 10µl. 2µl of 6x Laemmle 
sample loading buffer were added and samples were heated for 5min at 95°C. Then samples and the 
protein ladder (PageRuler™ Plus Prestained Protein Ladder, Fermentas) were loaded onto 12% SDS-
polyacrylamide gels and separated according to their molecular weight. Gel electrophoresis was 
performed at 60V for focusing proteins in the stacking gel and changed to 120V upon beginning of 
separation in the resolving gel. Stacking and resolving gels were mixed as described in the tables 
below.  
Stacking gel volume for 2 gels [ml] 
Acryamide/Bisacrylamide (40%) 0.5 
1 M Tris pH 6.8 0.625 
10% SDS 0.05 
H2O 3.8 
10% APS 0.025 
TEMED 0.005 
Table 10: Reagents and used volumes for 2 stacking gels. 
 
Resolving gel (12%) Volumes for 2 gels [ml] 
40% Acrylamide/Bisacrylamide 3.6 
1.5 M Tris pH 8.8 3 
10% SDS 0.12 
H2O 5.2 
10% APS 0.06 
TEMED 0.006 
Table 11: Reagents and used volumes for one resolving gel. 
Transfer 
The separated proteins were transferred from the gel to the membrane via wet blot in a blotting 
apparatus (Biorad). Therefore the gel was layered onto matching piece of PVDF membrane (GE-
healthcare) which was previously wetted with methanol followed by ddH2O and transfer buffer. The 
gel and membrane were covered with Whatman filter papers and sponges on both sides. The 
blotting apparatus was filled up with transfer buffer and transfer was performed over night at 25V 
and 4°C. Following the transfer, the membranes were stained with a Ponceau-S solution to make 
sure that the transfer from the gel to the membrane worked properly, that samples were loaded 
equally and no air bubbles disturbed the transfer. 
Immunodetection 
The stained membrane was washed with ddH2O to get rid of any residual Ponceau-S solution and 
incubated for approx. 5 min in the respective buffer that the primary antibody was diluted in. This 
was followed by blocking of the membrane with BSA (2-5%) or skim milk powder (2-3%) in the same 
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buffer at room temperature for 2 hours. After blocking, the membrane was incubated over night at 
4°C with the primary antibody. 
 
Antibody Dilution Fc-Domain Incubation MW [kDa] Supplier 
ppp38 1:1000 (PBST; 3% skim milk) Mouse Over night 38 Sigma 
p38 1:1000 (PBST; 3% skim milk) Rabbit Over night 38  
ppERK1/2 1:10000 (TBST; 3% BSA) Mouse Over night 42/44 Cell signaling
ERK1/2 1:1000 (TBST; 2% BSA) Rabbit Over night 42/44 Cell signaling
ppTAK1 1:1000 (TBST; 5% BSA) Rabbit Over night 82 Cell signaling
TAK1 1:1000 (TBST; 5% BSA) Rabbit Over night 82 Cell signaling
β-Actin 1:10000 (PBST; 1% skim milk) Mouse 1 hour 42 Sigma 
Table 12. Primary antibodies, dilutions, incubation periods and molecular weight. 
 
On the following day the membrane was washed 3 times for about 10 minutes in PBST/TBST, 
depending on the buffer of the primary antibody. Then the membrane was incubated with a HRP-
conjugated secondary antibody (see Table 13). 
 
Antibody Dilution Incubation Supplier
Goat anti mouse Ig 1:10000 2 hours  
Goat anti rabbit Ig 1:10000 2 hours  
Table 13. Secondary antibodies, dilutions and incubation periods. 
 
After incubation with the secondary antibody, the membrane was again washed 3 times for about 10 
minutes in PBST/TBST. Then the membrane was rinsed with the developing reagent ECL-Plus Western 
Blotting Detection Kit (GE Healthcare) for about 5 minutes. Finally the chemiluminiscence was 
detected via CL-XPosure (ThermoScientific) in a developing machine.  
 
Blotted membranes were subsequently used for hybridization with further varying primary and 
secondary antibodies. Upon detection of any previously used antibody, membranes had to be 
incubated with stripping buffer to remove these residual previously used antibodies. This was done 
by incubating the membrane twice for 10 min with stripping buffer, followed by incubation for 2x 10 
min with 1x PBS and 2x 5 min with TBSt. After that, membranes had to be blocked again.  
 
Enzyme-linked immunosorbent assay (ELISA) 
Rat TNFα Matched Antibody Pairs for ELISA kit (BenderMedSystems) was used for ELISA analysis of 
primary rat cell supernatant according to manufacturer’s instructions. 96-well plates for ELISA (BD 
Falcon) were used for coating with TNFα coating antibody. A 1:1 mixture of TMB and H2O2 (TMB 
Substrate Kit, Thermoscientific) was used as substrate solution for the conjugated HRP. The reaction 
was stopped by addition of 4N H2SO4. 
 
Human TNFα Matched Antibody Pairs for ELISA kit (BenderMedSystems) was used for ELISA analysis 
of human cell line supernatant according to manufacturer’s instructions. 96-well plates for ELISA 
(company) were used for coating with TNFα coating antibody. A 1:1 mixture of TMB and H2O2 (TMB 
Substrate Kit, Thermoscientific) was used as substrate solution for the conjugated HRP. The reaction 
was stopped by addition of 4N H2SO4. 
 
Extraction of serum from rat blood 
Rats were sacrificed by decapitation and blood was immediately collected in a 50ml tube. The blood 
was then transferred into a 15ml tube and allowed to clot at room temperature for at least 15 min to 
avoid water condensation and rupture of erythrocytes. This was followed by incubation of the blood 
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samples on ice for at least 1h. For separation of serum from cells the clotted blood was centrifuged 
for 15 min at 4°C and 2000xg. Supernatant was carefully collected and stored at -80°C until used for 
detection of free fatty acids. 
 
Detection of free fatty acids 
Concentrations of free fatty acids in sera of rats or supernatants of cells were determined using the 
Free Fatty Acid Quantification Kit (BioVision) according to manufactuer’s instruction by Helga 
Koudelka.  
 
ADAM17/TACE activity assay 
THP1 
For the final ADAM17/TACE activity assay 3x106 THP1 cells were incubated for varying time periods in 
5ml medium. LPS (10ng/ml) activated cells served as positive control, cells incubated in medium 
without LPS served as negative control. Following incubation, 2x105 cells per 96-well were 
centrifuged at 1000rpm (=218xg) for 2min, resuspended in TACE assay buffer and transferred into a 
96-well (Greiner 96 Flat Bottom Black plates). TACE inhibitor was added to wells if desired. Substrate 
was added to each well just before starting the measurement in a Tecan infinite 200Pro plate-reader 
(Tecan, Salzburg, Austria). The TACE activity of cells was assayed in duplicate.  
 
Rat primary Kupffer cells 
2x105 primary rat Kupffer cells were used per 96-well on Greiner 96 Flat Bottom Black plates (see 
also culture of Kupffer cells) in a total volume of 100µl of Kupffer cell medium. LPS (10gn/ml) 
activated cells served as a positive control, cells incubated in medium without LPS served as negative 
control. Following incubation, the medium was removed and TACE assay buffer was added. TACE 
inhibitor was added to wells if desired. Substrate was added to each well just before starting the 
measurement. The TACE activity of cells was assayed in duplicate. 
 
Tecan infinite 200Pro plate-reader protocol 
The Tecan infinite 200Pro plate-reader was heated to 37°C before starting the fluorescence 
measurements. Plates to be measured were shaken for 10 sec. and allowed to rest for another 10 
sec. Then fluorescence of each well was measured at λEM: 485nm when excited at λEX: 360nm. This 
was followed by a waiting period of 4 min to allow the enzyme reaction to go on. This cycle was 
repeated 20-26 times (see Table 14).  
 
Repeat Action Time period 
1 Wait for temp. 36.5°C - 37.5°C  
1x
 C
yc
le
 Shaking (orbital) 10 sec 
Wait 10 sec 
Measure fluorescence at 485nm  
Wait 4 min 
Table 14: Protocol for TACE activity measurement using the Tecan infinite 200Pro plate-reader. 
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Results 
Viability of primary rat hepatocytes depending on EtOH concentration 
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Figure 9: Viability of primary rat hepatocytes in response to increasing concentrations of ethanol as measured by neutral 
red assay. Values are expressed as fold of the lowest EtOH concentration (0.002%) and are represented as mean ±SEM, 
n=3. 
Viability of primary rat hepatocytes in response to increasing concentrations of ethanol, which is 
used as solvent for the treatment of cells with fatty acids, was found to be not significantly altered at 
concentrations ranging from 0.002 to 1% (see Figure 9).  
 
Viability of primary rat hepatocytes and non-parenchymal cells in response to α-
linolenic acid 
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Figure 10: Viability of primary rat HCs and NPCs in response to increasing concentrations of α-linolenic acid as measured 
by neutral red assay. Values are expressed as fold respective ethanol control and are represented as mean ±SEM, HC: 
n=3, NPC: n=1. 
Viability of primary rat liver cells when treated with increasing concentrations of α-linolenic acid was 
assayed by the uptake of neutral red in the medium by living cells. Therefore primary rat hepatocytes 
and mesenchymal cells were first purified from livers and incubated for 24 hours in the presence of 
α-linolenic acid or the corresponding concentration of solvent (see Table 2). Following this, neutral 
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red uptake of α-linolenic acid and solvent treated cells was assayed, respectively, and viability in 
response to α-linolenic acid was calculated as fold solvent control (see Figure 10).  
Primary rat hepatocytes tolerate higher concentrations of α-linolenic acid than mesenchymal cells. At 
a concentration of 500µM the viability of hepatocytes decreased to 85.5% whereas at the same 
concentration the viability of mesenchymal cells was down to 19%. 
 
Secretion of tumor-necrosis-factor-α from primary rat mesenchymal cells in 
response to free fatty acids 
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Figure 11: TNFα secretion into the supernatant of primary rat mesenchymal cells (NPCs) in response to free fatty acids 
(10µM), ethanol (0.02%), LPS (10ng/ml), SSO (250mM) or DMSO (0.1%), respectively, measured by ELISA. a) Absolute 
TNFα concentration in the supernatant of NPCs at different time points (see Table 15), b) TNFα secretion fold ethanol 
control. Values represent means ±SEM. 
TNFα 
[ng/ml] 
EtOH LH ALA LPS 
Mean SEM N Mean SEM n Mean SEM N Mean SEM N 
1h 0,964 0,434 5 1,643 0,653 2 1,292 0,672 3 4,645 0,939 2 
3h 2,129 0,989 6 3,665 1,902 3 2,968 1,715 4 13,822 3,833 2 
6h 2,242 1,042 6 3,681 1,900 3 2,936 1,508 4 15,540 3,239 2 
24h 1,626 0,621 5 1,422 0,9036 3 1,523 0,966 3 11,458 1,122 2 
 PA PA+SSO EtOH+SSO EtOH+DMSO 
Mean SEM N Mean SEM n Mean SEM N Mean SEM N 
1h 0,490 0,231 2 0,418 0,202 2 0,434 0,199 2 0,624 0,217 2 
3h 1,067 0,563 2 0,950 0,464 2 0,985 0,386 2 1,470 0,561 2 
6h 1,114 0,484 2 0,990 0,325 2 1,064 0,302 2 1,485 0,410 2 
24h 1,417 0,673 2 1,518 0,607 2 1,231 0,864 2 2,349 0,595 2 
Table 15: Means of TNFα concentrations [ng/ml], SEM and n of experiments used in Figure 11a). 
The secretion of tumor-necrosis-factor-α (TNFα) was assayed in primary rat mesenchymal cells after 
1 hour, 3 hours, 6 hours and 24 hours of treatment with ethanol, free fatty acids (LH, PA, ALA), LPS, 
PA in combination with the CD36 inhibitor SSO and DMSO, respectively. Figure 11a shows the 
calculated absolute concentration in the supernatant of treated cells. LPS induced the highest 
secretion of TNFα in mesenchymal cells which was 4-times (1h), 5-times (3h), 6-times (6h) or even 
8.5-times (24h) higher than from control cells. The used fatty acids, DMSO and the CD36 inhibitor 
SSO did not show any increase of TNFα secretion compared to the controls. 
 a)  b)
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Effects of α-linolenic acid treatment on p38MAPK and Erk phosphorylation 
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Figure 12: p38MAPK phosphorylation and Erk phosphorylation in primary rat non-parchenchymal cells treated with 
10µM α-linolenic acid for 10min, 30min, 1 hour and 24 hours. a) densitometric evaluation of the phosphorylation status 
of p38MAPK; b) densitometric evaluation of the phosphorylation status of ERK1/2; c) one of three similar blots. 
 p38 ERK1/2
mean SEM n mean SEM n
10min 0,856 0,026 3 0,784 0,076 2 
30min 1,027 0,163 3 1,408 0,261 2 
1h 0,970 0,314 3 1,085 0,077 3 
24h 2,595 0,884 2 0,790 0,297 2 
Table 16: mean volumes evaluated by densitometry of blots ± SEM and n of experiments used in Figure 12a) and b). 
 
Phosphorylation of p38MAPK was not increased compared to solvent controls at time points 10min, 
30min and 1 hour. After 24 hours a 2.5-fold increase could be detected. This might not only be a 
result of an actual change in phosphorylation, but also a result of the blot intensity itself, as the p38 
phosphorylation in α-linolenic acid treated and control cells were generally low. Therefore every 
minor change in the volumes evaluated by densitometry leads to major changes in fold-control 
ratios. Phosphorylation of p38MAPK can be considered increased after 24 hours when treated with 
α-linolenic acid compared to solvent control, but probably not to that extent. 
 a) b)
c) 
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Phosphorylation of ERK1/2 was slightly reduced after 10 min in α-linolenic acid treated cells. No 
significant change in α-linolenic acid treated cells compared to the solvent treated ones could be 
observed.  
 
Effects of free fatty acids on mRNA expression levels of COX-2, iNOS and TNFα in 
primary rat liver cells 
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Figure 13: Expression of iNOS (a) and TNFα (b) mRNA in response to 50µM of α-linolenic acid (ALA) or linoleic acid (LH) in 
primary rat hepatocytes after 6 and 24 hours of treatment, respectively. Values were calculated using the ΔΔCt method, 
normalized to β-2-microglobulin and expressed as fold ethanol control, values represent mean ±SEM. 
 ALA LH
iNOS Mean SEM n Mean SEM n
6h 0,815 0,273 4 1,145 0,476 3 
24h 0,727 0,447 3 
TNFα  
6h 0,583 0,132 2 1,212 0,991 2 
24h 1,822 0,356 2 
Table 17: means of ΔΔCt values, SEM and n of experiments used in Figure 13a) and b). 
COX-2 was undetectable in hepatocytes in response to free fatty acid treatment most of the time. 
iNOS and TNFα could be detected in most experiments, although neither iNOS nor TNFα were 
detectable after 24h when heptocytes were treated with 50µM linoleic acid (LH, see Figure 13).  
Treatment of hepatocytes with linoleic acid did not significantly change expression of iNOS or TNFα. 
α-Linolenic acid reduced expression of TNFα 0.5-fold after 6 hours of treatment but increased the 
expression about 1.82-fold compared to solvent treated cells. 
 
  
a) b) 
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Gene expression levels in primary rat mesenchymal cells 
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Figure 14: Expression of COX2 (a), iNOS (b) and TNFα (c) mRNA in response to 10µM of α-linolenic acid (ALA), linoleic acid 
(LH), palmitic acid (PA) or 10ng/ml LPS in primary rat mesenchymal cells after 6 and 24 hours of treatment, respectively. 
Values were calculated using the ΔΔCt method, normalized to β-2-microglobulin and expressed as fold ethanol control, 
values represent mean ±SEM. 
COX2 
ALA LH PA LPS 
Mean SEM n Mean SEM n Mean SEM n Mean SEM n 
6h 1,116 0,216 4 0,909 0,012 2 0,332 0,080 2 1,304 0,545 2 
24h 0,943 0,158 2 1,305 0,252 3 0,962 0,024 3 4,512 0,544 2 
iNOS       
6h 1,012 0,322 3 1,386 0,358 3 0,827 0,023 2 24,249 11,856 3 
24h 1,162 0,407 3 1,243 0,268 3 1,145 0,294 3 10,620 4,662 3 
TNFα       
6h 1,141 0,114 4 0,720 0,069 3 2,075 0,516 3 2,023 0,187 2 
24h 0,757 0,322 3 1,337 0,269 3 1,210 0,125 3 1,383 0,456 2 
Table 18: Means of ΔΔCt values, SEM and n of experiments used in Figure 14a), b) and c). 
COX-2 mRNA expression was elevated when mesenchymal cells were treated with LPS for 24h. α-
Linolenic acid, linoleic acid and palmitic acid showed no elevation of COX-2 expression. Palmitic acid 
tended to reduce the expression of COX-2 mRNA after 6 hours of treatment.  
mRNA levels of iNOS were only elevated when the cells were treated with LPS, leading to an 24-fold 
and 11-fold increase of expression after 6 and 24 hours of treatment, respectively. 
The expression level of TNFα was slightly decreased when cells were treated with linoleic acid for 6 
hours and around 2-fold increased after treatment with palmitic acid or LPS for the same period of 
time. α-Linolenic acid did not change the expression of TNFα compared to the ethanol controls. After 
24 hours of treatment TNFα levels were as high as in the ethanol controls, regardless of the 
treatment. 
 a)  b)  c) 
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Effects of inhibition of CD36 by SSO on primary rat liver cells 
 
As CD36 is one of the most studied receptors of free fatty acids and might also act as translocase for 
free fatty acids in several cell types (Silverstein & Febbraio, 2009; He, Lee, Febbraio, & Xie, 2011), we 
were interested whether inhibition of CD36 by sulfosuccinimidyl oleate (SSO) would result in any 
change in mRNA expression levels of inflammation-associated genes or phosphorylation of kinases in 
primary liver cells. 
Therefore we first estimated the general expression of CD36 in hepatocytes, endothelial cells and 
Kupffer cells of the rat liver. 
 
Expression of CD36 in primary rat liver cells 
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Figure 15: Expression of CD36 in primary rat hepatocytes (HC), Kupffer cells (KC) and endothelial cells (EC) expressed as 
densitometric volumes of CD36 fold volumes of β-actin. a) CD36 fold β-actin 6h after plating of cells at PCR cycles 33-42. 
b) CD36 fold β-actin 24h after plating of cells at PCR cycles 33-42. c) CD36 fold β-actin of HCs, KCs and ECs 6h and 24h 
after plating. Densitometric volumes were taken from PCR cycle 39. 
 
RNA of cultured primary rat hepatocytes, Kupffer cells and endothelial cells from collagenase-
perfused livers of untreated rats was harvested 6 hours and 24 hours after plating of the cells. 
Reverse-transcriptase-PCR was performed to convert RNA into cDNA. The obtained cDNA was used 
as template for PCR amplification using forward and reverse primers for CD36 and β-Actin. Amplified 
products from PCR cycles 33, 36, 39 and 42 were run on an agarose gel. Volumes of CD36 and β-actin 
PCR products of each cell type and PCR cycle were determined by densitometry and CD36-fold-β-
actin ratios were calculated.  
6 hours after plating of cells, CD36 expression was detectable in Kupffer cells and endothelial cells 
(see Figure 15a). Expression in hepatocytes could just be detected upon cycle 42. 24 hours after 
plating expression of CD36 was detectable in all three different cell types with Kupffer cells showing 
the highest expression, followed by hepatocytes and endothelial cells (see Figure 15b and c). Thus all 
three cell types express CD36 and might therefore be capable of detection of free fatty acids via 
CD36.  
 
  
 a)  b)  c) 
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Effects of CD36 inhibition on the phosphorylation status of p38MAPK and ERK 
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Figure 16: Effects of PA treatment and inhibition of CD36 by SSO on primary rat non-parenchymal cells, respectively. 
Shown blot represents one of three independent experiments. 
p38 
PA PA+SSO
mean SEM n mean SEM n
10min 0,765 0,105 3 0,624 0,071 3 
30min 0,819 0,221 3 0,798 0,075 3 
1h 1,037 0,273 3 0,700 0,392 3 
24h 1,188 0,261 3 1,103 0,654 3 
ERK1/2 
PA PA+SSO
Mean SEM n Mean SEM n
10min 0,907 0,308 3 0,924 0,376 3 
30min 0,922 0,198 3 0,755 0,316 3 
1h 1,386 0,326 3 1,147 0,160 3 
24h 0,689 0,282 3 0,794 0,417 3 
Table 19: mean volumes evaluated by densitometry of blots ± SEM and n of experiments used in Figure 16a) and b). 
Phosphorylation of p38MAPK was reduced to about 77% of controls when primary rat mesenchymal 
cells were treated with palmitic acid for 10 min. Treatment with palmitic acid in combination with 
SSO resulted in a further decrease of p38MAPK phosphorylation to about 62% of controls (see Figure 
16a) and Table 19). This suppressive effect of SSO was abrogated at time point 30min although SSO 
tended to reduce the phosphorylation of p38 more than palmitic acid alone. This trend could again 
be detected after 1 hour of treatment but was not significant. Phosphorylation was at the level of the 
controls after 24 hours. 
 a) b) 
c) 
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Treatment of primary rat mesenchymal cells with palmitic acid or palmitic acid in combination with 
SSO, respectively, had no significant effect on the phosphorylation status of Erk1/2, although palmitic 
acid tended to reduce it after 24 hours of treatment (see Figure 16b and Table 19). 
 
Effects of CD36 inhibition on mRNA levels of COX-2, iNOS and TNFα in primary rat mesenchymal 
cells 
 
For inhibition studies of CD36 by sulfosuccinimidyl-oleate (SSO) palmitic acid (PA) was used as a fatty 
acid as it showed the highest induction of inflammatory markers compared to α-Linolenic acid (ALA) 
and linoleic acid LH (see Figure 14).  
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Figure 17: mRNA expression levels of COX2 (a), iNOS (b) and TNFα (c) in response to 10µM PA or 10ng/ml LPS or 250mM 
SSO in primary rat mesenchymal cells after 6h and 24h of treatment. Values were calculated using the ΔΔCt method, 
normalized to β-2-microglobulin and expressed as fold EtOH control, values represent mean ±SEM 
 
COX2 
PA PA+SSO LPS
Mean SEM n Mean SEM n Mean SEM n 
6h 0,332 0,080 2 0,863 0,063 2 1,304 0,545 2 
24h 0,962 0,024 3 0,669 0,031 2 4,512 0,544 2 
 EtOH+SSO EtOH+DMSO
Mean SEM n Mean SEM n
6h 1,035 0,240 2 0,536 0,014 2 
24h 0,649 0,402 2 1,277 0,600 2 
iNOS 
PA PA+SSO LPS
Mean SEM n Mean SEM n Mean SEM n 
6h 0,827 0,023 2 1,587 0,287 2 24,249 11,856 3 
24h 1,145 0,294 3 0,722 0,437 2 10,620 4,662 3 
 EtOH+SSO EtOH+DMSO 
Mean SEM n Mean SEM n
6h 1,048 0,197 2 0,691 0,044 2 
24h 1,010 0,460 2 1,262 0,950 2 
TNFα PA PA+SSO LPS 
Mean SEM n Mean SEM n Mean SEM n 
6h 2,075 0,516 3 2,406 0,812 2 2,023 0,187 2 
24h 1,210 0,125 3 1,608 0,774 2 1,383 0,456 2 
 EtOH+SSO EtOH+DMSO 
Mean SEM n Mean SEM n
6h 0,974 0,072 2 0,690 0,039 2 
24h 1,031 0,189 2 1,152 0,213 2 
Table 20: means of ΔΔCt values, SEM and n of experiments used in Figure 17a), b) and c). 
mRNA expression of COX-2 was decreased after 6 hours of treatment with palmitic acid compared to 
solvent control (approx. 0.33-fold). This effect was not seen after 24 hours. Mesenchymal cells 
treated with palmitic acid in combination with SSO did not showed any significant effect neither 
 a)  b)  c) 
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compared to the treatment with palmitic acid alone nor to cells treated with ethanol and DMSO. LPS 
led to an increase in expression of COX-2 after 24 hours (approx. 4.5-fold) 
iNOS expression was slightly reduced (0.86-fold) when cells were treated with palmitic acid for 6 
hours and tended to be elevated (1.59-fold) when treated with palmitic acid and SSO for 6 hours. 
Neither of the controls showed any significant change in the mRNA expression levels of iNOS. 
Palmitic acid, LPS and palmitic acid in combination with SSO resulted in an approx. 2-fold elevation of 
TNFα expression after 6 hours of treatment. After 24 hours the expression of TNFα was on the same 
level as the solvent control. Neither of the controls for the CD36 inhibitor SSO (EtOH+DMSO, 
EtOH+SSO) had any effect on TNFα expression. 
 
Effects of CD36 inhibition on mRNA levels of COX-2, iNOS and TNFα in primary rat endothelial cells 
As the expression analysis of primary rat mesenchymal cells was not always conclusive, we decided 
to separate this cell fraction into endothelial cells and Kupffer cells and analyzed the expression 
levels of inflammation associated genes in both cell types separately.  
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Figure 18: Expression of COX2 (a), iNOS (b) and TNFα (c) mRNA in response to 10µM PA or 0.02% EtOH or 10ng/ml LPS or 
250mM SSO in primary rat endothelial cells after 6h and 24h of treatment, respectively. Values were calculated using the 
ΔΔCt method, normalized to β-2-microglobulin and expressed as fold medium control, values represent mean ±SEM. 
COX2 
PA PA+SSO LPS EtOH 
Mean SEM n Mean SEM n Mean SEM N Mean SEM n 
6h 1,150 1,001 2 1,036 0,763 2 1,589 1,048 2 0,828 0,626 2 
24h 1,290 1,035 2 1,285 1,146 2 1,965 0,721 2 0,378 0,226 2 
iNOS 
PA PA+SSO LPS EtOH 
Mean SEM n Mean SEM n Mean SEM n Mean SEM n 
6h 0,985 0,920 2 0,346 0,210 2 18,699 17,194 2 0,238 0,108 2 
24h 2,668 2,162 2 1,928 1,469 2 4,500 2,922 2 0,404 0,157 2 
TNFα PA PA+SSO LPS EtOH 
Mean SEM n Mean SEM n Mean SEM n Mean SEM n 
6h 0,519 0,406 2 0,322 0,185 2 2,826 2,272 2 0,385 0,264 2 
24h 1,385 1,070 2 1,026 0,638 2 1,889 1,198 2 0,531 0,057 2 
Table 21: means of ΔΔCt values, SEM and n of experiments used in Figure 18a), b) and c). 
The expression of COX-2 did not significantly change upon treatment with palmitic acid, nor was it 
changed by the treatment with the CD36 inhibitor SSO. LPS led to a 2-fold increase of expression 
after 24 hours. The solvent control decreased the expression after 24 hours of treatment. 
Palmitic acid had no significant influence on iNOS expression after 6 and 24 hours. The combination 
of palmitic acid and SSO resulted in a decrease of iNOS expression after 6 hours and was increased, 
 a) b) c) 
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although not significantly, after 24 hours. LPS did increase the expression of iNOS in endothelial cells 
after 6 and 24 hours but with a high variation in intensity. The ethanol treatment resulted in a 
decrease of iNOS expression after 6 and 24 hours. 
Expression of TNFα was slightly decreased upon treatment with palmitic acid after 6 hours, but was 
at the level of the medium control after 24 hours. Palmitic acid in combination with SSO had a similar 
effect, resulting in a decrease after 6 hours and coming back to the level of the medium control after 
24 hours. LPS increased the expression of TNFα only after 6 hours and also slightly after 24 hours but 
with considerable variation in intensity at both time points. The treatment with ethanol reduced the 
expression at both investigated time points. 
 
Effects of CD36 inhibition on mRNA levels of COX-2, iNOS, TNFα and IL6 in primary rat Kupffer cells 
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Figure 19: Expression of COX2 (a), iNOS (b), TNFα (c) and IL6 (d) mRNA in response to 10µM PA or 0.02% EtOH or 10ng/ml 
LPS or 250mM SSO in primary rat Kupffer cells after 6h and 24h of treatment, respectively. Values were calculated using 
the ΔΔCt method, normalized to β-2-microglobulin and expressed as fold medium control, values represent mean ±SEM. 
  
 a)  b)  
 c)  d)  
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COX2 
PA PA+SSO LPS EtOH 
Mean SEM n Mean SEM n Mean SEM N Mean SEM n 
6h 3,242 1,232 2 1,289 0,765 2 8,286 7,120 2 1,289 0,765 2 
24h 2,146 0,904 2 1,467 0,081 2 6,126 1,067 2 1,467 0,081 2 
iNOS 
PA PA+SSO LPS EtOH 
Mean SEM n Mean SEM n Mean SEM n Mean SEM n 
6h 4,289 2,778 2 1,681 0,981 2 7,466 5,548 2 1,191 0,701 2 
24h 1,830 0,624 2 2,253 0,082 2 7,366 1,889 2 1,359 0,327 2 
TNFα PA PA+SSO LPS EtOH 
Mean SEM n Mean SEM n Mean SEM n Mean SEM n 
6h 2,926 0,886 2 1,371 0,404 2 2,7305 0,869 2 0,833 0,387 2 
24h 1,489 0,495 2 1,345 0,399 2 1,359 0,706 2 1,026 0,079 2 
IL6 
PA PA+SSO LPS EtOH 
Mean SEM n Mean SEM n Mean SEM n Mean SEM n 
6h 1,003 0,132 2 0,877 0,054 2 5,789 3,042 2 1,064 0,272 2 
24h 1,507 0,346 2 1,265 0,311 2 1,473 0,766 2 0,775 0,674 2 
Table 22: means of ΔΔCt values, SEM and n of experiments used in Figure 19Table 11a), b), c) and d). 
 
Palmitic acid increased the expression of COX-2 in primary rat Kupffer cells 3.2-fold after 6 hours of 
treatment and 2.1-fold after 24 hours. This could be reduced to 1.3-fold and 1.5-fold after 6 hours 
and 24 hours, respectively, by addition of the CD36 inhibitor SSO. The solvent control had no 
significant effect on expression of COX-2. 
Expression of iNOS could also be induced by palmitic acid compared to the solvent control and led to 
a 4.3-fold and 1.8-fold increase after 6 hours and 24 hours, respectively. The elevation after 6 hours 
could be decreased by addition of SSO to 1.6-fold, but this had no effect after 24 hours. The solvent 
control had no significant effect on iNOS expression. 
The Expression of TNFα was 2.9-fold increased when Kupffer cells were treated with palmitic acid for 
6 hours. This could be decreased to 1.3-fold by SSO. The elevation caused by palmitic acid was 
reduced to 1.5-fold after 24 hours of treatment. The addition of SSO had a similar effect leading to an 
equal level of TNFα expression (1.3-fold). The elevation caused by palmitic acid alone was as high as 
the elevation caused by LPS (2.9-fold and 1.5-fold 6 and 24 hours, respectively, caused by palmitic 
acid and 2.7-fold and 1.4-fold 6 and 24 hours, respectively, caused by LPS). The solvent control had 
no significant effect on gene expression of TNFα. 
Gene expression of interleukin6 (IL6) was also analysed in Kupffer cells as its action is in part 
regulated by TNFα. Palmitic acid did not significantly change the levels of IL6 expression (1-fold and 
1.5-fold after 6 and 24 hours, respectively, compared to the solvent control), neither did the addition 
of SSO (0.8-fold and 1.3-fold after 6 and 24 hours, respectively). LPS induced IL6 expression after 6 
hours to approx. 5.8-fold compared to the solvent control. This elevation was not seen after 24 
hours.  
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Real-time measurement of ADAM17/TACE activity on live cells using a fluorogenic 
substrate 
 
Since TNFα secretion into the medium of primary rat mesenchymal cells could not always be 
measured to the same extent when cells were treated with free fatty acids and because the enzyme 
responsible for 80-90% of TNFα shedding (Arribas & Borroto, 2002) is also the sheddase for the 
soluble forms of TNFα receptors 1 and 2 (p75 TNFα-RII, p55 pro-TNFα-RI), which could have bound to 
secreted TNFα, we decided to directly measure the activity of this enzyme on primary rat Kupffer 
cells as these cells increased the expression of TNFα in response to the treatment with palmitic acid. 
As ADAM17/TACE is not only responsible for the shedding of TNFα, p75 TNFα-RII and p55 pro- TNFα-
RI, but also for the shedding of IL6-Rα, HB-EGF, TGFα, proamphiregulin and HER-4, direct 
measurement of the activity of this enzyme becomes even more interesting (Arribas & Borroto, 
2002).  
As a substrate for ADAM17/TACE we decided to use the commercially available DABCYL-TNFα-Edans 
(Bachem, Switzerland) and performed the TACE assay using an excitation wavelength of 360nm and 
measuring the emission at 485nm. 
 
Fluorescence of various buffers and media 
First of all we had to choose a suitable buffer for the enzyme reaction. It should not show any 
fluorescence at the used excitation and emission wavelengths, not lead to hydrolysis of the substrate 
without any enzyme present, allow the hydrolytic reaction to occur and should not do any major 
damage to the cells for the time of incubation with the substrate.  
Therefore we tested several buffers and media - that were either common or were reported to be 
used for the measurement of fluorescent reactions - for their fluorescence at the used wavelengths. 
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Figure 20: Fluorescence of various buffers and media. Fluorescence was measured once per cycle at λem: 485nm when 
samples were excited at λex: 360nm in 12 cylces, 6.23min per cycle. Colored curves indicate buffers/media used for TACE 
activity measured on live cells due to their superior properties (see text and Figure 21 - Figure 25) compared to other 
buffers. Starting values were arbitrarily set to 0 and values represent arbitrary units ±SD of duplicates.  
Fluorescence of 20mM Tris pH7.4, 50mM Tris pH7.4, 250mM Tris pH7.4, Tris-based-buffer (Tbb, see 
materials and methods), Tris-buffered-saline (TBS), phosphate-buffered-saline (PBS), distilled water 
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(aqua bidest.), RPMI-1640 medium, RPMI-1640 medium supplemented with 10%FCS (RPMI 1640 
10%FCS), HAM’s F-15 medium and Leibovitz L-15 medium was measured for 68 min at 37°C in 
duplicates at the used excitation and emission wavelengths (see Figure 20). Buffers and media with a 
minimal fluorescence were used for further experiments to estimate their applicability (20mM Tris 
pH7.4, 50mM Tris pH7.4, 250mM Tris pH7.4, TBS and HAM’s). 
The buffers with the lowest autofluorescence were found to be PBS, water, 20mM Tris pH7.4, 50mM 
Tris pH 7.4 and TBS (Figure 20). 
 
Stability of DABCYL-TNFα-Edans in various buffers and media 
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Figure 21: a) Fluorescence of DABCYL-TNFα-Edans in various buffers and media. Fluorescence was measured once per 
cycle at λem: 485nm when samples were excited at λex: 360nm in 12 cylces, 6.23min per cycle. Colored curves indicate 
buffers/media used for TACE activity measured on live cells due to their superior properties (see text and Figure 21 - 
Figure 25) compared to other buffers. Starting values were arbitrarily set to 0 and values represent arbitrary units ±SD of 
duplicates. B) values of Figure 20 were subtracted from values of Figure 21a) to compensate for buffer fluorescence. 
The second important property, besides low autofluorescence, of a suitable buffer is guaranteeing 
the stability of the used substrate. Hydrolysis of the substrate without any proteinase present has to 
be excluded in order to develop a sensitive and quantifiable assay. 
Fluorescence of 10µM DABCYL-TNFα-Edans in various buffers and media was measured every 6.23 
minutes for about 68 minutes at 37°C (see Figure 21a). The fluorescence of the buffers and media 
was subtracted from the fluorescence of the substrate in the respective buffers and media (see 
Figure 21b), to exclude any buffer that shows a negative autofluorescence (e.g. Figure 20: RPMI1640 
10%FCS) and hydrolysis of the substrate. A combination of these two effects would result in low 
fluorescence (the extent depending on the relative strength of the two effects) and therefore lead to 
the misleading conclusion that the buffer would be suitable. 
 
 a) b) 
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Cleavage of DABCYL-TNFα-Edans by trypsin measured in various buffers and media  
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Figure 22: Fluorescence of DABCYL-TNFα-Edans incubated with 1µg trypsin in various buffers and media. Fluorescence 
was measured once per cycle at λem: 485nm when samples were excited at λex: 360nm in 12 cylces, 6.23min per cycle. 
Colored curves indicate buffers/media used for TACE activity measured on live cells due to their superior properties 
compared to other buffers. Starting values were arbitrarily set to 0 and values represent arbitrary units ±SD of 
duplicates. 
The third property of the most appropriate buffer is its ability to allow the enzymatic reaction to 
happen. The cleaving reaction should also result in as much fluorescence as possible to ensure that 
the final assay has a maximum sensitivity. We therefore used trypsin as a proteinase for cleaving the 
substrate. This is possible because DABCYL-TNFα-Edans contains two arginin residues (DABCYL-Leu-
Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-Arg-EDANS) which are potential cleavage sites for trypsin. The 
reaction was performed in the already mentioned buffers and media (Figure 22). The highest 
fluorescence of cleaved substrate by trypsin could be measured in 250mM Tris pH7.4, TBS, 20mM 
Tris pH7.4 and 50mM Tris pH7.4. 
 
Signal-to-background ratio of DABCYL-TNFα-Edans in various buffers and media 
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Figure 23: Arbitrary fluorescence units of DABCYL-TNFα-Edans incubated with 1µg trypsin (Figure 22) were divided by 
arbitrary fluorescence units of substrate alone (Figure 21a). Fluorescence was measured once per cycle at λem: 485nm 
when samples were excited at λex: 360nm in 12 cylces, 6.23min per cycle. Colored curves indicate buffers/media used for 
TACE activity measured on live cells due to their superior properties compared to other buffers. Starting values were 
arbitrarily set to 0 and values represent arbitrary units ±SD of duplicates. 
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In addition to facilitate the stability of the substrate (see Figure 21b), the buffer of choice would have 
to allow the specific cleavage of the substrate to happen. The specificity of the reaction or the 
signal:background ratio was therefore calculated as the ratio of fluorescence of cleaved substrate to 
fluorescence of uncleaved substrate (see Figure 23). According to this calculation the Tris-buffers 
20mM Tris pH7.4, 50mM Tris pH7.4, TBS and 250mM Tris pH7.4, together with PBS showed the 
highest signal-to-background ratios.  
 
Difference in TACE activity of human monocytic THP1 cells depending on activation status 
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Figure 24: TACE activity measured by hydrolysis of DABCYL-TNFα-Edans by a) THP1 incubated for 27 hours in RPMI-1640; 
b) THP1 incubated for 27 hours in RPMI-1640 supplemented with 100nM PMA; c) THP1 incubated for 27h in RPMI-1640 
including the last 3 hours with 10ng/ml LPS; d) THP1 incubated in RPMI-1640 supplemented with 100nM PMA for 27 
hours including the last 3 hours with 10ng/ml LPS. Fluorescence was measured in 20mM Tris pH7.4, 50mM Tris pH7.4, 
250mM Tris pH7.4, TBS and HAM’s medium, respectively, at λem: 485nm when samples were excited at λex: 360nm in 12 
cylces (4.88min per cycle). Starting values were arbitrarily set to 0 and values represent arbitrary units ±SD of duplicates. 
The next step in testing assay conditions was to use live cells. Therefore we chose the human 
monocyte cell line THP1, as these cells express ADAM17/TACE on their cell surface (Alvarez-Iglesias, 
Wayne, O'Dea, Amour, & Takata, 2005; Gutiérrez-López, et al., 2011) and are quite easy to handle.  
THP1 cells were incubated for 24 hours in RPMI 1640 without FCS in the absence or presence of 
100nM PMA and were incubated for further 3 hours in the absence or presence of 10ng/ml LPS. 
TACE activity was measured in 20mM Tris pH7.4, 50mM Tris pH7.4, 250mM Tris pH7.4, TBS or HAM’s 
medium, respectively (see Figure 24). These buffers and HAM’s medium showed the best results in 
the preliminary experiments that were conducted to estimate the most appropriate buffer or 
medium for the reaction itself (see Figure 20, Figure 21, Figure 22 and Figure 23). 
 a)  b) 
 c)  d) 
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The highest fluorescence independent of activation status could be detected in 20mM Tris pH7.4 and 
50mM Tris pH7.4. 
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Figure 25: TACE activity measured by hydrolysis of DABCYL-TNFα-Edans by THP1 incubated for 27 hours in RPMI-1640 
(THP1); THP1 incubated for 27 hours in RPMI-1640 supplemented with 100nM PMA (THP1+PMA); THP1 incubated for 
27h in RPMI-1640 including the last 3 hours with 10ng/ml LPS (THP1+LPS); THP1 incubated in RPMI-1640 supplemented 
with 100nM PMA for 27 hours including the last 3 hours with 10ng/ml LPS (THP1+PMA+LPS). Fluorescence was measured 
once per cycle at λem: 485nm when samples were excited at λex: 360nm in 12 cylces, 4.88min per cycle using a) 20mM Tris 
pH7.4, b) 50mM Tris pH7.4, c) 250mM Tris pH7.4, d) TBS, e) HAMs medium as buffer for measuring TACE activity. Starting 
values were arbitrarily set to 0 and values represent arbitrary units ±SD of duplicates. 
The most prominent differences in TACE activity of THP1 cells due to their activation status could be 
detected in 250mM Tris pH7.4 and TBS followed by HAM’s medium. Only a slight difference in TACE 
activity could be measured in 20mM Tris pH7.4 and 50mM Tris pH7.4 but nevertheless the increase 
in fluorescence after 54 minutes was highest using these two buffers, so we therefore tended to use 
one of these buffers for the final assay. As it later turned out, this might have been not the best 
decision, as it was the primary task to identify a buffer which showed the biggest difference in 
activity of TACE on live cells depending on the activation stage and not just the buffer showing the 
highest increase in fluorescence.  
 a)  b) 
 c)  d) 
 e)  
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TACE activity in all buffers was highest in THP1 activated with PMA in combination with LPS followed 
by THP1 activated with LPS, and THP1 activated with PMA, with the exception of 20mM Tris pH7.4 
and HAM’s medium.  
 
Inhibition of TACE activity in THP1 by TAPI-2 
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Figure 26: Fluorescence of cleaved substrate (Subst+Trypsin), THP1, THP1 with substrate (THP1+Substr), THP1 with 
substrate and TACE inhibitor (THP1+Substr+TAPI2), THP1 with TACE inhibitor (THP1+TAPI2) and TACE inhibitor (TAPI2), 
respectively, was measured in a) 20mM Tris pH7.4 and b) 50mM Tris pH7.4 at λem: 485nm when samples were excited at 
λex: 360nm every 4.79min for 53min (12 cylces). Starting values were arbitrarily set to 0 and values represent arbitrary 
units ±SD of duplicates. 
Time [min] 0 4.8 9.6 14.4 19.1 23.9 28.7 33.5 38.3 43.1 47.9 52.6 
20mM Tris pH7.4 - 59.6% 17.0% 19.3% 23.3% 28.9% 34.6% 41.8% 45.9% 48.6% 49.8% 49.7% 
50mM Tris pH7.4 - 87.0% -21.4% 16.6% 33.1% 52.2% 62.6% 66.3% 79.7% 88.0% 94.0% 93.8% 
Table 23: Remaining TACE activity in 20mM Tris pH7.4 and 50mM Tris pH7.4 on THP1 when TACE is inhibited by addition 
of 50µM TAPI-2 at different time points.  
To make sure that the measured enzymatic activity was due to the action of TACE, we inhibited the 
enzyme with a specific inhibitor, TAPI-2 (Gutiérrez-López, et al., 2011; see Figure 26). 83% of TACE 
activity of THP1 cells incubated in 20mM Tris pH7.4 could be inhibited after 9.6 minutes of 
measurement, leaving 17% of the activity of uninhibited TACE (see Table 23). The maximum activity 
of TAPI-inhibited TACE reached about 49.7% of the activity of uninhibited TACE after an incubation 
period of about 52 minutes. 
When incubated in 50mM Tris pH7.4 the activity of TACE could be reduced to about 16% after 14 
minutes of incubation with the inhibitor and subsequently reached 94% of the activity of uninhibited 
TACE after 52 minutes. 
Therefore we chose the 20mM Tris pH7.4 buffer as the final assay buffer because of the stronger 
difference in TACE activity that could be achieved by the addition of TAPI-2. 
Neither the cells, nor the inhibitor TAPI-2, nor cells in combination with the TACE inhibitor TAPI-2 
showed any fluorescence in the assay. 
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Figure 27: TACE activity measured by hydrolysis of DABCYL-TNFα-Edans by THP1 incubated for a) 3 hours, b) 6 hours or c) 
24 hours in RPMI-1640 10%FCS supplemented with 10ng/ml LPS or without LPS in the presents or absence of 50µM TAPI-
2, respectively. Fluorescence was measured once per cycle at λem: 485nm when samples were excited at λex: 360nm using 
20mM Tris pH7.4 as buffer for measuring TACE activity. Starting values were arbitrarily set to 0 and values represent 
arbitrary units ±SD of duplicates. 
We were further interested in the activity of TACE in LPS-induced THP1 cells in the presence or 
absence of the inhibitor TAPI-2. Therefore we incubated THP1 cells in RPMI supplemented with 10% 
FCS in the presence or absence of 10ng/ml LPS for 3 hours, 6 hours or 24 hours and measured the 
activity of TACE with or without 50µM TAPI-2 (see Figure 27).  
TAPI-2 could inhibit the activity of TACE at each time point tested, but to different extents. After 78 
minutes of measurement the activity of TACE was reduced to about 70% in THP1 which were 
incubated for 3 hours with LPS and to 54% in THP1 incubated in medium for 3 hours. Unfortunately, 
there was no difference in the activity of TACE of cells incubated with and without LPS, respectively.  
TAPI-2 could reduce TACE activity in THP1 to about 78% after 80 minutes of measurement, when 
cells were incubated for 6 hours with LPS and to 62% when cells were incubated with medium. 
Surprisingly the activity of TACE on cells incubated with medium was 37% higher than the activity of 
cells incubated with LPS.  
Incubating THP1 with LPS for 24 hours resulted in a 20% higher activity of TACE compared to cells 
incubated in medium. Addition of TAPI-2 led to a reduction of TACE activity to about 66% in LPS-
induced cells and to about 82% in cells incubated in medium after 99 minutes of measurement.  
 
 a)  b)  c)
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Difference in TACE activity of THP1 cells depending on LPS concentration and incubation periods  
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Figure 28: TACE activity measured by hydrolysis of DABCYL-TNFα-Edans by THP1 incubated for a) 3 hours, b) 6 hours or c) 
24 hours in RPMI-1640 10%FCS supplemented with 10µg/ml LPS or 100ng/ml LPS or 10ng/ml LPS or without LPS, 
respectively. Fluorescence was measured at λem: 485nm when samples were excited at λex: 360nm using 20mM Tris 
pH7.4 as buffer for measuring TACE activity. Starting values were arbitrarily set to 0 and values represent arbitrary units 
±SD of duplicates. 
Our next attempt was to find the appropriate conditions at which the difference in TACE activity 
between LPS-induced and uninduced cells was most prominent. Therefore THP1 cells were incubated 
for 3 hours, 6 hours or 24 hours, respectively, in RPMI supplemented with 10% FCS and either 
10µg/ml LPS, 100ng/ml LPS or 10ng/ml LPS (see Figure 28). After 3 hours of incubation no difference 
in TACE activity could be detected.  
The activity of LPS-induced cells after 6 hours was not significantly different, although the activity in 
medium treated cells was found to be higher.  
LPS induction did also not result in different activities of TACE after 24 hours of treatment, although 
die average activity was higher than in medium treated cells.  
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Extent of inhibition of TACE activity in THP1 depending on inhibitor concentration 
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Figure 29: TACE activity measured by hydrolysis of DABCYL-TNFα-Edans by THP1 incubated for 6 hours in RPMI-1640 
10%FCS supplemented with a) 10µg/ml LPS or b) 100ng/ml LPS or c) 10ng/ml LPS or d) without LPS in the presents or 
absence of 50µM or 30µM or 10µM TAPI-2, respectively. Fluorescence was measured once per cycle at λem: 485nm when 
samples were excited at λex: 360nm using 20mM Tris pH7.4 as buffer for measuring TACE activity. Starting values were 
arbitrarily set to 0 and values represent arbitrary units ±SD of duplicates. 
As we could not detect any difference in TACE activity of THP1 cells treated with different 
concentrations of LPS, TACE activity is either entirely unaffected by LPS or there is another regulation 
that affects inhibition of TACE. To test this second possibility, we used different concentrations of the 
TACE inhibitor TAPI-2 so see whether this would result in different TACE activities.  
Therefore THP1 cells were incubated with increasing concentrations of LPS ranging from 10ng/ml to 
10µg/ml for 6 hours. TACE activity of these induced cells was afterwards measured in the presence or 
absence of 10µM, 30µM or 50µM TAPI-2 for about 81 minutes (see Figure 29). 
TACE activity could be inhibited in all cells regardless of the LPS concentration used, but the activities 
did not significantly decrease with increasing TAPI-2 concentration. 
 
 a)  b) 
 c)  d) 
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Figure 30: TACE activity measured by hydrolysis of DABCYL-TNFα-Edans by THP1 incubated for 6 hours in RPMI-1640 
10%FCS supplemented with a) 10µg/ml LPS or b) 100ng/ml LPS or c) 10ng/ml LPS or d) without LPS in the presents or 
absence of 50µM or 30µM or 10µM TAPI-2, respectively. Fluorescence was measured once per cycle at λem: 485nm 
when samples were excited at λex: 360nm using 20mM Tris pH7.4 as buffer for measuring TACE activity. Starting values 
were arbitrarily set to 0 and values represent arbitrary units ±SD of duplicates 
TACE activities in the presence of different concentrations of TAPI-2did also not significantly differ in 
THP1 cells which were incubated for 24 hours with LPS (see Figure 30).  
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Figure 31: TACE activity measured by hydrolysis of DABCYL-TNFα-Edans by THP1 incubated for 1 hour in RPMI-1640 
supplemented with a) 10% FCS or b) 5% FCS or c) 1% FCS in the presents or absence of 50µM TAPI-2, respectively. 
Fluorescence was measured once per cycle at λem: 485nm when samples were excited at λex: 360nm using 20mM Tris 
pH7.4 as buffer for measuring TACE activity. Starting values were arbitrarily set to 0 and values represent arbitrary units 
±SD of duplicates. 
As there might also be some proteinase inhibitors present in the serum of the medium, they could 
have an effect on TACE activity, although the assay itself is carried out in a simple Tris buffer without 
serum. Therefore THP1 cells were incubated for 1 hour with 10ng/ml LPS in RPMI-1640 medium 
supplemented with 1% FCS, 5% FCS or 10% FCS, respectively (see Figure 31). The TACE activity of LPS-
induced THP1 in medium containing 10%FCS was found to be lower than the medium control itself. 
This effect could be detected in several, but not all experiments. 
 a) b) c) 
 a)  b)  
 c)  d)  
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TACE activities of THP1 cells which were induced with LPS in medium containing only 1% or 5% serum 
on the other hand, were found to be higher than TACE activities in control cells (see Figure 31 b and 
c). When inhibited with 50µM TAPI-2 TACE activities of cells kept in medium containing 5% serum 
with or without LPS, respectively, were higher than the activity of TACE of controls without inhibitor. 
TACE activity of LPS-induced cells incubated in medium containing 1% serum was higher than the 
activity of control cells. The activity of TACE of LPS-induced cells could be inhibited by the addition of 
TAPI-2, whereas TACE activity of control cells could not (Figure 31c). 
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Figure 32: TACE activity measured by hydrolysis of DABCYL-TNFα-Edans by THP1 incubated for 1 hour in RPMI-1640 10% 
FCS in the presents or absence of 10ng/ml LPS, respectively. a) comparison of TACE activity at different cell densities 
incubated in medium or b) medium supplemented with LPS, c) TACE activity of 1x106 THP1, d) TACE activity of 2x105 
THP1, e) TACE activity of 1x104 THP1, f) TACE activity of 1x103 THP1. Fluorescence was measured once per cycle at λem: 
485nm when samples were excited at λex: 360nm using 20mM Tris pH7.4 as buffer for measuring TACE activity. Starting 
values were arbitrarily set to 0 and values represent arbitrary units ±SD of duplicates. 
To further evaluate the specificity and reproducibility of the assay we tested whether the measured 
activities of TACE correlate with cell densities as more available enzyme should result in faster 
cleavage of the substrate.  
 a)  b)
 c)  d)
 e)  f)
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Therefore THP1 cells which were previously incubated for 1 hour with or without LPS, respectively, 
were plated at different densities ranging from 1x103 to 1x106 and TACE activity was measured. A 
correlation between cell density and activity could be detected at densities ranging from 1x103 to 
2x105. In contrast, the activity of 1x106 cells was almost as high as seen in 1x104 cells (see Figure 32a). 
The same effects could be detected in cells which were treated with LPS previous to TACE activity 
measurement (see Figure 32b). 
Induction of cells with LPS resulted in a slight increase in TACE activity compared to medium-treated 
control cells at densities of 1x104 and 2x105 (see Figure 32d and e). TACE activities of cells at densities 
of 1x103 and 1x106 cells were found to differ not significantly (see Figure 32c and f). 
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Activity and inhibition of TACE in native and induced primary rat Kupffer cells 
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Figure 33: TACE activity measured by hydrolysis of DABCYL-TNFα-Edans by primary rat Kupffer cells incubated for 3 hours 
in RPMI-1640 0.1%BSA supplemented with 100ng/ml LPS, 10ng/ml LPS, 10µM palmitic acid (PA) or medium, respectively, 
in a) the absence or b) presence of 50µM TAPI-2. c) TACE activity of Kupffer cells incubated for 3 hours with 100ng/ml 
LPS, d) TACE activity of Kupffer cells incubated for 3 hours with 10ng/ml LPS, e) TACE activity of Kupffer cells incubated 
for 3 hours with 10µM PA, f) TACE activity of Kupffer cells incubated for 3 hours with RPMI 0.1%BSA. Fluorescence was 
measured in the absence or presence of 50µM, 30µM or 10µM TAPI-2, respectively, once per cycle at λem: 485nm when 
samples were excited at λex: 360nm using 20mM Tris pH7.4 as buffer for measuring TACE activity. Starting values were 
arbitrarily set to 0 and values represent arbitrary units ±SD of duplicates. 
We were further interested in the TACE activity of LPS-induced and native primary rat Kupffer cells. 
Therefore Kupffer cells were treated for 3 hours with 10ng/ml or 100ng/ml LPS and TACE activity was 
 a)  b) 
 c)  d) 
 e)  f) 
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measured in the presence or absence of the TACE inhibitor TAPI-2. Furthermore Kupffer cells were 
treated with 10µM palmitic acid followed by measurement of TACE activity (see Figure 33a-f).  
TACE activity in primary rat Kupffer cells did not significantly differ in cells treated with LPS, palmitic 
acid or medium, respectively, although TACE activity was slightly higher in cells treated with 
100ng/ml LPS than in cells treated with 10ng/ml LPS (see Figure 33a). TACE activities measured in the 
presence of TAPI-2 did also not differ significantly between treatments (see Figure 33b).  
TACE activities of Kupffer cells treated with 100ng/ml LPS could be inhibited by the addition of TAPI-
2, but activities did not decrease in a concentration dependent manner (see Figure 33c). TAPI-2 
(30µM and 50µM) decreased TACE activity of Kupffer cells incubated with 10ng/ml LPS. A 
concentration of 10µM TAPI-2 just led to a slight decrease in TACE activity (see Figure 33d). 
Treatment of Kupffer cells with palmitic acid could also just be slightly decreased by the addition of 
TAPI-2 and did therefore not significantly differ whether TACE was inhibited or not. Similarly, the 
TACE activity of medium treated cells showed no significant difference whether it was inhibited by 
different concentrations of TAPI-2 or not.  
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Figure 34: TNFα secretion into the supernatant of primary rat Kupffer cells in response to 10ng/ml LPS (LPS), medium 
(RPMI 10%FCS) and 100nM PMA in the absence or presents of 50µM TAPI-2. 
TNFα [ng/ml] LPS RPMI 10%FCS 100nM PMA LPS +TAPI-2 RPMI 10%FCS +TAPI-2 100nM PMA +TAPI-2 
1h 0.959 0.030 0.198 0.037 0.073 0.033 
3h 17.843 0.094 0.489 0.706 0.046 0.090 
6h 21.178 0.040 0.678 3.367 -0.033 -0.025 
24h 20.548 0.107 0.140 2.140 -0.087 -0.044 
Table 24: TNFα concentrations [ng/ml] in the supernatant of Kupffer cells used in Figure 34. 
Due to the inconclusive results of the measured TACE activities in primary rat Kupffer cells in 
response to treatment with LPS and palmitic acid, we measured the concentration of TNFα in the 
supernatant to verify the shedding of TNFα in our system (see Figure 34).  
LPS treatment of primary rat Kupffer cells resulted in a strong release of TNFα, reaching the highest 
concentration after 6 hours of treatment. Neither treatment with PMA nor medium resulted in 
significant release of TNFα into the supernatant.  
Addition of the TACE inhibitor TAPI-2 resulted in a significant decrease of TNFα release in LPS treated 
cells, resulting in a maximum concentration of TNFα of about 3.4ng/ml after 6 hours of treatment. 
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Effects of in-vivo oil treatment 
Effects of in-vivo oil treatment on FFA serum levels in rats after 20h 
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Figure 35: Levels of free fatty acids in the sera of oil treated and water treated rats, respectively. Values are mean ±SEM. 
FFA [µM] Mean SEM n
Oil treated 105,850 31,594 4 
Water treated 64,875 4,286 4 
Table 25: Mean, SEM and n of analyzed free fatty acid concentrations in sera of oil and water treated rats, respectively, 
used in Figure 35. 
In order to evaluate changes in gene expression in oil-treated compared to water-treated rats, we 
were interested in the levels of free fatty acids in the sera of these rats. Therefore rats were given oil 
(1ml/100ml bodyweight) or water (1ml/100g bodyweight) by gavage and serum was extracted after 
20 hours. FFA levels of oil-treated rats (105.85µM, see Figure 35 and Table 25) were found to be 
approx. 1.65-fold higher than in water-treated controls (64.88µM).  
 
Micro-array analysis of mRNA of liver cells 20h and 6d after oil treatment 
Since the levels of free fatty acids were about 2-fold higher in oil-treated rats compared to water-
treated controls 20 hours after a single administration by gavage, we were interested in the resulting 
changes in gene expression in the liver. Therefore total RNA was isolated from mesenchymal and 
parenchymal cells of livers of oil-treated and water-treated rats and gene expression was analyzed 
using Affymetrix’s GeneChip Rat Genome 230 array at the Core Facility Genomics of the Medical 
University of Vienna. Resulting gene expression data were delogarithmized and RMA-normalized and 
the values of each gene from oil-treated samples were divided by the mean of their respective 
controls. By calculating fold-controls of each oil-treated sample using control values from the same 
experiment instead of pooling oil-treated and water-treated samples from different experiments, we 
avoid to detect possible litter specific changes in gene expression. Gene expression in mesenchymal 
and parenchymal cells was than calculated as mean of these resulting fold-control values. 
When we compared the gene expression in livers of oil-treated rats with water-treated controls 20 
hours after oil or water administration, respectively, we found 18 genes more than 2-fold 
downregulated and 433 genes more than 2-fold upregulated (see Table 28) in mesenchymal cells and 
3 genes more than 2-fold downregulated and 9 genes more than 2-fold upregulated in hepatocytes 
(see Table 29). Resulting gene lists were cleared of genes which appeared more than once and were 
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not regulated in the same way and of genes whose expression was changed in just one animal by 
comparison of standard deviations with means. This was followed by assigning genes to pathways as 
specific as possible. Resulting tables of regulated genes of interest assigned to pathways are listed 
below (Table 26 and Table 27) and tables of total regulated genes may be found in supplementary 
(Table 28and Table 29). 
In lack of proper controls, the fold control of gene expression after 6 days of treatment was 
calculated by dividing the mean of gene expression values from oil-treated rats (6 days) by the mean 
of gene expression values of the water-treated controls from the one-time treatment experiment (20 
hours). 
Changes in gene expression in mesenchymal cells 
Pathway Gene title  Gene symbol Public ID Fold 
control 
20h 
Fold 
control 
6d 
Immune response chemokine (C-C motif) ligand 4 Ccl4 U06434 0.489 0.490
 collagen, type I, alpha 2 Col1a2 BM388837 2.010 0.918
 laminin, beta 1 Lamb1 BI296460 2.162 1.487
 nuclear protein, transcriptional regulator, 1 Nupr1 NM_053611 2.247 1.925 
 Vitronectin Vtn NM_019156 2.247 1.620 
 arginase, liver Arg1 NM_017134 2.390 2.573 
 retinoic acid receptor responder (tazarotene induced) 
2 
Rarres2 BI282993 2.507 1.333 
 orosomucoid 1 Orm1 NM_053288 2.758 1.348 
 serine (or cysteine) peptidase inhibitor, clade A, 
member 3N 
Serpina3n NM_031531 3.168 2.035 
Apoptosis granzyme B Gzmb AI029386 0.497 0.435 
 PERP, TP53 apoptosis effector Perp AI598971 2.127 1.596 
Acute phase 
reaction 
Haptoglobin Hp NM_012582 2.144 1.830 
 inter alpha-trypsin inhibitor, heavy chain 4 Itih4 NM_019369 2.230 1.863 
 fibrinogen gamma chain Fgg NM_012559 2.482 1.596 
Oxidative stress microsomal glutathione S-transferase 1 Mgst1 NM_134349 2.180 1.773 
 glutathione S-transferase, theta 2 Gstt2 NM_012796 2.233 1.520 
 glutathione S-transferase mu 2 Gstm2 AI169331 2.074 2.142 
Complement 
system activation 
mannose-binding lectin (protein A) 1 Mbl1 NM_012599 2.244 1.431 
 complement component 9 C9 NM_057146 2.981 1.837 
 complement component 8, alpha polypeptide C8a AA998638 3.147 1.874 
 mannan-binding lectin serine peptidase 2 Masp2 AA996755 3.850 1.626 
Complement 
system inhibition 
complement factor I Cfi NM_024157 2.521 2.048 
Amino acid 
metabolism 
glutathione transferase zeta 1 Gstz1 AI169075 2.013 2.003 
 cysteine dioxygenase, type I Cdo1 NM_052809 2.026 1.726 
 aminomethyltransferase Amt BF408907 2.114 1.735 
 methionine adenosyltransferase I, alpha Mat1a AI454484 2.214 1.854 
 nitrilase family, member 2 Nit2 AI411100 2.215 1.907 
 guanidinoacetate N-methyltransferase Gamt NM_012793 2.318 2.003 
 glycine C-acetyltransferase (2-amino-3-ketobutyrate-
coenzyme A ligase) 
Gcat AW525471 2.329 1.695 
 phenylalanine hydroxylase Pah NM_012619 2.444 1.914 
 aldehyde oxidase 1 Aox1 NM_019363 2.606 2.607 
 solute carrier family 38, member 4 Slc38a4 NM_130748 2.634 2.533 
 N-acetylglutamate synthase Nags AI030790 2.662 2.120 
 fumarylacetoacetate hydrolase Fah NM_017181 2.750 1.816 
 choline dehydrogenase Chdh BI293004 2.856 1.853 
 acireductone dioxygenase 1 Adi1 AA997430 2.896 2.670 
 monoamine oxidase B Maob NM_013198 2.916 2.569 
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Pathway Gene title  Gene symbol Public ID Fold 
control 
20h 
Fold 
control 
6d 
 aldehyde dehydrogenase 1 family, member B1 Aldh1b1 AA997683 3.080 1.820 
 glycine cleavage system protein H (aminomethyl 
carrier) 
Gcsh NM_133598 3.112 2.841 
 tyrosine aminotransferase Tat M18340 3.313 2.113 
 histidine ammonia lyase Hal NM_017159 3.562 1.424 
 alanine-glyoxylate aminotransferase Agxt NM_030656 3.636 1.715 
 homogentisate 1, 2-dioxygenase Hgd AI232328 3.647 2.055 
 cystathionase (cystathionine gamma-lyase) Cth NM_017074 3.855 5.592 
 cystathionine beta synthase Cbs NM_012522 4.247 2.057 
Fatty acid 
degradation 
acyl-CoA synthetase long-chain family member 1 Acsl1 D90109 2.020 2.063 
 2-hydroxyacyl-CoA lyase 1 Hacl1 AJ245707 2.041 1.916 
 acetyl-Coenzyme A acyltransferase 1 /// similar to 3-
ketoacyl-CoA thiolase B, peroxisomal precursor (Beta-
ketothiolase B) 
Acaa1 /// 
RGD1562373 
NM_012489 2.083 1.516 
 peroxisomal D3,D2-enoyl-CoA isomerase Peci BI278268 2.083 1.791 
 acyl-Coenzyme A dehydrogenase, C-2 to C-3 short 
chain 
Acads NM_022512 2.233 1.588 
 acyl-CoA thioesterase 2 Acot2 AA899721 2.306 1.554 
 cytochrome P450, family 4, subfamily a, polypeptide 3 Cyp4a3 M33936 2.308 1.535 
 alcohol dehydrogenase 7 (class IV), mu or sigma 
polypeptide 
Adh7 NM_134329 2.313 2.842 
 cytochrome P450, family 2, subfamily c, polypeptide 
12 (female specific) 
Cyp2c12 NM_031572 2.339 2.188 
 fatty acid binding protein 1, liver Fabp1 NM_012556 2.358 2.239 
 carnitine palmitoyltransferase 2 Cpt2 NM_012930 2.454 1.760 
 acyl-Coenzyme A dehydrogenase, C-4 to C-12 straight 
chain 
Acadm NM_016986 2.485 1.796 
 enoyl Coenzyme A hydratase domain containing 2 Echdc2 AI172274 2.499 2.190 
 acyl-Coenzyme A oxidase 2, branched chain Acox2 X95189 2.605 1.898 
 hydroxyacyl-Coenzyme A dehydrogenase Hadh AA799574 2.654 2.169 
 acyl-Coenzyme A dehydrogenase, long-chain Acadl NM_012819 2.748 2.187 
 cytochrome P450, family 2, subfamily b, polypeptide 3 Cyp2b3 M20406 2.765 2.063 
 phytanoyl-CoA 2-hydroxylase Phyh NM_053674 2.787 1.836 
 acyl-CoA thioesterase 12 Acot12 NM_130747 2.853 2.070 
 peroxisomal trans-2-enoyl-CoA reductase Pecr NM_133299 3.049 2.668 
 cytochrome P450, family 4, subfamily a, polypeptide 2 
/// cytochrome P450, family 4, subfamily a, 
polypeptide 3 
Cyp4a2 /// 
Cyp4a3 
AA893326 3.241 2.045 
 dodecenoyl-Coenzyme A delta isomerase (3,2 trans-
enoyl-Coenzyme A isomerase) 
Dci NM_017306 3.467 2.552 
 2,4-dienoyl CoA reductase 2, peroxisomal Decr2 AF044574 3.514 2.917 
 acetyl-Coenzyme A acyltransferase 2 Acaa2 NM_130433 3.583 2.539 
 fatty acid binding protein 2, intestinal Fabp2 NM_013068 4.087 3.254 
 glycerol kinase Gk AA945076 4.245 3.046 
 enoyl-Coenzyme A, hydratase/3-hydroxyacyl 
Coenzyme A dehydrogenase 
Ehhadh NM_133606 4.901 3.881 
 2,4-dienoyl CoA reductase 1, mitochondrial Decr1 NM_057197 5.276 3.894 
Regulation of lipid 
metabolism 
Hepatocyte nuclear factor 4, alpha Hnf4a BI288517 2.518 1.540 
Steroid 
biosynthesis 
NAD(P) dependent steroid dehydrogenase-like Nsdhl BF407232 2.043 1.556 
 phosphomevalonate kinase Pmvk BG378288 2.056 2.019 
 transmembrane 7 superfamily member 2 Tm7sf2 BM390364 2.067 1.599 
 hydroxysteroid (17-beta) dehydrogenase 7 Hsd17b7 NM_017235 2.073 1.982 
 cytochrome P450, family 51 Cyp51 NM_012941 2.261 2.300 
 hydroxysteroid (17-beta) dehydrogenase 4 Hsd17b4 NM_024392 2.362 1.957 
 farnesyl diphosphate synthase (farnesyl 
pyrophosphate synthetase, 
dimethylallyltranstransferase, 
geranyltranstransferase) 
Fdps NM_031840 2.421 2.017 
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Pathway Gene title  Gene symbol Public ID Fold 
control 
20h 
Fold 
control 
6d 
 protein kinase, AMP-activated, alpha 2 catalytic 
subunit 
Prkaa2 NM_023991 3.051 2.272 
 sulfotransferase family 2A, dehydroepiandrosterone 
(DHEA)-preferring, member 2 
Sult2a2 D14989 3.328 3.489 
 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 
(soluble) 
Hmgcs1 NM_017268 3.799 3.134 
 isopentenyl-diphosphate delta isomerase 1 Idi1 NM_053539 4.607 3.260 
Lipoprotein 
assembly 
cell death-inducing DFFA-like effector b Cideb AI137938 2.026 1.190 
Triglyceride 
biosynthesis 
1-acylglycerol-3-phosphate O-acyltransferase 2 
(lysophosphatidic acid acyltransferase, beta) 
Agpat2 AI012474 2.792 2.157 
Bile acid solute carrier organic anion transporter family, 
member 1a1 
Slco1a1 NM_017111 2.053 3.209 
 solute carrier family 27 (fatty acid transporter), 
member 5 
Slc27a5 NM_024143 2.160 1.797 
 solute carrier organic anion transporter family, 
member 1a4 
Slco1a4 NM_131906 2.193 3.516 
 nuclear receptor subfamily 1, group H, member 4 Nr1h4 NM_021745 2.458 1.880 
 aldo-keto reductase family 1, member D1 (delta 4-3-
ketosteroid-5-beta-reductase) 
Akr1d1 D17309 2.541 2.838 
 cytochrome P450, family 7, subfamily a, polypeptide 1 Cyp7a1 NM_012942 3.009 1.698 
 solute carrier family 10 (sodium/bile acid 
cotransporter family), member 1 
Slc10a1 NM_017047 3.097 2.480 
 bile acid Coenzyme A: amino acid N-acyltransferase 
(glycine N-choloyltransferase) 
Baat NM_017300 3.746 2.272 
Lipid transport apolipoprotein C-IV Apoc4 AA998783 2.867 1.929 
 lecithin cholesterol acyltransferase Lcat NM_017024 3.070 1.924 
 apolipoprotein A-IV Apoa4 NM_012737 3.150 1.584 
 apolipoprotein A-I Apoa1 NM_012738 4.021 3.806 
 butyrobetaine (gamma), 2-oxoglutarate dioxygenase 
(gamma-butyrobetaine hydroxylase) 1 
Bbox1 NM_022629 3.477 2.291 
Ketone bodies 3-hydroxybutyrate dehydrogenase, type 1 Bdh1 NM_053995 3.580 2.358 
 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 
(mitochondrial) 
Hmgcs2 M33648 4.954 2.408 
Retinoic acid 
metabolism 
retinol binding protein 1, cellular Rbp1 NM_012733 2.876 2.067 
 dehydrogenase/reductase (SDR family) member 4 Dhrs4 AB062758 3.559 3.142 
 retinol dehydrogenase 7 Rdh7 NM_133543 3.924 2.254 
 cytochrome P450, family 2, subfamily c, polypeptide 
22 
Cyp2c22 M58041 4.169 5.477 
Vitamin E 
transport 
tocopherol (alpha) transfer protein Ttpa NM_013048 3.245 3.596 
Liver regeneration hepatocyte growth factor activator Hgfac BE119649 2.042 1.866 
 heat-responsive protein 12 Hrsp12 NM_031714 2.167 2.219 
 apolipoprotein A-V Apoa5 AF202888 2.597 1.591 
 transmembrane 4 L six family member 4 Tm4sf4 NM_053785 4.238 2.647 
Detoxification aldehyde dehydrogenase 3 family, member A2 Aldh3a2 NM_031731 2.114 1.528 
 aldo-keto reductase family 7, member A2 (aflatoxin 
aldehyde reductase) 
Akr7a2 NM_134407 2.228 1.544 
 cytochrome P450, family 3, subfamily a, polypeptide 9 Cyp3a9 U46118 2.558 2.522 
 flavin containing monooxygenase 5 Fmo5 AI454611 2.663 1.603 
 cytochrome P450, family 1, subfamily a, polypeptide 2 Cyp1a2 K02422 2.728 1.483 
Eicosanoid 
biosynthesis 
fatty acid desaturase 2 Fads2 NM_031344 2.642 2.991 
 arginine vasopressin receptor 1A Avpr1a NM_053019 2.922 1.483 
 elongation of very long chain fatty acids (FEN1/Elo2, 
SUR4/Elo3, yeast)-like 2 
Elovl2 BG666735 4.083 2.272 
 acyl-CoA thioesterase 4 Acot4 AI411493 7.244 4.348 
Purine metabolism urate oxidase Uox M24396 2.514 2.776 
 similar to transthyretin (4L369) RGD1309350 BM387540 3.512 2.771 
DNA repair uracil-DNA glycosylase Ung AA848420 2.048 1.632 
Metabolism of 
sugars 
aldolase B, fructose-bisphosphate Aldob M10149 2.188 1.711 
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Pathway Gene title  Gene symbol Public ID Fold 
control 
20h 
Fold 
control 
6d 
 sorbitol dehydrogenase Sord NM_017052 2.391 1.480 
 pyruvate carboxylase Pc NM_012744 2.855 1.342 
 fructose-1,6-bisphosphatase 1 Fbp1 NM_012558 2.938 1.846 
 amylase, alpha 1A (salivary) Amy1a AB057450 3.852 4.055 
 glycogen synthase 2 Gys2 NM_013089 4.023 2.695 
G-Protein coupled 
receptors 
adrenergic, alpha-1B-, receptor Adra1b NM_016991 2.029 1.996 
 purinergic receptor P2Y, G-protein coupled, 2 P2ry2 NM_017255 2.956 1.893 
Kinin-Kallikrein-
system 
kininogen 2 Kng2 NM_012741 2.186 1.636 
 serine (or cysteine) proteinase inhibitor, clade A 
(alpha-1 antiproteinase, antitrypsin), member 4 
Serpina4 U51017 2.443 1.797 
 kininogen 1 /// kininogen 1-like 1 /// kininogen 2 Kng1 /// Kng1l1 
/// Kng2 
NM_012696 2.911 1.986 
Blood coagulation coagulation factor X F10 NM_017143 2.775 1.862 
 coagulation factor IX F9 AA963815 2.899 2.100 
Inhibition of 
Coagulation  
serine (or cysteine) peptidase inhibitor, clade D, 
member 1 
Serpind1 NM_024382 2.186 1.785 
 serine (or cysteine) peptidase inhibitor, clade C 
(antithrombin), member 1 
Serpinc1 BG377322 2.222 1.812 
 protein C Proc NM_012803 2.602 2.184 
 apolipoprotein H (beta-2-glycoprotein I) Apoh AI180413 2.635 1.786 
Regulation of 
blood pressure 
angiotensin II receptor, type 1a Agtr1a NM_030985 2.505 1.324 
Cell cycle interferon regulatory factor 6 Irf6 BF557891 2.240 1.818 
 activating transcription factor 5 Atf5 BM391471 4.366 3.126 
Hyperlipidemia 
associated 
angiopoietin-like 3 Angptl3 AI058911 2.138 1.673 
 apolipoprotein C-I Apoc1 NM_012824 2.181 1.612 
Obesity 
development 
solute carrier family 27 (fatty acid transporter), 
member 2 
Slc27a2 NM_031736 2.377 2.224 
Miscellaneous dimethylarginine dimethylaminohydrolase 1 Ddah1 NM_022297 2.512 1.955 
 regucalcin (senescence marker protein-30) Rgn NM_031546 2.579 1.735 
 SEC16 homolog B (S. cerevisiae) Sec16b NM_053571 2.676 2.038 
 G0/G1switch 2 G0s2 AI406939 2.718 1.565 
 phosphatidylethanolamine N-methyltransferase Pemt NM_013003 2.989 1.627 
 retinol binding protein 4, plasma Rbp4 AA858962 3.201 2.239 
 cytochrome P450, family 3, subfamily a, polypeptide 
23/polypeptide 1 
Cyp3a23/3a1 NM_013105 3.332 21.9921 
 cytochrome P450, family 2, subfamily f, polypeptide 4 Cyp2f4 NM_019303 3.338 2.505 
 growth factor receptor bound protein 14 Grb14 NM_031623 3.390 2.350 
 choline phosphotransferase 1 Chpt1 BF282951 3.457 2.683 
 keratin 18 Krt18 BI286012 3.653 2.198 
 glutathione S-transferase A2 /// LOC494499 protein Gsta2 /// 
LOC494499 
NM_017013 3.711 6.7902 
 interferon-induced protein with tetratricopeptide 
repeats 1 
Ifit1 NM_020096 3.740 2.875 
 keratin 8 Krt8 BF281337 4.207 2.080 
 asialoglycoprotein receptor 1 Asgr1 NM_012503 4.216 2.836 
 pantothenate kinase 1 Pank1 AA850195 4.465 3.245 
 kidney expressed gene 1 Keg1 AB019693 4.890 6.959 
Table 26: list of selected genes whose expression was more than 2-fold changed in primary mesenchymal cells of the 
livers of oil-treated vs. water-treated rats 20 hours after a single treatment and after 6 days of daily treatment. 
 
  
                                                            
1 Cyp3a23/3a1 was found to be 16.6-fold upregulated in just one rat.  
2 Gsta2 was found to be 62.8-fold upregulated in just one rat. 
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Changes in gene expression in hepatocytes 
Pathway Gene title Gene 
symbol 
Public ID Fold control 
20h 
Fold control 
6d 
Immune response activating transcription factor 3 Atf3 NM_012912 0.484 0.694
Amino acid 
transport 
solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 7 
Slc7a7 AF200684 2.100 1.384
Retinoic acid 
metabolism 
cytochrome P450, family 2, subfamily a, polypeptide 
2 
Cyp2a2 NM_012693 2.336 3.245
Fatty acid 
degradation 
acyl-CoA thioesterase 2 Acot2 AA899721 2.384 1.914
 fatty acid binding protein 2, intestinal Fabp2 NM_013068 2.577 2.274
Miscellaneous Sialophorin Spn BF550890 2.459 1.320
 vanin 1 Vnn1 BI289085 5.508 6.147
Table 27: list of selected genes whose expression was more than 2-fold changed in primary hepatocytes of oil-treated vs. 
water-treated rats 20 hours after a single treatment and after 6 days of daily treatment. 
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Discussion 
 
Effects of in-vitro FFA treatment on primary rat liver cells 
We isolated and purified primary rat hepatocytes and mesenchymal cells and treated these different 
cell types with α-linolenic acid, an n3-PUFA. Effects of treatment of primary rat liver cells with n6-
PUFAs and peroxidized fatty acids have already been studied by our group (Sagmeister, 2009). 
As the solvent had no significant effect on the viability of hepatocytes (Figure 9), the slight decrease 
in viability observed when the cells were treated with α-linolenic acid (Figure 10) is due to the fatty 
acid itself. Interestingly, primary rat mesenchymal cells are more susceptible to α-linolenic acid 
treatment using a concentration of 500µM. This observed difference between hepatocytes and 
mesenchymal cells is most probably due to a higher uptake and metabolic conversion or even 
storage of fatty acids in hepatocytes, as uptake of FFAs doesn’t seem to be tightly regulated in the 
liver leading to steatosis in some individuals (Greenfield, Cheung, & Sanyal, 2008) (Savage & Semple, 
2010). 
Treatment with α-linolenic acid (ALA) did not change secretion of TNFα from rat mesenchymal cells 
(Figure 11) compared to the solvent control. α-linoleic acid (LH) and palmitic acid (PA) did not change 
TNFα shedding either, although at least saturated fatty acids were reported to increase expression of 
TNFα in a TLR-mediated way in a monocyte cell line (Lee, Zhao, & Hwang, 2009) and increase in TNFα 
secretion into the medium of primary rat mesenchymal cells in response to palmitic acid could be 
detected by ELISA by our group (unpublished data). However, an elevation in TNFα concentration of 
up to 15.5ng/ml (~6.9-fold, Table 15) could be observed after 6 hours of treatment with bacterial 
lipopolysaccharide (LPS), thereby confirming that primary rat mesenchymal cells after liver perfusion 
are capable of TNFα shedding and are therefore an applicable system which resembles the in-vivo 
situation as close as possible. The usefulness of the system is further supported by the observation 
that neither the solvents (EtOH and DMSO) nor an inhibitor for CD36 (SSO) had any influence on 
TNFα shedding. 
Treatment of primary rat mesenchymal cells with ALA did not increase the phosphorylation status 
(Figure 12a) and thereby the activation of p38MAPK, a kinase activated during cellular stress, which 
induces COX2 and regulates the production of TNFα and IL-6 (Wagner & Nebreda, 2009), compared 
to the solvent control for up to a treatment period of 1 hour. After 24 hours phosphorylation was up 
to 2.6-fold increased (Table 16). This might rather be an effect of culturing of primary cells or even 
nutrient deprivation (although this is rather unlikely) than a real effect of the FFA treatment, as 
cellular stress resulting in activation of p38MAPK is a quite immediate event that would occur within 
1 hour (own, unpublished data). The second, already stated cause might just be the generally low 
phosphorylation of p38MAPK in ALA-treated and control cells. Thereby every minor change in blot 
intensity results in a quite significant alteration of the fold-change ratio. 
Activation of ERK1/2, as measured by phosphorylation, was also not affected by ALA treatment 
compared to solvent control (Figure 12b). ERK1/2 activation is involved in FFA mediated GPR 
signaling and is downregulated by n3-PUFA (Gleissman, Johnsen, & Kogner, 2010). This could not be 
reproduced in our system of primary rat cells. 
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Our next step in assessing the effects of ALA treatment on primary rat liver cells was assaying gene 
expression of the inflammation associated genes COX2, iNOS, TNFα and IL-6. COX-2 mRNA levels 
could not be detected in hepatocytes when they were treated with ALA or LH. The expression of 
iNOS and TNFα in LH-treated hepatocytes (see Figure 13) could just be detected after 6 hours of 
treatment, whereas expression of both mRNAs was detectable in ALA-treated hepatocytes. As cells 
were still viable after 24 hours of treatment, this phenomenon could not be explained. Treatment 
with ALA resulted in an approximately 2-fold decrease of TNFα mRNA levels after 6 hours and an 
almost 2-fold increase after 24 hours. As n3-PUFA are reported to reduce or even inhibit the 
production of TNF (Boutros, Somasundar, Razzak, Helton, & Espat, 2010), substantiated by our 
finding of a 2-fold decrease in TNFα expression after 6 hours, the increase in TNFα mRNA production 
after 24 hours seem contradictory. As LH did not lead to measurable TNFα mRNA levels that could be 
compared to the mRNA levels caused by ALA-treatment, other effects than FFA-treatment 
contributing to this increase cannot be completely excluded.  
COX2 expression in primary rat mesenchymal cells was unchanged by treatment with ALA or LH (see 
Figure 14a), but was decreased by treatment with palmitic acid after 6 hours. Conversely, an increase 
in COX2 expression upon PA-treatment was reported in a murine macrophage cell line and myoblasts 
(Lee, Zhao, & Hwang, 2009). The discrepancy might be explained by the lower concentration of PA 
(10µM) used in our experimental setting, as higher concentrations showed toxic effects in our system 
of primary cells. LPS, which was used as a positive control for inducing inflammation, resulted in a 
4.5-fold increase in COX2 expression after 24 hours, confirming the ability of primary mesenchymal 
cells to induce COX2 mRNA. iNOS mRNA levels were solely elevated by LPS-treatment (see Figure 
14b), although saturated fatty acids were reported to increase its expression in a macrophage cell 
line (Lee, Zhao, & Hwang, 2009). Again, as in the case of COX2, we used primary cells and therefore 
lower concentrations of fatty acids to avoid cytotoxic effects. In contrast, the expression of TNFα was 
increased in PA-treated mesenchymal cells, leading to a 2-fold elevation, which was as high as 
observed in LPS-treated cells (see Figure 14c). Treatment with LH led to a slight decrease in TNFα 
expression after 6 hours which was at the level of solvent treated cells after 24 hours. This indicates 
that there is a difference in how primary cells react to FFA-treatment compared to cell lines, namely 
by elevation of TNFα mRNA levels (rather than COX2 or iNOS mRNA levels) at a low concentration 
where no cytotoxic effects could be observed. Nevertheless, the increase in TNFα expression in cells 
treated with palmitic acid was as high as observed in LPS-treated cells confirming the TNFα-inducing 
effects of PA.  
 
Effects of inhibition of CD36 on primary rat liver cells 
As CD36 might be the translocase/transporter for free fatty acids into the liver (Silverstein & 
Febbraio, 2009) (He, Lee, Febbraio, & Xie, 2011), we were interested whether its inhibition would 
result in changes in gene expression of COX2, iNOS and TNFα and phosphorylation p38MAPK and 
Erk1/2, indicating a role of CD36 in binding and FFA-mediated signaling in our system. To make sure 
that CD36 was expressed in primary rat liver cells, as reported, we assayed its expression in 
hepatocytes, Kupffer cells and endothelial cells (see Figure 15). CD36 RNA was detectable in all three 
types of cells after 39 cycles of PCR using cDNA as template.  
Since palmitic acid induced expression of TNFα in mesenchymal cells we decided to use this fatty acid 
for our inhibition experiments. mRNA levels of COX2, iNOS and TNFα did not differ significantly 
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between PA-treated and PA+SSO-treated cells (see Figure 17). Cells treated with SSO (in the presence 
of EtOH) or with the solvent control (EtOH+DMSO) did not show any changes in gene expression 
levels compared to controls. 
As the mesenchymal cell fraction comprises many different celltypes including endothelial cells, 
Kupffer cells and stellate cells and the ratio between these cell types may vary, we decided to further 
separate Kupffer cells from endothelial cells and assay gene expression levels of PA-treated and 
PA+SSO treated cells separately.  
Endothelial cells did not significantly change gene expression of COX2 or iNOS when treated with 
palmitic acid, although the combination of PA with SSO resulted in a decrease of iNOS expression 
after 6 hours and an increase after 24 hours, as did the treatment with PA alone (see Figure 18). 
TNFα expression was decreased after 6 hours by both, PA and PA+SSO treatment which was also 
cause by the solvent. Over all, the expression of inflammation associated genes varied a lot which 
could also be demonstrated by the treatment with LPS and the solvent. These findings might also in 
part explain the variations in gene expression observed with total mesenchymal cells and which 
might further be aggravated by different ratios of cell type number in rat livers thereby 
demonstrating the need for cell type separation when studying inflammatory responses in primary 
cells. 
COX2 expression was increased 3-fold and 2-fold in PA-treated Kupffer cells after 6 hours and 24 
hours of treatment, respectively, and this could be attenuated by the addition of the CD36 inhibitor 
SSO (see Figure 19a). iNOS mRNA levels were elevated after 6 hours of treatment with PA which 
could be decreased by inhibition of CD36. Expression levels were still slightly elevated after 24 hours 
of treatment which was independent of CD36 inhibition. Both, iNOS and COX2, expression were not 
as highly induced as they were by LPS, whereas in contrast TNFα expression was. Inhibition of CD36 
by SSO led to a decrease in TNFα expression after 6 hours of treatment and mRNA levels of PA and 
PA+SSO-treated cells were almost at the level of the solvent control after 24 hours. Palmitic acid was 
unable to induce expression of IL-6 and addition of SSO did not change expression either. 
Nevertheless, IL-6 expression by primary rat Kupffer cells could be demonstrated by treatment with 
LPS, thereby showing the ability of these cells for inducing IL-6 production. Taken together, these 
results indicate the ability of palmitic acid to induce an - at least partially - CD36-mediated expression 
of the inflammation associated genes COX2, iNOS and TNFα in primary rat Kupffer cells, which seem 
to be the cell population which shows the highest response to FFA-treatment. Each of these genes 
showed stronger induction at the earlier time point investigated with COX2 levels being still 2-fold 
elevated after 24 hours of treatment, indicating an immediate response in iNOS and TNFα expression 
and an a prolonged expression for COX2. In every analyzed expression of inflammation associated 
genes, LPS-treatment led to an increase in transcription, whereas the solvent showed no influence 
thereby demonstrating the reliability of our primary cell system. 
The phosphorylation status of p38MAPK and Erk1/2 was investigated when CD36 was inhibited by 
SSO and cells were treated with palmitic acid (see Figure 16). After 10min phosphorylation of 
p38MAPK was slightly reduced in PA-treated cells and was further reduced in PA+SSO-treated cells. 
At time point 30min only PA+SSO-treated cells showed a slight reduction in p38 phosphorylation. At 
later time points there was no significant difference between treatments and compared to solvent 
control be detected, although CD36 inhibition tended to reduce p38 phosphorylation compared to 
PA-treatment. Phosphorylation of Erk1/2 was not affected by treatment with palmitic acid and 
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inhibition of CD36 had no significant influence either. As CD36 inhibition did not change Erk1/2 
phosphorylation, there might be no CD36-mediated downstream signaling affecting Erk1/2 activation 
in primary rat mesenchymal cells in response to palmitic acid. p38MAPK activation might in part be 
influenced by CD36, as shown by the difference of phosphorylation between PA and PA+SSO-treated 
cells after 10 minutes. But phopsphorylation of PA-treated cells was slightly decreased compared to 
the solvent control, although saturated fatty acids where reported to activate p38 (Silverstein, Li, 
Park, & Rahaman, 2010) in a CD36 dependent manner.  
 
Development of a real-time measurement assay of ADAM17/TACE 
ADAM17/TACE is supposed to be the main enzyme responsible for the shedding of TNFα. As it is 
reported to be upregulated in chronic liver injury and in HCC (Berasain, Castillo, Perugorria, Latasa, 
Prieto, & Avila, 2009) and is also responsible for the shedding of other factors involved in modulation 
of inflammation or cancer growth like TGFα, amphiregulin, HB-EGF, p55 TNFαR, p75 TNFαRII, IL-6R, 
ICAMs, VCAM and VEGFRs, we were interested whether its activity is influenced by free fatty acids. 
We were able to demonstrate TNFα gene expression to be elevated in response to palmitic acid in 
primary rat Kupffer cells (see Figure 19c) but could not show secretion of TNFα (Figure 11). We 
therefore attempted to develop an enzyme measurement assay using live cells and a fluorogenic 
substrate. 
First of all, a suitable buffer for the reaction had to be chosen, which would not interfere with the 
measurement of fluorescence at the used wavelengths and would not promote any unspecific 
hydrolysis of the substrate. Buffers with minimal changes in fluorescence during the measurement 
were PBS, aqua bidest., 20mM Tris pH7.4, 50mM Tris pH 7.4 and TBS (Figure 20). The stability of the 
substrate DABCYL-TNFα-EDANS was the second important aspect for the selection of an appropriate 
buffer, so the fluorescence of the substrate in each buffer was measured (see Figure 21a). The 
fluorescence of buffer alone was subtracted from the fluorescences of substrate in the respective 
buffer to evaluate the stability of the substrate (see Figure 21b). The third aspect to be considered in 
chosing a buffer was its property to allow the cleavage of the substrate. To evaluate the most 
appropriate buffer, the substrate was incubated with typsin and the cleavage was followed by 
measuring the fluorescene of formed cleavage product. The highest increase in fluorescence was 
found in the Tris-buffers (20mM Tris pH7.4, 50mM Tris pH7.4, 250mM Tris pH7.4 and TBS), which is 
necessary to yield maximal sensitivity. 
After calculating the signal:background ratio (see Figure 23) the Tris-buffers (20mM Tris pH7.4, 
50mM Tris pH7.4, 250mM Tris pH7.4 and TBS) together with PBS showed the highest specificity in 
substrate cleavage. Therefore these Tris-buffers and HAM’s medium were chosen as assay buffers for 
the cell based TACE assay.  
For the cell-based assay, human THP1 cells were incubated for 24 hours with or without PMA, as this 
phorbol ester was reported to increase TACE activity on DRM cells (murine monocytes) (Doedens, 
Mahimkar, & Black, 2003) and on MonoMac-6 cells (Alvarez-Iglesias, Wayne, O'Dea, Amour, & 
Takata, 2005) followed by addition of LPS for another 3 hours. LPS is reported to increase TACE 
activity on THP1 cells (Alvarez-Iglesias, Wayne, O'Dea, Amour, & Takata, 2005) and on primary 
human monocytes (Scott, et al., 2011). Both activating agents are reported to increase TACE activity 
on the cell surface without changing TACE abundance. As fluorescence resulting from cleaved 
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DABCYL-TNFα-EDANS was hightest using 20mM and 50mM Tris pH7.4 (see Figure 25c and d) we used 
these two buffers for further experiments, although the most significant difference in induced THP1 
cells compared to uninduced cells was found in 250mM Tris pH7.4 and TBS. This might seem 
counterproductive, but fluorescence in 20mM and 50mM Tris was almost twice as high as in 250mM 
Tris and TBS, resulting in higher sensitivity when using these buffers. 
Next, we had to evaluate whether the observed enzyme activity was due to TACE. Therefore we 
inhibited the enzyme with the specific inhibitor TAPI-2 (Gutiérrez-López, et al., 2011) and found 83% 
of TACE activity on THP1 cells inhibited by TAPI-2 after 9.6 minutes of incubation using 20mM Tris 
pH7.4 as an assay buffer (see Figure 26a). At the end of the measurement after about 52 minutes less 
than 50% of TACE activity could be observed. Inhibition using 50mM Tris pH7.4 was found to be less 
effective, resulting in 93.8% remaining TACE activity after 52 minutes of incubation (see Figure 26b). 
This was due to two facts, first, the activity of uninhibited THP1 cells was lower than observed in 
20mM Tris pH7.4 and second, the activity of inhibited THP1 cells was higher compared to TAPI-2-
treated cells in 20mM Tris pH7.4. Furthermore, no increase in fluorescence of sole THP1 cells, the 
inhibitor TAPI-2, nor the combination of cells with TAPI-2 could be observed, thereby proving that 
the measured fluorescence resulted solely from substrate cleavage. 
TACE activity of LPS-induced and TAPI-2-inhibited THP1 cells was also tested to see whether activities 
could be decreased to the level of uninduced THP1 cells. This was done after different incubation 
periods in the presence or absence of LPS (see Figure 27). TACE activities of LPS-induced and 
uninduced THP1 cells after 3 hours of incubation were found to be quite similar, except in the first 15 
minutes, indicating a slight increase in TACE activity in LPS-induced cells. TAPI-2 inhibited TACE 
activities to similar levels as already observed (~50-60% of remaining activity) and was found to be 
slightly higher in LPS-induced than in uninduced cells, especially within the first 30 minutes of 
measurement. After 6 and 24 hours of incubation, respectively, inhibition of LPS-induced and 
uninduced THP1 cells resulted in similar remaining activities which were also higher than after 3 
hours of incubation when compared to the respective uninhibited activities. This may point to a 
probable reduction of TACE abundancy after longer incubation periods with LPS given that the used 
substrate concentration is high enough to ensure enzyme saturation or to a reduction in the 
responsiveness to LPS as it is reported in PMA-treated THP1 cells (Daigneault, Preston, Marriott, 
Whyte, & Dockrell, 2010). Nevertheless, TACE activity of LPS-treated cells was about 20% higher than 
in untreated cells.  
Therefore we used higher concentrations of LPS than 10ng/ml. THP1 cells were incubated for 3, 6 or 
24 hours with 10ng/ml, 100ng/ml or even 10µg/ml LPS (see Figure 28). No significant difference in 
TACE activity could be detected when cells were treated with different LPS concentrations; we 
therefore considered using higher concentrations than 10ng/ml of LPS unnecessary. This was further 
supported by the finding that TACE activities of induced and uninduced cells could also be inhibited 
using lower concentrations than of TAPI-2, but inhibition did not decrease with decreasing 
concentration of TAPI-2 (see Figure 29 and Figure 30). 
A further explanation for the absence of a significant difference between TACE activities in LPS-
induced and uninduced THP1 cells is the possible presence of TACE inhibitors in the serum (Doedens, 
Mahimkar, & Black, 2003). Although the assay is performed in a buffer without serum, there might 
still be inhibitors bound to TACE from the incubation with LPS. To test this hypothesis, THP1 cells 
were incubated with and without LPS in medium containing 1% or 5% FCS (see Figure 31). The TACE 
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activity of uninduced cells (without LPS) incubated in 5% FCS prior to the assay was lower than the 
activities of TAPI-2-inhibited cells. After LPS treatment of cells in medium containing 1% FCS, 
measured TACE activities were significantly higher in LPS-induced than in noninduced cells. This 
supports the possible presence of inhibitor of TACE in the serum which may interfere with the assay 
even though the medium is changed for the assay buffer. Apparently, some inhibitors are still 
present after medium removal. Inhibition of TACE by TAPI-2 reduced substrate cleavage of LPS-
induced cells significantly. Surprisingly, the activity of TACE on noninduced cells could not further be 
inhibited, assuming, that in low serum TACE is either inactivated or not expressed unless cells are 
preincubated with LPS. 
Substrate cleavage was further found to correlate with cell density (see Figure 32) and increased with 
increasing cell number independent of LPS treatment with the exception of the highest used density 
of 1x106 cells. This points to a limitation in cell density above which substrate cleavage is impaired.  
TACE activities in primary rat Kupffer cells were not significantly different when cells were 
preincubated with medium, palmitic acid or two different concentrations of LPS for 3 hours (see 
Figure 33). Substrate cleavage could be inhibited by addition of TAPI-2 but not in a clear, dose-
dependet manner, except when cells were preincubated with 100ng/ml LPS (see Figure 33c). 
Therefore, primary rat Kupffer cells may not respond to LPS with a significantly increased TACE 
activity. The expression of TACE in primary rat Kupffer cells was previously demonstrated by 
members of our group (Bintner, 2011). Further experiments are therefore required to test whether a 
shorter period of incubation with LPS using medium with just 1% FCS would result in more significant 
differences of TACE activities.  
To make sure that there is a response of Kupffer cells to the LPS treatment, the secretion of TNFα 
into the supernatant was measured by ELISA (see Figure 34). TNFα could be detected in the 
supernatant of LPS treated cells at all time points investigated. Secretion of TNFα was also 
significantly decreased by the addition of TAPI-2, indicating that TACE is the primary sheddase for 
TNFα in primary rat Kupffer cells. Cells kept in medium or incubated with PMA, which is reported to 
increase TACE activity on DRM-cells (Doedens, Mahimkar, & Black, 2003) and MonoMac-6 cells 
(Scott, et al., 2011), did not secrete significant amounts of TNFα into the supernatant, although some 
shedding occurred after 6 hours in PMA-treated cells (about 680pg/ml; see Table 24). Nevertheless, 
TNFα concentrations after 6 hours in the supernatant of LPS-induced and TACE-inhibited (TAPI-2) 
cells was higher than in the supernatant of PMA-treated cells indicating that LPS is a far stronger 
inducer of TACE activity than PMA in primary rat Kupffer cells. 
The fact that cleavage of the substrate could never be completely abrogated by the TACE specific 
inhibitor TAPI-2 indicates that further proteinases are involved in substrate cleavage on the 
membrane of primary rat Kupffer cells. Furthermore, it has to be taken into account that there might 
as well be inhibitors present in the incubation medium (FCS) that still inhibit TACE activity after 
changing the medium for the assay buffer, as it seems to be the case with THP1 cells. Another fact 
that has to be considered in establishing a fluorescence based assay is the stability of the used 
substrate DABCYL-TNFα-EDANS. In every assay that was performed, a positive control for the 
cleavage of the substrate was included. In this postitive control, trypsin was used for the cleavage of 
the substrate. The measured maximal fluorescent values (of trypsin-cleaved substrate after 68 min of 
assay time) decreased from 8500 arbitrary units to 2400 arbitrary units within 12 weeks during which 
aliquots of the substrate in assay buffer remained stored at -20°C. To achieve maximum sensitivity in 
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the sense of highest measureable fluorescence, experiments should be carried out within the first 
few weeks after solubilisation of the substrate to avoid loss of sensitivity. 
 
Effects of in-vivo oil treatment on FFA serum levels and gene expression  
Apart from in-vitro experiments we were interested in the in-vivo effects of oil ingestion, particularly 
in the transcriptional changes in the liver. Therefore rats were administered oil (1ml/100g body 
weight) or the same volume of water by gavage. The rats were sacrified 20 hours after administration 
and the concentration of free fatty acids in the sera and the gene expression in the liver was 
analyzed. Furthermore, another group of rats was administered oil daily on 6 consecutive days by 
gavage and gene expression in mesenchymal and parenchymal cells of the liver was compared with 
water-treated controls from the one-time administration experiment (20 hours). 
The concentration of free fatty acids in the sera of oil-treated rats was found to be almost twice as 
high as in water-treated controls (see Figure 35 and Table 25) 20 hours after a one-time 
administration. After this period of time the administered oil is therefore already taken up and 
transported throughout the body and reaches the liver.  
As inflammatory responses in the liver are mainly mediated by cells of the mesenchyme, we focused 
on the transcriptional changes in these cells, but also investigated changes in hepatocytes. 
Surprisingly, more genes were differentially expressed in mesenchymal cells (18 genes 
downregulated and 433 genes upregulated) than in parenchymal cells (3 genes downregulated and 9 
upregulated) between oil-treatment and water-control. This leads to the assumption that oil-
treatment has a greater effect on mesenchymal cells than on hepatocytes. The latter might not have 
to adapt their gene expression to a higher content of lipids in total metabolites as they basically 
represent the center of lipid metabolism and distribution in the body.  
Genes with differential expression in mesenchymal cells of the livers of oil-treated animals compared 
to water-treated controls are involved in several pathways including immune 
response/inflammation, apoptosis, acute phase reactions, oxidative stress, regulation of the 
complement system, sugar, amino acid, purine and lipid metabolism, bile acid metabolism, lipid 
transport and lipoprotein assembly, ketone bodies and retinoic acid metabolism, liver regeneration, 
detoxification, eicosanoid production, the kinin-kallikrein-system, regulation of blood coagulation 
and blood pressure, cell cycle and genes associated with hyperlipidemia and obesity among others 
that will be discussed separately. The pathways involving most of the upregulated genes were 
metabolic ones including amino acid metabolism, fatty acid degradation (mitochondrial and 
peroxisomal), steroid and triglyceride biosynthesis and regulation and transport of lipids in 
lipoprotein particles as well as genes involved in bile acid metabolism and production of ketone 
bodies indicating the need of mesenchymal cells to adapt to a higher lipid content in metabolites. 
Nine genes could be assigned to having a role in immune response with Ccl4 being 2-fold 
downregulated 20 hours after treatment as well as after 6 days of treatment; the other eight genes 
were found to be upregulated. Nupr1, for example, was reported to be a transcription factor 
upregulated in inflammatory processes regulating cell proliferation and tissue stress and is also 
induced by LPS via TNFα and NF-κB signaling in rat hepatoma cells (Kallwellis, Grempler, Günther, 
Päth, & Walther, 2006). Arginase, an enzyme of the urea cycle which enables mammals to dispose 
  Discussion   
75 
 
otherwise toxic ammonia, was also found to play a role in regulating immune responses in the liver 
(Thomson & Knolle, 2010) and in cell proliferation of endothelial cells by the production of essential 
polyamines (Li, Meininger, Kelly, Hawker, Morris, & Wu, 2002). Rarres2 is a chemoattractant for cells 
of the innate and adaptive immune system (via binding to the receptors CCRL2 and GPR1 on immune 
cells), its plasma level correlates with BMI and its expression was also found to be induced by TNFα 
and IL-1β, whereas its loss was shown to affect the expression of GLUT4, DGAT2, leptin and 
adiponectin, all of which are involved in metabolism (Ernst & Sinal, 2010). Orm1 (also termed α1-acid 
glycoprotein, AAG) is a typical acute phase reactant and inflammation associated protein in rats 
comparable to C-reactive protein in humans (Kuribayashi, Tomizawa, Seita, Tagata, & Yamamoto, 
2011). A further acute phase reactant is haptoglobin, a hemoglobin-binding protein and antioxidant. 
Its expression is induced by IL-6 via STAT3 signaling and it is hypothesized to regulate the level and 
duration of inflammatory processes (Wang, Kinzie, Berger, Lim, & Baumann, 2001). Expression of 
inter alpha-trypsin inhibitor, heavy chain 4 (Itih4), together with haptoglobin, was found to be 
induced in hepatoma cells treated with IL-6 (Piñeiro, et al., 1999). Fgg, together with others, was 
found to be increased during CCl4 induced liver fibrosis in rats (Cai, Shen, Zhou, & Wang, 2006). Most 
of these genes were not more than 2-fold upregulated anymore after 6 days of daily treatment, 
except for arginase (2.573-fold) and Serpina3n (2.035-fold), indicating that oil-treatment might 
induce an acute inflammatory response in the liver mesenchyme of rats which is attenuated after 
some days of treatment, pointing to an adaption to high fat content. 
Genes of the complement system were also found to be upregulated including Mbl1, C9, C8a, Masp2 
and Cfi. Upregulation of all genes 20 hours after the one-time oil treatment was attenuated after 6 
days of treatment, with the exception of Cfi, which is an inhibitor of the C3 convertase, thus, 
indicating an induction and a concomitant, prolonging inhibition of the complement system. Linked 
to this system is the Kinin-kallikrein system, of which Kng1 and Kng2 were found to be induced 20 
hours after the one-time oil administration. As it was the case in activation of the complement 
system, an inhibitor, Serpina4, was also found to be induced by the oil administration. The human 
homolog of Serpina4, kallistatin, was reported to inhibit kallikrein, the proteinase that cleaves and 
activates kininogens into mature kinins (Chao, Miao, Chen, Chen, & Chao, 2001). The third system 
besides the complement system and the kinin-kallikrein system that is regulated by factor F12 is 
blood coagulation of which the factors F9, F10, Serpinc1, Serpind1, Proc and Apoh were found to be 
upregulated. Serpinc1 is an inhibitor for F9, which in turn activates F10. Protein C (Proc) inhibits 
activation of F5 which would further activate thrombin which is also inhibited by Serpind1. Apoh was 
found to be an inhibitor of the intrinsic pathway of blood coagulation (Schousboe, 1985). With 
angiotensin II receptor 1a being also upregulated, this indicates to an overall increase of mRNA of 
components of systems regulating inflammation, blood pressure and coagulation including immature 
precursors and inhibitors. Although the upregulation of these genes was mostly just detectable after 
a one-time administration of oil (with the exception of Proc, F9 and Cfi) this might be the pathways 
responsible for the development of hypertension and chronic inflammation upon long-time challenge 
of the body with high contents of lipids.  
Factors contributing to liver regeneration (Hgfac, Hrsp12, Apoa5 and Tm4sf4) were found to be 
upregulated. Hepatocyte growth factor activator (Hgfac) converts immature hepatocyte growth 
factor (HGF) into its mature, active form, which is involved in the recovery of the injured liver 
(Kaibori, et al., 2002). Heat-responsive protein 12 (Hrsp12) was also found to be upregulated during 
liver regeneration and probably acts as a fatty acid inducible protein in enterocytes (Kanouchi, et al., 
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2006) (Kanouchi, et al., 2006). Apoa5 is also reported to be upregulated during liver regeneration, 
more specifically during the early phase (van der Vliet, et al., 2001). Transmembrane 4 L six family 
member 4 (Tm4sf4) was found to be overexpressed during CCl4-induced liver injury and also seems 
to accelerate it by affecting TNFα and TNFR1 expression (Qiu, et al., 2007). Altogether, upregulation 
of these genes, two of which (Hrsp12 and Tm4sf4) were still more than 2-fold upregulated after 6 
days of treatment, leads to the assumption that some stress or even damage occurs in the liver upon 
oil administration leading to the expression of genes involved in regeneration of this organ. This is 
further supported by the finding of the upregulation of genes involved in oxidative stress responses 
(Mgst1, Gstt2 and Gstm2) and the high increase in a vitamin E transporter (Ttpa), of which Gstm2 
and Ttpa were still 2.14-fold and 3.59-fold, respectively, upregulated after 6 days of oil-treatment 
compared to controls. Furthermore, genes involved in detoxification reactions were upregulated, 
such as Aldh3a2, which is responsible for the detoxification of lipid peroxidation products (Demozay, 
et al., 2004) which arise and accumulate in livers after ingestion of peroxidized oil (Sagmeister, 2009). 
Among these were also genes responsible for the detoxification of xenobiotics like aflatoxin or 
nicotine (Akr7a2, Cyp3a9, Fmo5 and Cyp1a2). 
In addition, factors reported to be overexpressed or involved in the development of obesity or of its 
symptom, hypertriglyceridemia, were found to be upregulated after oil administration. Solute carrier 
family 27 (fatty acid transporter), member 2 (Slc27a2) is implicated in lipid biosynthesis and fatty acid 
degradation and was found to be overexpressed in a diet-induced obesity model of rats and might be 
a possible marker for overweight development as its overexpression correlates with body weight 
increase (Caimari, Oliver, Rodenburg, Keijer, & Palou, 2010). Angiopoietin-like 3 (Angptl3) is a LXR 
induced, liver specific gene whose expression accounts for hypertriglyceridemia and its absence leads 
to triglyceride accumulation in the liver (Inaba, et al., 2003). Similarly apolipoprotein C-I (Apoc1) 
inhibits the binding of lipoprotein particles to the LDL-receptor, thereby aggravating 
hypertriglyceridemia (Jong, Hofker, & Havekes, 1999). Of these only Slc27a2 was found to be still 
upregulated after 6 days of daily oil administration supporting the hypothesis of a possible marker 
for overweight development. 
Further genes found to be upregulated included dimethylarginine dimethylaminohydrolase 1 (Ddah1) 
which metabolizes asymmetric dimethylarginine, an inhibitor of nitric oxide synthesis. 
Overexpression of Ddah1 was shown to increase NO production and expression of VEGF resulting in 
increased angiogenesis and seems to play an important role in tumor associated angiogenesis 
(Kostourou, Robinson, Cartwright, & Whitley, 2002). Induction of similar intensity was found for 
regucalcin (Rgn) which is a calcium-induced gene reported to suppress NO production in the cytosol 
of rat livers (Yamaguchi, Takahashi, & Tsurusaki, 2003). In addition the transcription factor or 
regucalcin, Sec16b, was also found to be upregulated. Overexpression of Sec16b was shown to 
inhibit the gene expression of Casp3 and Casp8, thereby suppressing cell death (Yamaguchi, 2009). 
This shows additionally the increased expression of genes involved in the regulation of critical 
pathways implicated in inflammation (NO production) and cancer related angiogenesis. 
G0/G1switch2 was reported to be a direct PPARγ and probable PPARα target gene which is expressed 
in the liver and is upregulated during adipogenesis (Zandbergen, et al., 2005). Rbp4 is an adipokine 
produced by adipose tissue and liver and was found to contribute to insulin resistance development 
and positively correlates with blood pressure (Ou, Wu, Yang, Wu, Cheng, & Chang, 2011). Further, 
Grb14, a negative regulator of insulin signaling in the liver (Desbuquois, Béréziat, Authier, Girard, & 
Burnol, 2008), was 3.39-fold upregulated upon oil administration and was still upregulated 2.35-fold 
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after 6 days of oil administration. Asialoglycoprotein receptor 1 (Asgr1) mRNA and protein are 
downregulated in ethanol-induced fatty livers of rats as shown by Casey and colleagues (Casey, 
McVicker, Donohue, McFarland, Wiegert, & Nanji, 2004). Conversely, we found Asgr1 4.2-fold and 
2.8-fold upregulated in livers of rats treated once or for 6 days with oil, respectively, compared to 
water-treated controls. Casey et al. compared fish-oil and ethanol treated rats with medium-chain 
triglyceride and ethanol treated rats and found a more pronounced downregulation of Asgr1 in the 
fish-oil treated group. As also ethanol was present in both groups of rats and Asgr1 is already 
downregulated in ethanol-treated rats, Asgr1 might be a possible ‘marker’ for distinguishing between 
alcohol caused and non-alcohol-caused steatosis. Kidney expressed gene 1 (Keg1, HP33) expression is 
stimulated in the regenerating liver and in hepatocellular carcinoma and also seems to play a role in 
the interphase of the cell cycle. 
The gene showing the highest upregulation in hepatocytes was vanin-1 (vnn1) which was 5.5-fold 
increased in rats administered oil once compared to water-treated controls and was even 6.15-fold 
increased in livers of rats treated with oil for 6 days. Vanin-1 is a pantetheine hydrolase and catalyzes 
the conversion of pantetheine into cysteamine (an anti-oxidant) and pantothenate (or pantothenic 
acid, vitamin B5), therefore indicating a role for vanin-1 in fatty acid metabolism, inflammation, 
oxidative stress response (detoxification of lipid peroxidation products) and numerous diseases. 
Vanin-1 knockout mice showed enhanced resistance to oxidative stress and reduced oxidative stress-
induced tissue inflammation. As the gene might also show anti-inflammatory and protective 
properties, its expression has to be tightly controlled to avoid deregulation resulting in a disease 
state (Kaskow, Proffit, Blangero, Moses, & Abraham, 2012). 
Taking all the expressed genes and pathways together, this forms the picture of an increased 
metabolism (lipid, steroid, sugar, and bile acid), increased immune response (inflammation, 
complement), upregulation of components involved in the regulation of blood pressure and clotting, 
liver regeneration, oxidative stress response, regulation of NO-production and angiogenesis and 
factors involved in the development of insulin resistance, hypertriglyceridemia and obesity 
development. Although these genes were mostly found to be upregulated after a one-time 
administration of oil and just some of them were still upregulated after a 6 day oil-treatment, these 
genes might be the first ones of many whose deregulation contributes to the development of the 
various symptoms of the metabolic syndrome, one of which is the fatty liver that clearly predisposes 
towards NASH and HCC. 
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Abstract 
 
Hepatocellular carcinoma (HCC) is the most common form of liver cancer and the third most 
common cause of cancer death. It develops in the background of chronic liver inflammation which 
might arise in a fatty liver. Predisposing conditions for the development of non-alcoholic 
steatohepatitis (NASH) are obesity and non-alcoholic fatty liver disease (NAFLD), both of which were 
shown to dramatically increase the risk of developing cancer, especially HCC. As inflammation plays a 
major role in the development and progression of HCC, we tried to elucidate the role of free fatty 
acids in the onset of inflammation, since their concentration is increased in obesity and NAFLD. 
Therefore we performed in-vitro experiments treating primary rat mesenchymal and parenchymal 
cells with free fatty acids and taking a closer look at protein phosphorylation, gene expression and 
secretion of the pro-inflammatory cytokine TNFα. As ADAM17/TACE, a ‘sheddase’, seems to be 
involved in the conversion of inflammation-associated precursors into their mature forms and this 
sheddase is also found to be overexpressed in chronic liver injury and HCC, we were interested 
whether its activity could be increases by free fatty acids and therefore aimed to develop a real-time 
enzyme assay using live cells. In order to estimate in-vivo changes caused by a high lipid content in 
food, rats were administered oil by gavage and we analysed the content of free fatty acids in the 
plasma and the changes of gene expression in the liver. 
We found that treatment of primary rat mesenchymal cells which palmitic acid, a saturated fatty 
acid, led to a 2-fold increase in the mRNA level of TNFα which seemed mainly be mediated by Kupffer 
cells. Endothelial cells did not respond to FFA-treatment by increasing the expression of COX-2, iNOS 
or TNFα, thereby masking the upregulation of these genes in total mesenchymal cells, as also COX-2 
and iNOS expression were only found to be elevated in Kupffer cells. Inhibition of CD36, a fatty acid 
receptor and translocase, which is expressed in hepatocytes, endothelial cells and Kupffer cells, 
resulted in a reduction of COX-2, iNOS and TNFα expression levels in palmitic acid treated Kupffer 
cells. CD36-mediated downstream signaling seemed to be independent of p38MAPK or Erk1/2 since 
we found no activating phosphorylation of these kinases in palmitic acid treated cells. 
In-vivo oil administration to rats resulted in a 2-fold increase in the concentration of free fatty acids 
in the serum and in the upregulation of genes involved in metabolism (fatty acids, steroids and 
sugars), immune responses (inflammation and complement system), regulation of blood pressure 
and coagulation, oxidative stress, angiogenesis and liver regeneration in cells of the liver 
mesenchyme indicating the increased challenge of the liver by the ingestion of food which contains a 
high lipid content. Among the upregulated genes were also some which were reported to correlate 
with the development of insulin resistance, hypertriglyceridemia and obesity, all of which contribute 
to the metabolic syndrome and predispose towards non-alcoholic steatohepatitis and HCC. Most 
changes in gene expression were found to occur in mesenchymal cells rather than in parenchymal 
cells indicating a substantial contribution of the liver mesenchyme and most probably of Kupffer cells 
in the early onset of immune reactions. Additionally, the highest upregulated gene found in 
hepatocytes was vanin-1 which seems to connect fatty acids metabolism with inflammation and 
oxidative stress responses urging the need for a tight regulation and control of this gene in the cell.
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Zusammenfassung 
Das Hepatozellulare Karzinom ist die häufigste Form des Leberkrebses und die dritthäufigste 
Krebstodesursache. Es entsteht in Folge einer chronischen Leberentzündung, deren Ursache häufig 
eine Fettleber ist. Fettleibigkeit und die entstehende Fettleber (nichtalkoholische Fettleber; NAFLD) 
sind prädestinierende Vorrausetzungen für die Entwicklung einer Fettleberentzündung 
(nichtalkoholische Fettleberentzündung, NASH). In beiden Erkrankungen zeigt sich ein erhöhtes 
Risiko für die Entstehung von Krebs, speziell für das hepatozellulare Karzinom. Da Entzündungen eine 
große Rolle bei der Entstehung und weiteren Entwicklung von Leberkrebs spielen, haben wir 
versucht, die Rolle der freien Fettsäuren, deren Konzentration bei Fettleibigkeit und 
Fettlebererkrankungen erhöht ist, aufzuklären. 
 Dafür haben wir in-vitro Experimente mit mesenchymalen und parenchymalen Primärzellen der 
Ratte durchgeführt, in denen die Zellen mit freien Fettsäuren behandelt und anschließend die 
Proteinphosphorylierung, die Genexpression und die Sekretion des pro-inflammatorischen Zytokins 
TNFα analysiert wurde. Da die „Sheddase“ ADAM17/TACE in der Konvertierung von Vorstufen von  
entzündungsbeteiligten Faktoren in ihre lösliche, aktive Form beteiligt zu sein scheint, und des 
Weiteren auch in chronischen Lebererkrankungen und Leberkrebs überexprimiert sein dürfte, waren 
wir daran interessiert zu sehen, ob ihre Enzymaktivität sich durch freie Fettsäuren erhöhen würde. 
Daher haben wir versucht, eine Möglichkeit zu entwickeln, die Enyzmaktivität auf lebenden Zellen zu 
messen. Um die in-vivo Veränderungen, die durch eine fettreiche Nahrung entstehen, abschätzen zu 
können, wurde Ratten Öl mittels Schlundsonde verabreicht und die freien Fettsäuren im Plasma 
bestimmt und die Änderungen der Genexpression in der Leber analysiert. 
Die Behandlung von primären Rattenzellen mit Palmitinsäure, einer gesättigten Fettsäure, führte zu 
einem zweifachen Anstieg der TNFα mRNA, was hauptsächlich durch Kupfferzellen versucht wurde. 
Endothelzellen reagierten auf die Fettsäurebehandlungen nicht mit einer Veränderung in der 
Genexpression von COX-2, iNOS oder TNFα, was auch die Expressionsänderung in der 
mesenchymalen Zellenfraktion maskiert haben dürfte, da diese Gene nur in Kupfferzellen erhöht 
exprimiert wurden. Die Inhibierung von CD36, einem Fettsäurerezeptor und -transporter, der von 
Hepatozyten, Endothelzellen und Kupfferzellen exprimiert wird, resultierte in einer verminderten 
Expression von COX-2, iNOS und TNFα in palmitinsäurebehandelten Kupfferzellen. Die durch CD36 
verursachte Signalweiterleitung scheint unabhängig von den Kinasen p38 und Erk zu sein, da keine 
aktivierenden Phosphorylierungen in palmitinsäurebehandelten Zellen gefunden wurde. 
Die Ölschlundierung von Ratten führte zu einer zweifachen Erhöhung der freien Fettsäuren im Serum 
der Tiere und zu der Expression von Genen, die im Metabolismus (von Fetten, Steroiden und 
Zuckern), in der Immunantwort (Entzündungen und Komplementsystem), in der Regulierung des 
Blutdrucks und der –koagulation, bei oxidativem Stress, Angiogenese sowie in der 
Leberregenerierung involviert sind. Das deutet auf eine erhöhte Forderung der Leber durch 
fettreiche Nahrung hin. Unter den erhöht exprimierten Genen waren solche, die mit der Entstehung 
von Insulinresistenz, Hypertriglyceridämien und Fettleibigkeit korrelieren. All diese Erkrankungen 
tragen zum Metabolischen Syndrom bei und erhöhen das Risiko für Leberentzündung und Krebs. Die 
meisten Veränderungen in der Genexpression wurden in mesenchymalen Zellen beobachtet, was auf 
deren wesentliche Rolle (und im Speziellen von Kupfferzellen) in der frühen Entstehung von 
Immunreaktionen hindeuten könnte. Zusätzlich scheint das am Höchsten raufregulierte Gen in 
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Hepatozyten (Vanin-1) den Fettsäuremetabolismus mit Entzündungsreaktionen und oxidativem 
Stress zu verknüpfen, was es besonders notwendig erscheinen lässt, dass dieses Gen ganz genau in 
den Zellen reguliert und kontrolliert wird. 
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List of abbreviations 
ACOX – acyl coenzyme A oxidase 1 
ADAM17 – a disintegrin and metalloproteinase 17 (synonym for TACE) 
AhR – aryl hydrocarbon receptor 
ALA – α-linolenic acid 
ALT – alanine aminotransferase 
AST – aspartate aminotransferase 
ATGL – Adipose triglyceride lipase 
BMI – Body-mass-index 
BSA – bovine serum albumin 
cAMP – cyclic adenosine monophosphate 
COX2 – cyclooxygenase 2, prostaglandin synthase 2 
CPT-I – carnitine palmitoyltransferase-I 
CRP – C-reactive-protein 
DAMP – damage-associated molecular pattern 
DEN – diethylnitrosamine 
DGAT – diacylglycerol acyl transferase 
DHA – docosahexaenoic acid 
DMSO – dimethyl sulfoxide 
DNL – de-novo lipogenesis 
EC – endothelial cell 
EGFR – epidermal growth factor receptor 
EMT – epithelial-mesenchymal transition 
EPA – eicosapentaenoic acid 
EtOH – ethanol 
FFA – free fatty acid (synonym for NEFA) 
GPR – G-protein-coupled receptor 
HB-EGF – heparin-binding epidermal growth factor 
HBV – hepatitis B virus 
HC – hepatocytes 
HCC – hepatocellular carcinoma 
HCV – hepatitis C virus 
HFD – high fat diet 
HGF – hepatocyte growth factor 
IL6 – interleukin 6 
iNOS – inducible nitric oxide synthase 
JAK – Janus Kinase 
KC – Kupffer cell 
LH – linolic acid 
LOX – lipoxygenase 
LXR – liver X receptor 
MAPK – mitogen-activated protein kinase 
MCP-I – monocyte chemoattractant protein 1, (synonym for CCL2) 
MIF – macrophage migration inhibitory factor 
MMP – Matrix metalloproteinase 
NAFLD – non-alcoholic fatty liver disease 
NASH – non-alcoholic steatohepatitis 
NEFA – non-esterified fatty acid (synonym for FFA) 
NOD – Nucleotide-binding oligomerization domain protein 
NPC – non-parenchymal cell, mesenchymal cell 
PA – palmitic acid 
PAMP – pathogen-associated molecular pattern 
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PGE2 – prostaglandin E2 
PKA – protein kinase A 
PMA – phorbol 12-myristate 13-acetate 
PRR – pattern recognition receptor 
PUFA – polyunsaturated fatty acid 
PXR – pregnane X receptor 
ROS – reactive oxygen species 
SFA – saturated fatty acid 
SOCS – suppressor of cytokine signaling 
SREBP – sterol regulatory element-binding protein 
SSO - Sulfosuccinimidyl oleate sodium 
STAT – signal transducer and activator of transcription 
T2D – type 2 diabetes 
TACE – TNFα converting enzyme (synonym for ADAM17) 
TAK – TGFβ activated kinase 
TG – triglyceride 
TNFα – tumor necrosis factor alpha 
UPR – unfolded protein response 
VEGFR – vascular endothelial growth factor 
VLDL – very low-density lipoprotein 
WHO – World Health Organization 
 
 
 
 
  Appendix   
87 
 
Supplementary data 
Changes in gene expression in mesenchymal cells after 20h 
Affymetrix ID Public ID Gene Symbol Gene Title 
fold 
control SD 
1378690_at BI291986 Ly6al lymphocyte antigen 6 complex, locus A-like 0,195 0,244
1387839_at NM_012646 
RT1-N1 /// 
RT1-N2 RT1 class Ib, locus N1 /// RT1 class Ib, locus N2 0,395 0,160 
1391279_at AI112564 Scin Scinderin 0,417 0,128
1388275_at AW919577 Tcrb T-cell receptor beta chain 0,422 0,085
1388968_at BF402642 Mpped1 metallophosphoesterase domain containing 1 0,431 0,151
1376908_at AW531805 Ifit3 interferon-induced protein with tetratricopeptide repeats 3 0,433 0,196
1370499_at M62891 Klrb1a killer cell lectin-like receptor subfamily B, member 1A 0,439 0,085
1377626_at AA924350 LOC690768 Hypothetical protein LOC690768 0,445 0,162
1382999_at AI411747 Art2b ADP-ribosyltransferase 2b 0,450 0,102
1379653_a_at AI176327 Sh2d1a SH2 domain protein 1A 0,474 0,152
1380967_at BE101670 Nts neurotensin 0,478 0,098
1373994_at BM388789 Aplf aprataxin and PNKP like factor 0,483 0,201
1392309_at BI300426 Jam2 junctional adhesion molecule 2 0,484 0,211
1377163_at BM385741 Inhbb inhibin beta-B 0,485 0,205
1370394_at L22654 IgG-2a gamma-2a immunoglobulin heavy chain 0,486 0,373
1370832_at U06434 Ccl4 chemokine (C-C motif) ligand 4 0,489 0,133
1371015_at X52711 Mx1 myxovirus (influenza virus) resistance 1 0,493 0,088
1379794_at AI029386 Gzmb granzyme B 0,497 0,111
1380066_at BF401956 Tfr2 transferrin receptor 2 2,005 0,736
1370019_at AF394783 Sult1a1 sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1 2,008 1,677
1373134_at BE329450 Fahd2a fumarylacetoacetate hydrolase domain containing 2A 2,010 1,204
1370155_at BM388837 Col1a2 collagen, type I, alpha 2 2,010 1,300
1388526_at AI169075 Gstz1 glutathione transferase zeta 1 2,013 1,808
1387372_at NM_133623 Slc6a13 
solute carrier family 6 (neurotransmitter transporter, GABA), 
member 13 2,016 1,082 
1370939_at D90109 Acsl1 acyl-CoA synthetase long-chain family member 1 2,020 0,984
1367598_at NM_012681 Ttr transthyretin 2,022 1,381
1391538_at AI137938 Cideb cell death-inducing DFFA-like effector b 2,026 1,474
1367755_at NM_052809 Cdo1 cysteine dioxygenase, type I 2,026 1,414
1370821_at AF120100 Tpmt thiopurine S-methyltransferase 2,026 1,228
1372158_at BI295768 Macrod1 MACRO domain containing 1 2,028 1,397
1382235_at BF549700 RGD1306809 similar to hypothetical protein FLJ30596 2,028 1,499
1371379_at AI011738 RGD1563422 similar to Brain protein 44 2,029 0,896
1370547_at M84000 Pzp pregnancy-zone protein 2,029 1,386
1368574_at NM_016991 Adra1b adrenergic, alpha-1B-, receptor 2,029 0,635
1377192_a_at BM384629 Clpx ClpX caseinolytic peptidase X homolog (E. coli) 2,031 1,423
1370676_at AF436847 RGD1564614 similar to complement factor H-related protein 2,033 1,043
1371012_at AJ245707 Hacl1 2-hydroxyacyl-CoA lyase 1 2,041 0,857
1381006_at BE119649 Hgfac hepatocyte growth factor activator 2,042 1,049
1368702_at U05989 Pawr PRKC, apoptosis, WT1, regulator 2,042 0,837
1392988_at BF407232 Nsdhl NAD(P) dependent steroid dehydrogenase-like 2,043 1,377
1369531_at NM_133547 Sult1c2 sulfotransferase family, cytosolic, 1C, member 2 2,048 1,182
1389738_at AA848420 Ung uracil-DNA glycosylase 2,048 0,845
1387567_at NM_017111 
LOC100360270 
/// Slco1a1 
solute carrier organic anion transporter family member 1A1-like /// 
solute carrier organic anion transporter family, member 1a1 2,053 1,205 
1368964_at NM_030856 Lrrn3 leucine rich repeat neuronal 3 2,054 1,361
1368536_at NM_057104 Enpp2 ectonucleotide pyrophosphatase/phosphodiesterase 2 2,055 0,766
1373243_at BG378288 Pmvk phosphomevalonate kinase 2,056 1,462
1368931_at NM_031238 Sh3gl3 SH3-domain GRB2-like 3 2,064 1,319
1393239_at BI296413 Mtfr1 Mitochondrial fission regulator 1 2,066 1,376
1389725_at BM390364 Tm7sf2 transmembrane 7 superfamily member 2 2,067 0,786
1367818_at NM_019187 Coq3 coenzyme Q3 homolog, methyltransferase (S. cerevisiae) 2,068 1,017
1371094_at L06804 Lhx2 LIM homeobox 2 2,072 1,308
1387233_at NM_017235 Hsd17b7 hydroxysteroid (17-beta) dehydrogenase 7 2,073 1,237
1370952_at AI169331 Gstm2 glutathione S-transferase mu 2 2,074 1,532
1387783_a_at NM_012489 
Acaa1 /// 
RGD1562373 
acetyl-Coenzyme A acyltransferase 1 /// similar to 3-ketoacyl-CoA 
thiolase B, peroxisomal precursor (Beta-ketothiolase B) 2,083 1,178 
1388908_at BI278268 Peci peroxisomal D3,D2-enoyl-CoA isomerase 2,083 1,181
1369720_at NM_053986 Myo1b myosin Ib 2,088 1,057
1369657_at NM_016998 Cpa1 carboxypeptidase A1 2,091 1,527
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Affymetrix ID Public ID Gene Symbol Gene Title 
fold 
control SD 
1393241_at BI295197 Prss32 protease, serine, 32 2,091 1,169
1389551_at AI008160 Lactb2 lactamase, beta 2 2,097 1,165
1376847_at BI302283 Mosc1 MOCO sulphurase C-terminal domain containing 1 2,100 0,759
1368244_at NM_080890 As3mt arsenic (+3 oxidation state) methyltransferase 2,100 1,278
1368943_at NM_020082 Rnase4 ribonuclease, RNase A family 4 2,101 1,407
1378536_at AI638960 Hook1 hook homolog 1 (Drosophila) 2,102 1,310
1370377_at M25143 
Cyp2d1 /// 
Cyp2d5 
cytochrome P450, family 2, subfamily d, polypeptide 1 /// 
cytochrome P450, family 2, subfamily d, polypeptide 5 2,108 1,086 
1368316_at NM_019158 Aqp8 aquaporin 8 2,109 1,422
1392825_at AA923852 RGD1559600 RGD1559600 2,111 1,416
1386904_a_at AF007107 Cyb5a cytochrome b5 type A (microsomal) 2,111 1,106
1374947_at BI286041 Bcar3 breast cancer anti-estrogen resistance 3 2,112 0,858
1368365_at NM_031731 Aldh3a2 aldehyde dehydrogenase 3 family, member A2 2,114 0,934
1383920_at BF408907 Amt aminomethyltransferase 2,114 1,182
1387821_at NM_017313 Rab3ip RAB3A interacting protein (rabin3) 2,118 0,973
1389177_at AI598971 Perp PERP, TP53 apoptosis effector 2,127 1,373
1368418_a_at AF202115 Cp ceruloplasmin 2,133 0,952
1385668_at AI044864 LOC683460 hypothetical protein LOC683460 2,135 1,446
1393403_at AI058911 Angptl3 angiopoietin-like 3 2,138 1,863
1376733_at AI407898 Igsf11 immunoglobulin superfamily, member 11 2,141 1,588
1391806_at AA957557 LOC498793 similar to inter-alpha-inhibitor H2 chain 2,142 1,476
1368087_a_at NM_133545 Ptpn21 protein tyrosine phosphatase, non-receptor type 21 2,143 1,103
1370148_at NM_012582 Hp haptoglobin 2,144 1,390
1390172_at AI409946 Dhtkd1 dehydrogenase E1 and transketolase domain containing 1 2,145 1,180
1398252_at NM_017209 Mecr mitochondrial trans-2-enoyl-CoA reductase 2,153 1,113
1387082_at NM_053348 Fetub fetuin B 2,154 1,642
1394483_at AW535310 Adamts5 ADAM metallopeptidase with thrombospondin type 1 motif, 5 2,155 0,747
1387325_at NM_024143 Slc27a5 solute carrier family 27 (fatty acid transporter), member 5 2,160 1,438
1373210_at BI296460 Lamb1 laminin, beta 1 2,162 1,743
1372260_at BI296304 Rogdi rogdi homolog (Drosophila) 2,163 1,659
1390131_at BE112936 Srr serine racemase 2,166 1,492
1379606_at BM392291 Rab30 RAB30, member RAS oncogene family 2,167 1,276
1368060_at NM_031714 Hrsp12 heat-responsive protein 12 2,167 1,517
1387825_at NM_031533 Ugt2b UDP glycosyltransferase 2 family, polypeptide B 2,170 1,823
1383826_at AA924620 Rab40b Rab40b, member RAS oncogene family 2,179 1,984
1367612_at NM_134349 Mgst1 microsomal glutathione S-transferase 1 2,180 1,481
1383469_at BG377269 Aldh1a3 aldehyde dehydrogenase 1 family, member A3 2,180 1,410
1368587_at NM_012824 Apoc1 apolipoprotein C-I 2,181 1,458
1370396_x_at AF198441 Rup2 urinary protein 2 2,182 1,666
1387531_at NM_053307 Msra methionine sulfoxide reductase A 2,185 1,373
1369225_at NM_012741 Kng2 kininogen 2 2,186 1,744
1398260_a_at NM_024382 Serpind1 serine (or cysteine) peptidase inhibitor, clade D, member 1 2,186 1,376
1370299_at M10149 Aldob aldolase B, fructose-bisphosphate 2,188 1,459
1376546_at BE120498 RGD1565432 similar to hypothetical protein 2,190 1,299
1387093_at NM_131906 Slco1a4 solute carrier organic anion transporter family, member 1a4 2,193 1,618
1374959_at AA945624 Nqo2 NAD(P)H dehydrogenase, quinone 2 2,196 1,340
1388884_at BM390774 RGD1310224 similar to RIKEN cDNA 1810022C23 2,199 1,083
1368662_at NM_134374 Rnf39 ring finger protein 39 2,203 1,397
1391491_a_at BG377084 Rad23b RAD23 homolog B (S. cerevisiae) 2,204 1,203
1368824_at BM392106 Cald1 caldesmon 1 2,214 1,643
1371031_at AI454484 Mat1a methionine adenosyltransferase I, alpha 2,214 1,450
1388441_at BG379987 LOC689574 hypothetical protein LOC689574 2,214 1,359
1372438_at AI411100 Nit2 nitrilase family, member 2 2,215 1,325
1392090_at BG377322 Serpinc1 
serine (or cysteine) peptidase inhibitor, clade C (antithrombin), 
member 1 2,222 1,433 
1367843_at NM_134407 Akr7a2 
aldo-keto reductase family 7, member A2 (aflatoxin aldehyde 
reductase) 2,228 1,387 
1368707_at NM_019369 Itih4 inter alpha-trypsin inhibitor, heavy chain 4 2,230 1,314
1368409_at NM_012796 Gstt2 glutathione S-transferase, theta 2 2,233 1,325
1367828_at NM_022512 Acads acyl-Coenzyme A dehydrogenase, C-2 to C-3 short chain 2,233 1,325
1388422_at BI275904 Lims2 LIM and senescent cell antigen like domains 2 2,234 1,468
1375530_at BG374612 Gnpnat1 glucosamine-phosphate N-acetyltransferase 1 2,236 1,471
1386568_at BF557891 Irf6 interferon regulatory factor 6 2,240 1,661
1393242_at BE104107 Snrnp25 small nuclear ribonucleoprotein 25 (U11/U12) 2,242 1,373
1387765_at NM_012599 Mbl1 mannose-binding lectin (protein A) 1 2,244 1,440
1367847_at NM_053611 Nupr1 nuclear protein, transcriptional regulator, 1 2,247 1,653
1368380_at NM_019156 Vtn vitronectin 2,247 1,501
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1386954_at NM_030986 Ak2 adenylate kinase 2 2,249 1,213
1375056_at AA943310 LOC100365923 rCG57079-like 2,254 2,009
1369840_at NM_134379 UST4r integral membrane transport protein UST4r 2,259 1,595
1367979_s_at NM_012941 Cyp51 cytochrome P450, family 51 2,261 1,236
1387145_at NM_017251 Gjb1 gap junction protein, beta 1 2,261 1,431
1374478_at AA819329 RGD1305347 similar to RIKEN cDNA 2610528J11 2,265 2,046
1371083_at D00752 LOC299282 Serine protease inhibitor 2,269 1,652
1367917_at NM_012730 Cyp2d2 cytochrome P450, family 2, subfamily d, polypeptide 2 2,273 1,603
1369960_at NM_031648 Fxyd1 FXYD domain-containing ion transport regulator 1 2,278 2,217
1367720_at NM_012899 Alad aminolevulinate, delta-, dehydratase 2,288 1,242
1368431_at NM_017112 Hpn hepsin 2,300 1,042
1391433_at AA899721 Acot2 acyl-CoA thioesterase 2 2,306 1,083
1383654_a_at BE112523 Fn3k fructosamine 3 kinase 2,308 1,456
1370397_at M33936 Cyp4a3 cytochrome P450, family 4, subfamily a, polypeptide 3 2,308 1,399
1372000_at AI180187 Net1 neuroepithelial cell transforming 1 2,312 1,445
1369072_at NM_134329 Adh7 alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide 2,313 1,845
1393061_at AI030103 Ttc36 tetratricopeptide repeat domain 36 2,316 1,738
1368253_at NM_012793 Gamt guanidinoacetate N-methyltransferase 2,318 1,809
1372440_at BI275818 Serpine2 serine (or cysteine) peptidase inhibitor, clade E, member 2 2,318 1,656
1392189_at BE105136 Rfx4 Regulatory factor X, 4 (influences HLA class II expression) 2,328 1,172
1382325_at AW525471 Gcat 
glycine C-acetyltransferase (2-amino-3-ketobutyrate-coenzyme A 
ligase) 2,329 1,804 
1387228_at NM_012879 Slc2a2 solute carrier family 2 (facilitated glucose transporter), member 2 2,335 2,119
1368155_at NM_031572 Cyp2c12 cytochrome P450, family 2, subfamily c, polypeptide 12 2,339 1,791
1381574_at BF403907 Tmem195 transmembrane protein 195 2,340 1,738
1368397_at NM_031980 Ugt2b36 UDP glucuronosyltransferase 2 family, polypeptide B36 2,344 2,178
1376537_at AW435010 Ptpn3 Protein tyrosine phosphatase, non-receptor type 3 2,346 1,583
1368304_at NM_053433 Fmo3 flavin containing monooxygenase 3 2,347 2,288
1368583_a_at NM_133428 Hrg histidine-rich glycoprotein 2,348 2,472
1388569_at AI179984 Serpinf1 serine (or cysteine) peptidase inhibitor, clade F, member 1 2,354 1,606
1388617_at AW914746 Bphl biphenyl hydrolase-like (serine hydrolase) 2,357 1,634
1373748_at AW532566 Pdzrn3 PDZ domain containing RING finger 3 2,357 0,371
1369111_at NM_012556 Fabp1 fatty acid binding protein 1, liver 2,358 1,452
1367672_at NM_024392 Hsd17b4 hydroxysteroid (17-beta) dehydrogenase 4 2,362 1,160
1370496_at AB008424 Cyp2d3 cytochrome P450, family 2, subfamily d, polypeptide 3 2,366 1,519
1379744_at AI137930 Saa4 serum amyloid A4, constitutive 2,366 2,045
1388537_at BF554891 Nipsnap1 
4-nitrophenylphosphatase domain and non-neuronal SNAP25-like 
protein homolog 1 (C. elegans) 2,371 1,875 
1368150_at NM_031736 Slc27a2 solute carrier family 27 (fatty acid transporter), member 2 2,377 1,613
1396103_at BF556107 Cmbl carboxymethylenebutenolidase homolog (Pseudomonas) 2,382 1,760
1368266_at NM_017134 Arg1 arginase, liver 2,390 1,643
1369635_at NM_017052 Sord sorbitol dehydrogenase 2,391 1,813
1373924_at AI712686 Cpped1 calcineurin-like phosphoesterase domain containing 1 2,398 1,268
1370235_at AI175009 Dbi 
diazepam binding inhibitor (GABA receptor modulator, acyl-
Coenzyme A binding protein) 2,402 1,704 
1376765_at BF283408 Mro maestro 2,412 1,895
1377018_at BF284124 Pamr1 
peptidase domain containing associated with muscle regeneration 
1 2,414 1,751 
1374625_at AI176616 Hes6 hairy and enhancer of split 6 (Drosophila) 2,416 1,251
1393751_at AA859029 Fabp12 Fatty acid binding protein 12 2,421 2,195
1367667_at NM_031840 Fdps 
farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, 
dimethylallyltranstransferase, geranyltranstransferase) 2,421 1,699 
1371615_at BI279069 Dgat2 diacylglycerol O-acyltransferase homolog 2 (mouse) 2,422 1,486
1373625_at AI412012 Shmt1 serine hydroxymethyltransferase 1 (soluble) 2,422 1,426
1368400_at NM_053370 Timm8a1 translocase of inner mitochondrial membrane 8 homolog a1 (yeast) 2,424 1,563
1382864_at AI231808 Palmd palmdelphin 2,426 1,676
1375504_at BM390747 Polg2 polymerase (DNA directed), gamma 2, accessory subunit 2,430 1,881
1371519_at AA851258 Etfdh electron-transferring-flavoprotein dehydrogenase 2,430 1,571
1369764_at NM_012516 C4bpa complement component 4 binding protein, alpha 2,441 1,774
1389648_at AI170382 Ripk4 receptor-interacting serine-threonine kinase 4 2,442 1,681
1370836_at U51017 Serpina4 
serine (or cysteine) proteinase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 4 2,443 1,671 
1377048_at H31813 Dak dihydroxyacetone kinase 2 homolog (S. cerevisiae) 2,443 1,483
1387034_at NM_012619 Pah phenylalanine hydroxylase 2,444 1,684
1368336_at NM_017126 Fdx1 ferredoxin 1 2,444 2,178
1386274_at AI169925 Slc17a2 solute carrier family 17 (sodium phosphate), member 2 2,444 1,537
1384512_at AI072137 LOC100363441 hypothetical protein LOC100363441 2,444 1,827
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1377758_at BF415386 Hsd17b13 hydroxysteroid (17-beta) dehydrogenase 13 2,448 1,838
1386927_at NM_012930 Cpt2 carnitine palmitoyltransferase 2 2,454 1,213
1369073_at NM_021745 Nr1h4 nuclear receptor subfamily 1, group H, member 4 2,458 1,720
1370414_at M94043 Rab38 RAB38, member RAS oncogene family 2,463 2,139
1391417_at AA925145 Bhmt2 betaine-homocysteine methyltransferase 2 2,476 1,792
1384628_at AI549292 Iyd iodotyrosine deiodinase 2,478 1,628
1398516_at BF283013 Golt1a golgi transport 1 homolog A (S. cerevisiae) 2,481 1,885
1370086_at NM_012559 Fgg fibrinogen gamma chain 2,482 1,973
1367702_at NM_016986 Acadm acyl-Coenzyme A dehydrogenase, C-4 to C-12 straight chain 2,485 1,712
1379592_at AI045151 Slc25a13 solute carrier family 25, member 13 (citrin) 2,495 1,590
1374527_at AI172274 Echdc2 enoyl Coenzyme A hydratase domain containing 2 2,499 1,756
1368814_at NM_031057 Aldh6a1 aldehyde dehydrogenase 6 family, member A1 2,500 1,651
1376174_at AI137506 Serpina11 
serine (or cysteine) peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 11 2,505 1,843 
1369291_at NM_030985 Agtr1a angiotensin II receptor, type 1a 2,505 0,714
1387905_at AB062135 Dnajc12 DnaJ (Hsp40) homolog, subfamily C, member 12 2,506 1,756
1371691_at BI282993 Rarres2 retinoic acid receptor responder (tazarotene induced) 2 2,507 1,370
1390789_at BI296347 Acad11 acyl-Coenzyme A dehydrogenase family, member 11 2,508 1,467
1387111_at NM_022297 Ddah1 dimethylarginine dimethylaminohydrolase 1 2,512 2,311
1387963_a_at M24396 Uox urate oxidase 2,514 1,595
1367871_at NM_031543 Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 2,516 2,054
1393947_at BG377383 Slc25a15 
Solute carrier family 25 (mitochondrial carrier; ornithine 
transporter) member 15 2,517 1,394 
1391679_at AA944639 LOC691083 hypothetical protein LOC691083 2,517 1,892
1382496_at BI288517 Hnf4a Hepatocyte nuclear factor 4, alpha 2,518 1,448
1391483_at BF282264 Creb3l3 cAMP responsive element binding protein 3-like 3 2,519 1,613
1368205_at NM_024157 Cfi complement factor I 2,521 1,821
1377051_at AA849966 LOC100366119 Mpv17 transgene, kidney disease mutant-like (predicted)-like 2,526 2,221
1372860_at BE112971 Lhpp 
phospholysine phosphohistidine inorganic pyrophosphate 
phosphatase 2,531 2,079 
1370511_at U05675 Fgb fibrinogen beta chain 2,537 1,961
1367885_at NM_031587 Pxmp2 peroxisomal membrane protein 2 2,537 1,736
1377921_at AA875050 Etnk2 ethanolamine kinase 2 2,540 1,634
1387955_at M31109 Ugt2b5 UDP glucuronosyltransferase 2 family, polypeptide B5 2,540 2,335
1398310_at D17309 Akr1d1 
aldo-keto reductase family 1, member D1 (delta 4-3-ketosteroid-5-
beta-reductase) 2,541 1,570 
1372765_a_at BM390774 
Peci /// 
RGD1310224 
peroxisomal D3,D2-enoyl-CoA isomerase /// similar to RIKEN cDNA 
1810022C23 2,557 1,442 
1385767_at BF411017 LOC304000 cell adhesion molecule JCAM 2,557 1,878
1370387_at U46118 Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 2,558 2,086
1384103_at BE106350 RGD1561416 similar to novel protein (HT036) 2,559 1,688
1370420_at J05035 Srd5a1 
steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-
steroid delta 4-dehydrogenase alpha 1) 2,561 1,914 
1371542_at BI284599 Tuba4a tubulin, alpha 4A 2,567 2,278
1390421_at AI232524 Npl2 N-acetylneuraminate pyruvate lyase 2 (putative) 2,576 2,050
1368627_at NM_031546 Rgn regucalcin (senescence marker protein-30) 2,579 1,865
1386571_at BF567145 RGD1562626 Similar to adaptor molecule SRCASM 2,580 1,890
1395041_at BM385230 Mttp microsomal triglyceride transfer protein 2,581 1,771
1376792_at AW251313 Fam176a family with sequence similarity 176, member A 2,582 1,271
1368686_at NM_012901 Ambp alpha-1-microglobulin/bikunin precursor 2,585 1,838
1383165_at BM390462 RGD1310209 similar to KIAA1324 protein 2,586 2,230
1388988_at AI175070 Abhd14b abhydrolase domain containing 14b 2,587 1,969
1398267_at NM_053537 Slc22a7 solute carrier family 22 (organic anion transporter), member 7 2,588 1,555
1379833_at BE110171 Lingo4 /// Rorc 
leucine rich repeat and Ig domain containing 4 /// RAR-related 
orphan receptor C 2,589 1,843 
1370936_at AA892345 Dmgdh dimethylglycine dehydrogenase 2,589 1,981
1387121_a_at NM_133583 Ndrg2 N-myc downstream regulated gene 2 2,593 1,679
1369011_at AF202888 Apoa5 apolipoprotein A-V 2,597 1,695
1368467_at NM_019623 Cyp4f1 cytochrome P450, family 4, subfamily f, polypeptide 1 2,599 2,401
1369286_at NM_012803 Proc protein C 2,602 1,652
1371137_at X95189 Acox2 acyl-Coenzyme A oxidase 2, branched chain 2,605 1,612
1387376_at NM_019363 Aox1 aldehyde oxidase 1 2,606 1,712
1369206_at NM_053617 Cpb2 carboxypeptidase B2 (plasma) 2,607 1,942
1377407_at BI290154 Acsm5 acyl-CoA synthetase medium-chain family member 5 2,616 1,983
1382678_at AA859019 Cfhl1 complement component factor h-like 1 2,631 2,234
1369074_at NM_130748 Slc38a4 solute carrier family 38, member 4 2,634 1,923
1389350_at AI180413 Apoh apolipoprotein H (beta-2-glycoprotein I) 2,635 2,018
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1368453_at NM_031344 Fads2 fatty acid desaturase 2 2,642 1,647
1377672_at BI300997 
RGD1559960 
/// Sult1c2 
similar to Sulfotransferase K1 (rSULT1C2) /// sulfotransferase 
family, cytosolic, 1C, member 2 2,648 2,188 
1370237_at AA799574 Hadh hydroxyacyl-Coenzyme A dehydrogenase 2,654 1,766
1373386_at AI179953 Gjb2 gap junction protein, beta 2 2,660 1,511
1391907_at AI030790 Nags N-acetylglutamate synthase 2,662 1,786
1383248_at AI454611 Fmo5 flavin containing monooxygenase 5 2,663 1,904
1387511_at NM_012692 Cyp2a1 cytochrome P450, family 2, subfamily a, polypeptide 1 2,671 2,348
1387209_at NM_053571 Sec16b SEC16 homolog B (S. cerevisiae) 2,676 1,430
1387926_at AB052846 Sc5dl 
sterol-C5-desaturase (ERG3 delta-5-desaturase homolog, S. 
cerevisiae)-like 2,680 1,766 
1368178_at NM_031712 Pdzk1 PDZ domain containing 1 2,683 1,864
1372462_at AI412322 Acat2 acetyl-Coenzyme A acetyltransferase 2 2,685 1,779
1393826_at AI043761 Apon apolipoprotein N 2,691 1,832
1388605_at BM384938 Wfdc3 WAP four-disulfide core domain 3 2,707 2,527
1369492_at NM_020538 Aadac arylacetamide deacetylase (esterase) 2,717 2,161
1388395_at AI406939 G0s2 G0/G1switch 2 2,718 1,245
1387243_at K02422 Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 2,728 1,506
1368794_at NM_020076 Haao 3-hydroxyanthranilate 3,4-dioxygenase 2,729 2,058
1367994_at NM_031027 Dpyd dihydropyrimidine dehydrogenase 2,735 1,609
1393397_at AI576488 Cpa2 carboxypeptidase A2 (pancreatic) 2,741 2,534
1387223_at NM_017193 Aadat aminoadipate aminotransferase 2,745 2,206
1367735_at NM_012819 Acadl acyl-Coenzyme A dehydrogenase, long-chain 2,748 1,577
1368092_at NM_017181 Fah fumarylacetoacetate hydrolase 2,750 2,203
1382384_at BM383783 Rassf6 Ras association (RalGDS/AF-6) domain family member 6 2,752 2,211
1373452_at AI232273 Rcl1 RNA terminal phosphate cyclase-like 1 2,753 2,239
1386754_at BF521617 Trim14 tripartite motif-containing 14 2,756 1,751
1368731_at NM_053288 Orm1 orosomucoid 1 2,758 1,710
1370475_at M20406 Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 2,765 1,945
1369863_at NM_017270 
Adh4 /// 
LOC100364917 
alcohol dehydrogenase 4 (class II), pi polypeptide /// alcohol 
dehydrogenase 4-like 2,768 1,858 
1368121_at NM_013215 Akr7a3 
aldo-keto reductase family 7, member A3 (aflatoxin aldehyde 
reductase) 2,770 2,042 
1387503_at NM_053526 Cpn1 carboxypeptidase N, polypeptide 1 2,770 1,701
1368401_at M85035 Gria2 glutamate receptor, ionotropic, AMPA 2 2,772 2,068
1369746_a_at AF147740 Slco1b3 solute carrier organic anion transporter family, member 1b3 2,775 1,890
1369852_at NM_017143 F10 coagulation factor X 2,775 1,960
1373337_at AI412065 Grhpr glyoxylate reductase/hydroxypyruvate reductase 2,782 1,945
1393221_at AA866264 RGD1564865 similar to 20-alpha-hydroxysteroid dehydrogenase 2,786 2,329
1387271_at NM_053674 Phyh phytanoyl-CoA 2-hydroxylase 2,787 2,033
1374570_at AI012474 Agpat2 
1-acylglycerol-3-phosphate O-acyltransferase 2 (lysophosphatidic 
acid acyltransferase, beta) 2,792 2,146 
1388358_at AW252650 Etfb electron-transfer-flavoprotein, beta polypeptide 2,818 2,007
1370943_at AI168953 
Sult1c2 /// 
Sult1c2a 
sulfotransferase family, cytosolic, 1C, member 2 /// 
sulfotransferase family, cytosolic, 1C, member 2a 2,826 2,276 
1369493_at NM_012630 Prlr prolactin receptor 2,837 1,863
1368289_at AA944965 Gc group specific component 2,840 2,371
1369485_at NM_130747 Acot12 acyl-CoA thioesterase 12 2,853 1,794
1386917_at NM_012744 Pc pyruvate carboxylase 2,855 1,456
1377666_at BI293004 Chdh choline dehydrogenase 2,856 2,028
1384417_at AA998783 Apoc4 apolipoprotein C-IV 2,867 2,471
1367939_at NM_012733 Rbp1 retinol binding protein 1, cellular 2,876 1,370
1393464_at BM383378 RGD1311251 similar to RIKEN cDNA 4930550C14 2,895 2,331
1389363_at AA997430 Adi1 acireductone dioxygenase 1 2,896 1,825
1370698_at M13506 Ugt2b1 UDP glucuronosyltransferase 2 family, polypeptide B1 2,898 2,341
1369275_s_at NM_012692 
Cyp2a1 /// 
Cyp2a2 
cytochrome P450, family 2, subfamily a, polypeptide 1 /// 
cytochrome P450, family 2, subfamily a, polypeptide 2 2,898 2,347 
1380104_at AA963815 F9 coagulation factor IX 2,899 2,488
1369799_at U29701 Abat 4-aminobutyrate aminotransferase 2,903 2,655
1387050_s_at NM_012696 
Kng1 /// 
Kng1l1 /// 
Kng2 kininogen 1 /// kininogen 1-like 1 /// kininogen 2 2,911 2,117 
1389654_at BM392070 Pls1 Plastin 1 (I isoform) 2,914 1,755
1368514_at NM_013198 Maob monoamine oxidase B 2,916 2,087
1374828_at AI045590 Pdia5 protein disulfide isomerase family A, member 5 2,917 2,416
1369727_at NM_013112 Apoa2 apolipoprotein A-II 2,918 2,853
1369664_at NM_053019 Avpr1a arginine vasopressin receptor 1A 2,922 2,472
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1370108_a_at AF090134 Lin7a lin-7 homolog a (C. elegans) 2,928 2,549
1370241_at AA800502 
Cyp2c7 /// 
LOC100361347 
cytochrome P450, family 2, subfamily c, polypeptide 7 /// 
cytochrome P450 2C7-like 2,928 1,837 
1368695_at NM_016995 C4bpb complement component 4 binding protein, beta 2,931 2,755
1393260_at BG661061 LOC360228 WDNM1 homolog 2,936 2,282
1378739_at AA818135 Cidec cell death-inducing DFFA-like effector c 2,936 2,309
1368077_at NM_012558 Fbp1 fructose-1,6-bisphosphatase 1 2,938 2,188
1384934_at AA893454 Slc41a2 Solute carrier family 41, member 2 2,942 2,100
1387994_at U89280 Hsd17b6 hydroxysteroid (17-beta) dehydrogenase 6 2,948 3,135
1368940_at NM_017255 P2ry2 purinergic receptor P2Y, G-protein coupled, 2 2,956 2,137
1379246_at AI169938 RGD1308742 similar to Complement C5 precursor 2,958 2,668
1369296_at NM_031732 Sult1c3 sulfotransferase family, cytosolic, 1C, member 3 2,968 2,934
1373803_a_at AI170771 Ghr growth hormone receptor 2,969 2,612
1388948_at AI104759 Stard10 StAR-related lipid transfer (START) domain containing 10 2,974 2,510
1368741_at NM_057146 C9 complement component 9 2,981 2,338
1391194_at BG377337 Sall1 Sal-like 1 (Drosophila) 2,982 2,561
1369581_at NM_013003 Pemt phosphatidylethanolamine N-methyltransferase 2,989 2,442
1397419_at AI101314 Mpp6 
Membrane protein, palmitoylated 6 (MAGUK p55 subfamily 
member 6) 3,000 2,694 
1373686_at AA893495 Serpina6 serine (or cysteine) peptidase inhibitor, clade A, member 6 3,006 2,479
1378819_at AW435096 Aspdh aspartate dehydrogenase domain containing 3,006 2,194
1370580_a_at M18336 
Cyp2c6 /// 
LOC293989 
cytochrome P450, family 2, subfamily c, polypeptide 6 /// 
cytochrome P450-like 3,008 2,302 
1368458_at NM_012942 Cyp7a1 cytochrome P450, family 7, subfamily a, polypeptide 1 3,009 2,656
1387234_at NM_012826 Azgp1 alpha-2-glycoprotein 1, zinc-binding 3,019 2,358
1374006_at BI295878 
Kat3 /// 
LOC100361841 
kynurenine aminotransferase III /// kynurenine aminotransferase 
III-like 3,022 2,279 
1374512_at AI232341 LOC684314 similar to CG9886-like 3,039 2,423
1368016_at NM_133299 Pecr peroxisomal trans-2-enoyl-CoA reductase 3,049 2,367
1369654_at NM_023991 Prkaa2 protein kinase, AMP-activated, alpha 2 catalytic subunit 3,051 2,704
1371824_at AA891949 Ak3l1 adenylate kinase 3-like 1 3,052 2,058
1390326_at BF564217 Ang1 angiogenin, ribonuclease A family, member 1 3,058 2,417
1398634_at AI030835 LOC678836 hypothetical protein LOC678836 3,059 2,767
1367887_at NM_017024 Lcat lecithin cholesterol acyltransferase 3,070 1,843
1387282_at NM_053612 Hspb8 heat shock protein B8 3,072 2,244
1383472_at AA997683 Aldh1b1 aldehyde dehydrogenase 1 family, member B1 3,080 1,966
1372485_at BF281220 Pcbd1 
pterin-4 alpha-carbinolamine dehydratase/dimerization cofactor of 
hepatocyte nuclear factor 1 alpha 3,084 2,509 
1398282_at NM_053902 Kynu kynureninase (L-kynurenine hydrolase) 3,089 2,893
1368609_at NM_017047 Slc10a1 
solute carrier family 10 (sodium/bile acid cotransporter family), 
member 1 3,097 2,544 
1384499_at BG373566 Bucs1 butyryl Coenzyme A synthetase 1 3,100 2,335
1387314_at NM_022513 Sult1b1 sulfotransferase family, cytosolic, 1B, member 1 3,107 2,609
1367908_at NM_133598 Gcsh glycine cleavage system protein H (aminomethyl carrier) 3,112 2,449
1384834_at AI028942 Cobl cordon-bleu homolog (mouse) 3,116 2,057
1397740_at AA964229 Sfxn1 sideroflexin 1 3,117 1,933
1382554_at AA998638 C8a complement component 8, alpha polypeptide 3,147 2,462
1398326_at BI282332 Chchd10 coiled-coil-helix-coiled-coil-helix domain containing 10 3,149 2,762
1368520_at NM_012737 Apoa4 apolipoprotein A-IV 3,150 2,256
1374176_at AI408727 RGD1308059 
similar to DNA segment, Chr 4, Brigham & Womens Genetics 0951 
expressed 3,154 2,254 
1373947_at BI278545 Dpt dermatopontin 3,154 2,169
1387284_at NM_031705 Dpys dihydropyrimidinase 3,163 2,965
1368224_at NM_031531 Serpina3n serine (or cysteine) peptidase inhibitor, clade A, member 3N 3,168 2,485
1394022_at BE116009 Id4 inhibitor of DNA binding 4 3,170 2,650
1383606_at BI302544 Tc2n tandem C2 domains, nuclear 3,186 2,261
1372841_at BG376982 Reep6 receptor accessory protein 6 3,194 2,434
1371762_at AA858962 Rbp4 retinol binding protein 4, plasma 3,201 2,482
1370352_at AB023630 
Cesl1 /// Es22 
/// 
LOC100125372 carboxylesterase-like 1 /// esterase 22 /// carboxylesterase ES-4 3,202 2,130 
1383904_at BM386541 Fgl1 fibrinogen-like 1 3,203 2,658
1373108_at BM390827 Ppp1r3c protein phosphatase 1, regulatory (inhibitor) subunit 3C 3,220 3,075
1369491_at NM_053626 Dao D-amino-acid oxidase 3,222 3,348
1383732_at AA819810 RGD1307603 similar to hypothetical protein MGC37914 3,238 2,780
1391652_at AI411140 Glyat glycine-N-acyltransferase 3,239 2,655
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Affymetrix ID Public ID Gene Symbol Gene Title 
fold 
control SD 
1394844_s_at AA893326 
Cyp4a2 /// 
Cyp4a3 
cytochrome P450, family 4, subfamily a, polypeptide 2 /// 
cytochrome P450, family 4, subfamily a, polypeptide 3 3,241 2,298 
1369435_at NM_013048 Ttpa tocopherol (alpha) transfer protein 3,245 2,749
1368569_at NM_053781 Akr1b7 aldo-keto reductase family 1, member B7 3,251 3,013
1383692_at BG377830 Prelid2 PRELI domain containing 2 3,257 2,978
1369663_at NM_022936 Ephx2 epoxide hydrolase 2, cytoplasmic 3,281 2,763
1368362_a_at M16347 Asgr2 asialoglycoprotein receptor 2 3,282 2,590
1374816_at AI103939 Gcom1 GRINL1A complex locus 3,283 3,099
1386980_at NM_019373 Apom apolipoprotein M 3,284 2,974
1369790_at M18340 Tat tyrosine aminotransferase 3,313 2,120
1387936_at D14989 Sult2a2 
sulfotransferase family 2A, dehydroepiandrosterone (DHEA)-
preferring, member 2 3,328 2,906 
1372297_at AI234527 Gsta4 glutathione S-transferase alpha 4 3,329 3,000
1387118_at NM_013105 Cyp3a23/3a1 
cytochrome P450, family 3, subfamily a, polypeptide 
23/polypeptide 1 3,332 3,131 
1368608_at NM_019303 Cyp2f4 cytochrome P450, family 2, subfamily f, polypeptide 4 3,338 3,127
1370563_at D17310 Akr1c14 aldo-keto reductase family 1, member C14 3,354 2,824
1387877_at BE096729 Ftcd formiminotransferase cyclodeaminase 3,371 2,477
1368618_at NM_031623 Grb14 growth factor receptor bound protein 14 3,390 2,438
1367937_at AF230096 Miox myo-inositol oxygenase 3,391 2,397
1383395_at AI028979 Agmat agmatine ureohydrolase (agmatinase) 3,431 2,705
1379770_at BF282951 Chpt1 choline phosphotransferase 1 3,457 3,447
1367659_s_at NM_017306 Dci 
dodecenoyl-Coenzyme A delta isomerase (3,2 trans-enoyl-
Coenzyme A isomerase) 3,467 2,396 
1388432_at BI294994 Optn optineurin 3,470 2,754
1369546_at NM_022629 Bbox1 
butyrobetaine (gamma), 2-oxoglutarate dioxygenase (gamma-
butyrobetaine hydroxylase) 1 3,477 2,546 
1383437_at AI547691 Rab17 RAB17, member RAS oncogene family 3,481 2,821
1368790_at NM_133617 Serpina10 
serine (or cysteine) peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 10 3,490 2,749 
1387396_at NM_053469 Hamp hepcidin antimicrobial peptide 3,510 2,058
1367758_at NM_012493 Afp alpha-fetoprotein 3,511 3,618
1377660_at BM387540 RGD1309350 similar to transthyretin (4L369) 3,512 2,758
1370818_at AF044574 Decr2 2,4-dienoyl CoA reductase 2, peroxisomal 3,514 2,881
1387018_at NM_053770 Sorbs2 sorbin and SH3 domain containing 2 3,520 3,069
1390944_at BM384937 Chmp4c chromatin modifying protein 4C 3,548 2,364
1370814_at AB062758 Dhrs4 dehydrogenase/reductase (SDR family) member 4 3,559 2,890
1387307_at NM_017159 Hal histidine ammonia lyase 3,562 2,662
1390591_at AI169163 Slc17a3 solute carrier family 17 (sodium phosphate), member 3 3,563 2,964
1368387_at NM_053995 Bdh1 3-hydroxybutyrate dehydrogenase, type 1 3,580 2,984
1386880_at NM_130433 Acaa2 acetyl-Coenzyme A acyltransferase 2 3,583 2,627
1393612_a_at AI059270 Depdc7 DEP domain containing 7 3,594 2,715
1371363_at BI277042 Gpd1 glycerol-3-phosphate dehydrogenase 1 (soluble) 3,599 2,658
1367804_at NM_017170 Apcs amyloid P component, serum 3,619 2,767
1394112_at AA945123 Hao1 hydroxyacid oxidase (glycolate oxidase) 1 3,633 2,939
1387215_at NM_030656 Agxt alanine-glyoxylate aminotransferase 3,636 2,725
1398514_at AI232328 Hgd homogentisate 1, 2-dioxygenase 3,647 3,442
1388155_at BI286012 Krt18 keratin 18 3,653 2,861
1368180_s_at NM_017013 
Gsta2 /// 
LOC494499 glutathione S-transferase A2 /// LOC494499 protein 3,711 3,081 
1369836_at NM_020096 Ifit1 interferon-induced protein with tetratricopeptide repeats 1 3,740 2,446
1387508_at NM_017300 Baat 
bile acid Coenzyme A: amino acid N-acyltransferase (glycine N-
choloyltransferase) 3,746 2,864 
1367932_at NM_017268 Hmgcs1 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble) 3,799 2,971
1382569_at BF386242 Paqr9 Progestin and adipoQ receptor family member IX 3,842 3,398
1387006_at NM_012695 Sult2al1 
sulfotransferase family 2A, dehydroepiandrosterone (DHEA)-
preferring-like 1 3,844 3,478 
1371098_a_at AA996755 Masp2 mannan-binding lectin serine peptidase 2 3,850 2,653
1370359_at AB057450 Amy1a amylase, alpha 1A (salivary) 3,852 3,201
1367838_at NM_017074 Cth cystathionase (cystathionine gamma-lyase) 3,855 4,180
1392172_at AI169984 Ccl9 chemokine (C-C motif) ligand 9 3,858 3,599
1379400_at AI044556 Aldh1l2 aldehyde dehydrogenase 1 family, member L2 3,875 2,925
1393123_at BM392153 C8g complement component 8, gamma polypeptide 3,920 3,591
1387240_at NM_133543 Rdh7 retinol dehydrogenase 7 3,924 3,064
1385707_at BF550221 Lect2 leukocyte cell-derived chemotaxin 2 3,954 3,167
1368335_at NM_012738 Apoa1 apolipoprotein A-I 4,021 2,810
1368328_at NM_013089 Gys2 glycogen synthase 2 4,023 2,684
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1371030_at BI291181 Spp2 secreted phosphoprotein 2 4,064 3,307
1374657_at AA848437 Anks4b ankyrin repeat and sterile alpha motif domain containing 4B 4,067 3,289
1391534_at BG666735 Elovl2 
elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, 
yeast)-like 2 4,083 3,861 
1369195_at NM_013068 Fabp2 fatty acid binding protein 2, intestinal 4,087 3,319
1381976_at BE103004 Kif21a kinesin family member 21A 4,155 2,601
1387949_at M58041 Cyp2c22 cytochrome P450, family 2, subfamily c, polypeptide 22 4,169 3,139
1371530_at BF281337 Krt8 keratin 8 4,207 3,343
1370149_at NM_012503 Asgr1 asialoglycoprotein receptor 1 4,216 3,431
1391397_at BF418393 LOC684055 hypothetical protein LOC684055 4,232 3,214
1368706_at NM_053785 Tm4sf4 transmembrane 4 L six family member 4 4,238 3,639
1391661_at AA945076 Gk glycerol kinase 4,245 3,801
1387178_a_at NM_012522 Cbs cystathionine beta synthase 4,247 3,751
1370024_at NM_030832 Fabp7 fatty acid binding protein 7, brain 4,286 4,368
1372601_at BM391471 Atf5 activating transcription factor 5 4,366 3,706
1373963_at BF284337 Hdhd3 haloacid dehalogenase-like hydrolase domain containing 3 4,410 2,903
1382924_at AA850195 Pank1 pantothenate kinase 1 4,465 4,081
1379326_at AI169837 RGD1305679 similar to 9530008L14Rik protein 4,542 4,079
1370167_at BG668421 Sdc2 syndecan 2 4,552 3,670
1368878_at NM_053539 Idi1 isopentenyl-diphosphate delta isomerase 1 4,607 5,003
1372755_at AI102073 Mal2 mal, T-cell differentiation protein 2 4,623 4,813
1368720_at NM_022403 Tdo2 tryptophan 2,3-dioxygenase 4,701 4,205
1379452_at AI411492 Gas2 growth arrest-specific 2 4,707 4,533
1370334_at AF081582 Plekhb1 
pleckstrin homology domain containing, family B (evectins) 
member 1 4,786 4,635 
1369509_a_at AJ302031 A1bg alpha-1-B glycoprotein 4,795 3,588
1387022_at NM_022407 Aldh1a1 aldehyde dehydrogenase 1 family, member A1 4,874 4,798
1370592_at AB019693 Keg1 kidney expressed gene 1 4,890 3,638
1368283_at NM_133606 Ehhadh 
enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A 
dehydrogenase 4,901 4,931 
1370310_at M33648 Hmgcs2 
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 
(mitochondrial) 4,954 4,214 
1382084_at AA850264 RGD1562988 Similar to EHM2 4,964 4,152
1393139_at BM385272 Apoc2 apolipoprotein C-II 4,995 4,292
1369502_a_at NM_031502 
Amy1a /// 
Amy2 /// 
Amy2-2 
amylase, alpha 1A (salivary) /// amylase 2, pancreatic /// amylase 
2-2, pancreatic 5,243 6,756 
1367777_at NM_057197 Decr1 2,4-dienoyl CoA reductase 1, mitochondrial 5,276 4,030
1391429_at AW434961 Hfe2 hemochromatosis type 2 (juvenile) homolog (human) 5,286 5,286
1368934_at NM_016999 
Cyp4a1 /// 
Cyp4a10 
cytochrome P450, family 4, subfamily a, polypeptide 1 /// 
cytochrome P450, family 4, subfamily a, polypeptide 10 5,507 3,953 
1377037_at AI411493 Acot4 acyl-CoA thioesterase 4 7,244 6,750
1369765_at NM_022384 Ascl1 achaete-scute complex homolog 1 (Drosophila) 10,821 12,681
Table 28: Affymetrix IDs, public IDs, gene symbols, full gene titles, mean fold control of gene expression compared to 
controls (NPC 24h oil-treated, n=4, fold NPC 20h water treated, n=3) and SD of genes which were at least 2-fold up- or 
downregulated in primary rat mesenchymal cells. 
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Changes in gene expression in hepatocytes after 20h 
Affymetrix ID  Public ID 
Gene 
Symbol Gene Title 
fold 
control SD 
1395403_at BM385735 Stac3 SH3 and cysteine rich domain 3 0,450 0,319
1384525_at AI549335 Dock11 dedicator of cytokinesis 11 0,479 0,406
1369268_at NM_012912 Atf3 activating transcription factor 3 0,484 0,392
1387808_at AF200684 Slc7a7 solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 7 
2,100 1,327
1367553_x_at NM_033234 Hbb hemoglobin, beta 2,268 1,956
1369424_at NM_012693 Cyp2a2 cytochrome P450, family 2, subfamily a, polypeptide 2 2,336 0,995
1391433_at AA899721 Acot2 acyl-CoA thioesterase 2 2,384 1,372
1370987_at BF550890 Spn sialophorin 2,459 0,884
1369195_at NM_013068 Fabp2 fatty acid binding protein 2, intestinal 2,577 1,566
1384064_at AI502703 Krt23 keratin 23 (histone deacetylase inducible) 2,673 2,104
1369765_at NM_022384 Ascl1 achaete-scute complex homolog 1 (Drosophila) 3,025 1,864
1389253_at BI289085 Vnn1 vanin 1 5,508 4,764
Table 29: Affymetrix IDs, public IDs, gene symbols, full gene titles, mean fold control of gene expression compared to 
controls (HC 24h oil-treated, n=4, fold HC 20h water treated, n=3) and SD of genes which were at least 2-fold up- or 
downregulated in primary rat hepatocytes. 
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